Culture medium composition and method of culturing cell or tissue using thereof

ABSTRACT

The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a divisional of co-pending U.S. patentapplication Ser. No. 15/448,557, filed on Mar. 2, 2017, which is acontinuation of U.S. patent application Ser. No. 13/949,310, filed onJul. 24, 2013, now U.S. Pat. No. 9,664,671, issued on May 30, 2017,which claims the benefit of U.S. Provisional Patent Application No.61/675,133 filed on Jul. 24, 2012, U.S. Provisional Patent ApplicationNo. 61/731,824 filed on Nov. 30, 2012, and U.S. Provisional PatentApplication No. 61/759,172 filed on Jan. 31, 2013, each of which isincorporated by reference in its entirety herein.

TECHNICAL FIELD

The present invention relates to a medium composition containing astructure capable of suspending cells or tissues, and a method ofculturing cells or tissues by using the medium composition. The mediumcomposition and cell culture method using same of the present inventioncan be preferably utilized for cultivating cells and/or tissues of ananimal or plant particularly in a suspension state.

BACKGROUND ART

In recent years, techniques for proliferating or maintaining in vitrovarious organs, tissues and cells that play 30 distinct roles in thebody of animals and plants have been developed. Proliferation ormaintenance of the organs and tissues in vitro is called organ cultureand tissue culture, respectively, and proliferating, differentiating ormaintaining in vitro the cells separated from an organ or tissue iscalled cell culture. Cell culture is a technique for proliferating,differentiating or maintaining separated cells in vitro in a medium, andis indispensable for detailed analyses of the in vivo function andstructure of various organs, tissues and cells. In addition, the cellsand/or tissues cultured by the technique are utilized in various fieldsfor efficacy and toxicity evaluation of chemical substances,pharmaceutical products and the like, large-scale production of usefulsubstances such as enzymes, cell growth factors, antibodies and thelike, regenerative medicine supplementing organ, tissue and cell thatwere lost by disease and deficiency, improvement of plant brand,production of gene recombinant products, and the like.

Animal-derived cells are broadly divided into non-adherent cells andadherent cells based on the properties thereof. Non-adherent cells arecells that do not require a scaffold for growth and proliferation, andadherent cells are cells that require a scaffold for growth andproliferation. Most of the cells constituting the living body are thelatter, adherent cells. As culture methods of adherent cells, singlelayer culture, dispersion culture, embedded culture, microcarrierculture, sphere culture and the like are known.

Single layer culture is a method of cultivating the object cell as asingle layer by using, as a scaffold, a culture container made of glassor a synthetic polymer material that underwent various surfacetreatments, or supportive cells called feeder cells, and is mostgenerally prevalent. For example, culture methods using culturecontainers of various shapes or properties such as polystyrene appliedwith various surface treatments (plasma treatment, corona treatmentetc.), coated with cell adhesion factors such as collagen, fibronectin,polylysine and the like, or plated with feeder cells in advance and thelike have been developed. However, the single layer culture isproblematic in that cells cannot maintain the specific functions theyhave in vivo for a long term, since the two-dimensional cultureenvironment thereof is completely different from the in vivoenvironment, the cells cannot reconstruct a tissue similar to that invivo, it is not suitable for a mass culture of cells since the cellnumber per a constant area is limited, and the like (patent document 1).In addition, a method of cultivating the object cell on feeder cellssometimes faces a problem in separation of the object cells from thefeeder cells (non-patent document 1).

Dispersion culture is a method of cultivating adherent cells in asuspended state, which includes seeding the cells in a medium, andstirring the culture medium in a culture container applied with asurface treatment for inhibiting cell adhesion, to inhibit attachment ofthe cells to the culture container. However, the adherent cells culturedby the method cannot adhere to a scaffold, and therefore, the methodcannot be applied to a cell that essentially requires adhesion to ascaffold for cell proliferation. In addition, being constantly disruptedby a shear force, the cell cannot exhibit its inherent cell function,and therefore, functional cells sometimes cannot be cultivated in alarge amount (non-patent document 2).

Embedded culture is a method of cultivating cells by embedding andfixing the cells in a solid or semisolid gel substrate such as agar,methylcellulose, collagen, gelatin, fibrin, agarose, alginates and thelike. Since the method enables three-dimensional cultivation of thecells in a state closer to in vivo and the gel substrate itselfsometimes promotes proliferation and differentiation of the cells, thecells can be cultivated at high density while maintaining the functionof the cell, as compared to single layer culture and dispersion culture(patent documents 2, 3). Furthermore, a method of cultivating cells,including forming a microcapsule with a size of 100-300 μm by embeddingthe cells in the gel substrate, and cultivating the cells in an aqueoussolution medium while dispersing the microcapsule has also beendeveloped (non-patent document 3). However, these methods have problemsin that successive observation of cultured cells is not possible unlessa visible light permeates the gel substrate, recovery of cells from themedium requires a complicated operation that damages the cells such asan enzyme treatment (e.g., collagenase treatment in the case of collagengel) and the like, since the medium and microcapsule containing a gelsubstrate have high viscosity, medium exchange necessary for long-termcultivation is difficult and the like. In recent years, techniquesenabling cell recovery from a gel substrate by a treatment with heat,shear force and the like have been developed. However, the heat, shearforce and the like may exert an adverse effect on the cell function, andthe safety of the gel substrate for the living body has not beenclarified yet (patent documents 4, 5, non-patent documents 4, 5, 6, 7).In addition, a sol food for preventing precipitation and floating of aparticulate food such as fruit, vegetable and the like cut small to keepthe food uniformly dispersed and suspended has been developed in thefood field. However, the sol food does not consider recovery of thedispersed particulate food, and whether the cells and tissues can besubjected to suspension culture has not been examined (patent document6).

Microcarrier culture is a method of cultivating cells in a suspendedstate by proliferating cells in a single layer on the surface of a fineparticle slightly heavier than water (hereinafter to be also referred toas a microcarrier), and stirring the fine particles in a culturecontainer such as a flask and the like. Generally, the microcarrier usedfor the method is a spherical particle having diameter 100-300 μm,surface area 3000-6000 cm²/g, specific gravity 1.03-1.05, and iscomposed of a material such as dextran, gelatin, alginic acid,polystyrene and the like. Collagen, gelatin, or a charged group such asdimethylaminoethyl and the like may also be provided to the surface of amicrocarrier to facilitate attachment of the cell. This method isapplied to a mass culture of a cell since it can markedly increase theculture area (patent documents 7, 8). However, it is difficult to attachthe object cell almost uniformly to all microcarriers, and problemsoccur such as detachment of the cells from the microcarrier due to ashear force during stirring, damage on the cells and the like(non-patent document 8).

Sphere culture is a culture method including forming an aggregatecomposed of several dozen-several hundred object cells (hereinafter tobe also referred to as a sphere), and culturing the aggregates withstanding or shaking in a medium. It is known that a sphere has a highcell density, reconstructs cell-cell interactions and cell structureclose to those in the in vivo environment, and can be cultured whilemaintaining the cell function for a longer term as compared to a singlelayer culture and a dispersion culture method (non-patent documents 9,10). However, the sphere culture cannot form a large sphere, sincesupply of nutrition inside the sphere and discharge of wastes aredifficult when the size of the sphere is too large. In addition, sincethe formed sphere needs to be cultivated in a dispersed state on thebottom of a culture container, the number of spheres per a given volumecannot be increased with ease, and it is not suitable for a massculture. Furthermore, as a method of forming a sphere, hanging dropculture, culture on cell non-adhesive surface, culture inside microwell,rotation culture, culture utilizing cell scaffold, coagulation bycentrifugal force, ultrasonication, electric field or magnetic field andthe like are known. However, these methods are problematic in that theoperation is complicated, recovery of sphere is difficult, size controland large-scale production are difficult, influence on the cell isunknown, special exclusive container and apparatus are necessary and thelike (patent document 9).

On the other hand, as for plants, cell, protoplast without a cell wallor organ, tissue, callus of plant such as leaf, stalk, root, growingpoint, seed, embryo, pollen and the like can also be grown by culture inan aseptic state. Using a culture technique for such plant tissues andcells, brand improvement of plant and production of useful substanceshave been made possible. As a method for proliferating plant cells andtissues in a large amount in a short time, a method of suspensioncultivation of plant cells and tissues in a liquid medium is known(non-patent document 11). To achieve good proliferation thereof, supplyof sufficient oxygen, maintenance of a uniform mixing state, preventionof cell damage and the like are important. The oxygen supply to aculture medium and suspending of cells and tissues may be performed bycombining aeration and mechanical stirring, or aeration alone. Theformer may result in defective proliferation due to a damage on thecells and tissues by stirring, and the latter is problematic in that,even though shearing of cells and tissues is less, since a uniformmixing state may be difficult to maintain in high density culture, thecells and tissues form sediment to lower the proliferation efficiencyand the like.

Moreover, for the research and development of an anticancer drug orselection of an appropriate anticancer drug in a cancer treatment, theanticancer activity of a medicament for cancer cells is evaluated bycultivating cancer cells in vitro in a culture medium containing acandidate drug or anticancer drug. However, the existing evaluationmethods of anticancer activity have problems of a gap between in vitroevaluation results and actual clinical effects and the like. To improvethe problems, methods of evaluating the activity under cell cultureconditions reproducing the in vivo environment as much as possible havebeen developed. For example, a method including embedding cancer cellsin a support such as soft agar, collagen gel, hydrogel and the like toallow for culture of the cancer cells in an environment inhibitingadhesion to a culture container, and evaluating the anticancer drug hasbeen developed (patent document 10, non-patent documents 12, 13). Inaddition, a method including inhibiting cell adhesion by coating asurface of a culture container with a material inhibiting cell adhesion,or applying a special processing of the surface, culturing cancer cellsin a coagulated state (sphere culture), and evaluating the anticanceractivity has been developed (patent documents 11, 12).

However, those cancer cell culture methods have various problems in thatthe production process of a culture container and an operation for cellculture are complicated, an operation for recovery of the cell from asupport such as collagen and the like followed by evaluation ofanticancer activity is complicated, supply of support is sometimeslimited when the support is an animal-derived component, since it isexpensive, cell aggregates (spheres) are associated to have an excessivesize, thereby decreasing the cell survival rate and reproducibility, andthe like. Moreover, when an anticancer drug is screened for, a culturemethod of cancer cells, which is convenient, can treat a large amount ofuniform samples, and has high reproducibility, is desired.

Additionally, various activities of a pharmaceutical product candidatedrug and a pharmaceutical product on hepatocytes have been evaluated bycultivating hepatocytes in vitro in a culture medium containing thepharmaceutical product candidate drug or the pharmaceutical product.However, since the function inherently exhibited by hepatocytes in vivomay be lost by cultivating the hepatocytes in vitro, existing hepatocyteculture methods have problems in that a precise evaluation of apharmaceutical product candidate drug and a pharmaceutical product isnot available, evaluation of many samples is difficult and the like. Toovercome such problems, a method of performing activity evaluation undercell culture conditions reproducing the in vivo environment as much aspossible has been developed. For example, a method including culturinghepatocytes on an extracellular matrix such as collagen, laminin,Matrigel (registered trade mark) and the like, maintaining the functionof hepatocytes has been developed (patent document 13, non-patentdocuments 14, 15). In addition, a method including forming an aggregate(sphere) of hepatocytes by treatments, for example, inhibiting celladhesion by coating a surface of a culture container with a materialinhibiting cell adhesion or applying a special processing of the surfaceof a container, vibrating a culture container and the like, thereby tomaintain the function of the hepatocytes has been developed (patentdocuments 14, 15, non-patent documents 16, 17).

However, those hepatocyte culture methods have various problems in thatthe production process of a culture container and an operation for cellculture are complicated, an operation for recovery of the cell from asupport such as collagen and the like and evaluation of the function ofhepatocytes is complicated, supply of support is sometimes limited whenthe support is an animal-derived component, since it is expensive, cellaggregates (spheres) are associated to have an excessive size, therebydecreasing the cell survival rate and reproducibility, and the like.Moreover, when a pharmaceutical product candidate drug or apharmaceutical product is screened for, a culture method of hepatocytes,which is convenient, can treat a large amount of uniform samples, andhas high reproducibility, is desired.

DOCUMENT LIST Patent Documents

-   [0014]-   [patent document 1] JP-A-2001-128660-   [patent document 2] JP-A-S62-171680-   [patent document 3] JP-A-S63-209581-   [patent document 4] JP-A-2009-29967-   [patent document 5] JP-A-2005-60570-   [patent document 6] JP-A-8-23893-   [patent document 7] JP-A-2004-236553-   [patent document 8] WO2010/059775-   [patent document 9] JP-A-2012-65555-   is [patent document 10] JP-A-2008-11797-   [patent document 11] JP-A-2008-61609-   [patent document 12] JP-A-2012-249547-   [patent document 13] WO2005/028639-   [patent document 14] WO2010/079602-   [patent document 15] JP-A-2009-50194

Non-Patent Documents

-   [non-patent document 1] Klimanskaya et al., Lancet 2005,    365:1636-1641-   [non-patent document 2] King et al., Curr Opin Chem Biol. 2007,    11:394-398-   [non-patent document 3] Murua et al., J. of Controlled Release 2008,    132:76-83-   [non-patent document 4] Mendes, Chemical Society Reviews 2008,    37:2512-2529-   [non-patent document 5] Moon et al., Chemical Society Reviews 2012,    41:4860-4883-   [non-patent document 6] Pek et al., Nature Nanotechnol. 2008,    3:671-675-   [non-patent document 7] Liu et al., Soft Matter 2011, 7:5430-5436-   [non-patent document 8] Leung et al., Tissue Engineering 2011,    17:165-172-   [non-patent document 9] Stahl et al., Biochem. Biophys. Res. Comm.    2004, 322:684-692-   [non-patent document 10] Lin et al., Biotechnol J. 2008, 3:1172-1184-   [non-patent document 11] Weathers et al., Appl Microbiol Biotechnol    2010, 85:1339-1351-   [non-patent document 12] Takamura et al., Int. J. Cancer 2002, 98:    450-455-   [non-patent document 13] Yang et al., Proc. Natl. Acad. Sci. USA    1979, 76: 3401-3405-   [non-patent document 14] Bissell et al., J. Clin. Invest. 1987, 79:    801-812-   [non-patent document 15] LeCluyse et al., Critical Reviews in    Toxicology 2012, 42:501-548-   [non-patent document 16] Brophy et al., Hepatology 2009, 49:578-586-   [non-patent document 17] Franziska et al., World J Hepatol 2010,    2:1-7

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

An object of the present invention is to solve the above-mentionedproblems of the prior art, and provide a medium composition forcultivating cells and/or tissues of an animal or plant particularly in athree-dimensional or suspended state, and a method of culturing cellsand/or tissues of an animal or plant by using the medium composition.

Also, an object of the present invention is to solve the above-mentionedproblems of the prior art, and provide a medium composition forcultivating a cell aggregate (sphere) of cancer cells in athree-dimensional environment and a test method of cancer cell by usingthe medium composition.

Alternatively, an object of the present invention is to solve theabove-mentioned problems of the prior art, and provide a mediumcomposition for cultivating a cell aggregate (sphere) of hepatocytes ina three-dimensional environment and a test method of cancer cell byusing the medium composition.

Furthermore, an object of the present invention is to provide a mediumadditive that promotes proliferation of cancer cell in culturing thecancer cell and a medium additive that suppresses a decrease in thenumber of hepatocytes in culturing the hepatocytes.

Means of Solving the Problems

The present inventors have conducted intensive studies of variouscompounds and the effect of suspending cells and/or tissues in a liquidmedium containing them and succeeded in finding a structure capable ofuniformly dispersing cells and/or tissues in a suspended state withoutsubstantially increasing the viscosity of the liquid medium. They havefound that cells and/or tissues can be proliferated, differentiated ormaintained while keeping the suspended state, by using a mediumcomposition containing at least said structure. Moreover, they have alsofound that cultured cells and/or tissues can be easily recovered fromthe medium composition, which resulted in the completion of the presentinvention.

The present inventors have also conducted intensive studies of theeffect of various compounds and liquid media containing same on cancercell aggregate (sphere), and succeeded in finding a medium compositionthat prevents association of the spheres and affords uniform dispersion.They have found that the sphere can be cultivated with a high survivalrate and the activity of an anticancer drug against a cancer cell can beevaluated efficiently and with good sensitivity by using the mediumcomposition. Moreover, they have also found that a cultured sphere canbe easily recovered from the medium composition and evaluated, whichresulted in the completion of the present invention.

Also, the present inventors have conducted intensive studies of theeffect of various compounds and liquid media containing same onhepatocyte aggregate (sphere), and succeeded in finding a mediumcomposition that prevents association of the spheres and affords uniformdispersion. They have found that the sphere can be cultivated with ahigh survival rate while maintaining the function of hepatocytes and theeffect of a pharmaceutical product candidate drug or pharmaceuticalproduct on the hepatocytes can be evaluated efficiently and with goodsensitivity by using the medium composition. Moreover, they have alsofound that cultured spheres can be easily recovered from the mediumcomposition and evaluated, which resulted in the completion of thepresent invention.

Furthermore, the present inventors have found that the proliferation ofcancer cell can be markedly promoted by adding a deacylated gellan gumor a salt thereof to a medium containing the cancer cell, which resultedin the completion of the present invention.

In addition, the present inventors have found that a decrease in thenumber of hepatocytes can be suppressed by adding a deacylated gellangum or a salt thereof to a medium containing the hepatocytes, whichresulted in the completion of the present invention.

Accordingly, the present invention provides the following:

(1) A medium composition comprising a structure capable of culturingcells or tissues by suspending them.

(2) The medium composition of (1), permitting an exchange treatment ofthe medium composition during culture and recovery of the cells ortissues after completion of the culture.

(3) The medium composition of (1), which does not require any of atemperature change, a chemical treatment, an enzyme treatment and ashear force, during recovery of the cells or tissues from the mediumcomposition.

(4) The medium composition of (1), having a viscosity of not more than 8mPa·s.

(5) The medium composition of (1), wherein the aforementioned structurehas a size that passes a filter having a pore size of 0.2 μm to 200 μmwhen it is passed through a filter.

(6) The medium composition of (1), wherein the aforementioned structurecontains a polymer compound.

(7) The medium composition of (6), wherein the aforementioned polymercompound includes a polymer compound having an anionic functional group.

(8) The medium composition of (6), wherein the aforementioned polymercompound is a polysaccharide.

(9) The medium composition of (7), wherein the aforementioned anionicfunctional group is at least one kind selected from the group consistingof a carboxy group, a sulfo group and a phosphate group.

(10) The medium composition of (8), wherein the aforementionedpolysaccharide is at least one kind selected from the group consistingof hyaluronic acid, gellan gum, deacylated gellan gum, rhamsan gum,diutan gum, xanthan gum, carageenan, fucoidan, pectin, pectic acid,pectinic acid, heparan sulfate, heparin, heparitin sulfate,keratosulfate, chondroitin sulfate, dermatan sulfate, rhamnan sulfateand a salt thereof.

(11) The medium composition of (10), wherein the aforementionedpolysaccharide is at least one kind selected from the group consistingof hyaluronic acid, deacylated gellan gum, diutan gum, xanthan gum,carageenan and a salt thereof.

(12) The medium composition of (10) or (11), wherein the aforementionedpolysaccharide is deacylated gellan gum or a salt thereof.

(13) The medium composition of (12), wherein a final concentration ofthe aforementioned deacylated gellan gum or a salt thereof in the mediumcomposition is 0.001-1.0% (weight/volume).

(14) The medium composition of (13), further comprising a polysaccharideother than deacylated gellan gum or a salt thereof.

(15) The medium composition of (14), wherein the aforementionedpolysaccharide is at least one kind selected from the group consistingof xanthan gum, alginic acid, carageenan, diutan gum and a salt thereof.

(16) The medium composition of (14), wherein the aforementionedpolysaccharide is at least one kind selected from the group consistingof methylcellulose, locust bean gum and a salt thereof.

(17) The medium composition of any one of (1) to (16), furthercomprising a metal ion.

(18) The medium composition of (17), wherein the aforementioned metalion is a divalent metal ion.

(19) The medium composition of (18), wherein the aforementioned metalion is at least one kind selected from the group consisting of a calciumion, a magnesium ion, a zinc ion, a ferrous ion and a copper ion.

(20) The medium composition of (19), wherein the aforementioned metalion is a calcium ion.

(21) The medium composition of (20), further comprising a metal ionother than a calcium ion.

(22) The medium composition of (21), wherein the aforementioned metalion is at least one kind selected from the group consisting of amagnesium ion, a sodium ion and a potassium ion.

(23) The medium composition of any one of (1) to (22), furthercomprising an extracellular matrix and/or a cell adhesion molecule.

(24) The medium composition of (23), wherein the aforementionedextracellular matrix is at least one kind selected from the groupconsisting of collagen, hyaluronic acid and proteoglycan.

(25) The medium composition of (23), wherein the aforementioned celladhesion molecule is at least one kind selected from the groupconsisting of cadherin, laminin, fibronectin and vitronectin.

(26) The medium composition of any one of (1) to (25), which is for cellculture.

(27) The medium composition of (26), wherein the aforementioned cell isan adherent cell or a non-adherent cell.

(28) The medium composition of (27), wherein the aforementioned adherentcell is attached to a microcarrier.

(29) The medium composition of (27), wherein the aforementioned adherentcell is embedded in a carrier.

(30) The medium composition of (27), wherein the aforementioned adherentcell is a sphere.

(31) The medium composition of (27), wherein the aforementioned adherentcell is selected from the group consisting of a pluripotent stem cell, acancer cell and a hepatocyte.

(32) A cell or tissue culture comprising the medium composition of anyone of (1) to (31) and cells or tissues.

(33) A method of culturing a cell or tissue, comprising cultivating thecell or tissue in the medium composition of any one of (1) to (31).

(34) The culture method of (33), wherein the aforementioned cell isselected from the group consisting of a pluripotent stem cell, a cancercell and a hepatocyte.

(35) A method of recovering a cell or tissue, comprising separating thecell or tissue from the culture of (32).

(36) The recovery method of (35), wherein the aforementioned separationis performed by filtration, centrifugation or magnetic separation.

(37) A method of producing a sphere, comprising cultivating an adherentcell in the medium composition of any one of (1) to (31).

(38) A method of screening for an anticancer drug, comprising

(a) a step of cultivating a cancer cell in the presence of a testsubstance and in the absence thereof in the medium composition of anyone of claims 1 to 31, and

(b) a step of analyzing changes in the proliferation of the cancer cell.

(39) The method of (38), further comprising a step of selecting, as acandidate substance, a substance that suppresses the proliferation ofthe cancer cell than in the absence of the test substance.

(40) A method of screening for a pharmaceutical product candidatesubstance that acts on hepatocytes, comprising

(a) a step of cultivating hepatocytes in the presence of a testsubstance and in the absence thereof in the medium composition of anyone of claims 1 to 31, and

(b) a step of analyzing changes in the physiological function of thehepatocytes.

(41) The method of (40), further comprising a step of selecting, as acandidate substance, a substance that suppresses or increases thephysiological function of the hepatocytes than in the absence of thetest substance.

(42) A method of evaluating the efficacy or toxicity of a pharmaceuticalproduct candidate substance that acts on hepatocytes, comprising

(a) a step of cultivating hepatocytes in the presence of a testsubstance and in the absence thereof in the medium composition of anyone of claims 1 to 31, and

(b) a step of analyzing changes in the physiological function of thehepatocytes.

(43) A medium additive for preparing a medium composition capable ofculturing cells or tissues by suspending them, comprising a polymercompound dissolved or dispersed in a solvent.

(44) The medium additive of (43), which is in a sterilized state.

(45) The medium additive of (43) or (44), wherein the aforementionedpolymer compound is a polymer compound having an anionic functionalgroup.

(46) The medium additive of (43) or (44), wherein the aforementionedpolymer compound is a deacylated gellan gum or a salt thereof.

(47) A method of producing a medium composition capable of culturingcells or tissues by suspending them, comprising mixing a polymercompound and a medium.

(48) The method of (47), comprising mixing the medium additive of anyone of (43) to (46) and a medium.

(49) The method of (48), wherein the aforementioned medium is dissolvedor dispersed in a solvent.

(50) The method of (47), wherein the aforementioned polymer compound isa polymer compound having an anionic functional group.

(51) The method of (50), wherein the aforementioned polymer compound isdeacylated gellan gum or a salt thereof.

(52) The method of (47), wherein the aforementioned polymer compound andthe medium are mixed with water.

(53) The method of (52), comprising heating at 80-130° C. after mixingwith water.

(54) The method of (53), comprising heating at 100-125° C.

(55) The method of (47), comprising filtration sterilization.

(56) The method of (55), wherein the aforementioned filtrationsterilization includes passage through a 0.1-0.5 μm filter.

(57) An additive for a medium for cancer cells, comprising deacylatedgellan gum or a salt thereof, or diutan gum or a salt thereof.

(58) The additive of (57) that promotes proliferation of a cancer cellin culturing the cancer cell.

(59) The additive of (57), which is used for evaluating the anticanceractivity of an anticancer drug.

(60) A medium composition for cancer cells, comprising the additive ofany one of (57) to (59).

(61) A method of culturing a cancer cell, comprising cultivating thecancer cell in the presence of the additive of any one of (57) to (59),or in the medium composition of (60).

(62) A method of evaluating the activity of an anticancer drug to acancer cell, comprising cultivating the cancer cell in the presence ofthe additive of any one of (57) to (59), or in the medium composition of(60).

(63) The method of (61) or (62), wherein the cancer cells form a cellaggregate in the medium composition for the cancer cell.

(64) The method of (61) or (62), wherein a culture container forcultivating the cancer cell suppresses attachment of the cancer cell.

(65) An additive for a medium for hepatocytes, comprising deacylatedgellan gum or a salt thereof, or diutan gum or a salt thereof.

(66) The additive of (65), which suppresses a decrease in the number ofhepatocytes in culturing the hepatocytes.

(67) The additive of (65), which is used for evaluating the effect of apharmaceutical product and a pharmaceutical product candidate drug onhepatocytes.

(68) A medium composition for hepatocytes, comprising the additive ofany one of (65) to (67).

(69) A method of evaluating the activity of a pharmaceutical product anda pharmaceutical product candidate drug to hepatocytes, comprisingcultivating the hepatocytes in the presence of the additive of any oneof (65) to (67), or in the medium composition of (68).

(70) The method of (69), wherein the hepatocytes form a cell aggregatein the medium composition for hepatocytes.

(71) The method of (69), wherein a culture container for cultivatinghepatocytes suppresses attachment of the hepatocyte.

Effects of the Invention

The present invention provides a medium composition containing astructure of a particular compound (hereinafter to be also referred toas a particular compound), particularly a polymer compound having ananionic functional group. Using the medium composition, cells and/ortissues can be cultivated in a suspended state without an operation suchas shaking, rotation and the like having a risk of causing injury andloss of functions of cells and tissues. Furthermore, using the mediumcomposition, the medium can be exchanged easily during culture, and thecultured cells and/or tissues can also be recovered easily. The presentinvention applies the culture method to the cells and/or tissuescollected from an animal body or a plant body, and can prepare theobject cells and/or tissues in a large amount without impairing thefunctions thereof. The cells and/or tissues obtained by the culturemethod can be utilized when performing efficacy and toxicity evaluationof chemical substances, pharmaceutical products and the like,large-scale production of useful substances such as enzymes, cell growthfactors, antibodies and the like, regenerative medicine forsupplementing organ, tissue and cell that were lost by disease anddeficiency, and the like. Particularly, a medium composition prepared byusing deacylated gellan gum is superior, and has the followingcharacteristics. Since the concentration for expressing the property isextremely low (one order or so lower), an influence on the mediumcomponent can be suppressed to the minimum. Since lump is not easilyformed when dissolved in water, large-scale production does not easilycause trouble. Furthermore, since the viscosity in the concentrationrange where the property is expressed is low, the operability such asrecovery of cells and/or tissues and the like is extremely good.

In addition, using the medium composition of the present invention,association of the cancer cell aggregates (spheres) can be suppressed,and the sphere can be cultivated in a dispersed state, and therefore,the proliferation of cancer cell can be promoted. Moreover, when ananticancer drug is evaluated using the medium composition, theanticancer drug can be easily added to a medium, and a detection reagentfor evaluating cell proliferation can be easily added. In addition,since the cultured cancer cells can be recovered, a function evaluationof the recovered cells can also be easily performed. The presentinvention can be preferably utilized when performing efficacy evaluationof and screening for a chemical substance, an anticancer drug and thelike with cancer cells obtained by the culture method.

When cultivated in the medium composition of the present invention,since an influence from the non-in vivo environment in two-dimensionalculture is small and only an adhesion between cells occurs, thesensitivity of HB-EGF (heparin binding epidermal growth factor-likegrowth factor) that promotes canceration becomes high in cancer cells,and the sensitivity to an EGF receptor inhibitor at the downstreamthereof can be enhanced. Furthermore, the sensitivity to inhibitors ofMEK and Akt, which are important signal transduction pathways for cancercell scaffold-independent proliferation, can also be enhanced.

Alternatively, using the medium composition of the present invention,association of hepatocyte aggregates (spheres) can be suppressed, andthe spheres can be cultivated in a dispersed state. Therefore, thesurvival and cell function of hepatocytes can be maintained in vitro.Furthermore, when evaluation of a pharmaceutical product candidate drugor a pharmaceutical product is performed using the medium composition,the pharmaceutical product candidate drug or pharmaceutical product canbe easily added to the medium, and a detection reagent for evaluation ofcell function can be added easily. Since cultured hepatocytes can berecovered, a functional evaluation of the recovered cells can beperformed easily. The present invention can be preferably utilized whenperforming efficacy and toxicity evaluation and screening for a chemicalsubstance, an anticancer drug and the like with hepatocytes obtained bythe culture method.

Moreover, the medium additive of the present invention containingdeacylated gellan gum or a salt thereof can markedly promote theproliferation of cancer cells when culturing the cancer cells.

Also, the medium additive of the present invention containing deacylatedgellan gum or a salt thereof can suppress a decrease in the number ofhepatocytes when culturing the hepatocytes.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIG. 1 is a Figure showing that, when spheres of HepG2 cells werecultured in the medium composition of the present invention, the sphereswere uniformly dispersed and could be cultured in a suspended state.

FIG. 2 is a Figure showing that, when spheres of HeLa cells werecultured in the medium composition of the present invention, the sphereswere uniformly dispersed and could be cultured in a suspended state.

FIG. 3 is a Figure showing that, when spheres of HeLa cells werecultured in the medium composition of the present invention and observedwith a microscope, association of the spheres could be suppressedcompared to existing media.

FIG. 4 is a Figure showing that, when pluripotent stem cells werecultured in the medium composition of the present invention, toxicity tothe cells was not found.

FIG. 5 is a Figure showing that, when spheres of pluripotent stem cellswere cultured in the medium composition of the present invention, thespheres were uniformly dispersed and were in a suspended state.

FIG. 6 is a Figure showing that, when spheres of pluripotent stem cellswere cultured in the medium composition of the present invention, thepluripotent stem cells were efficiently proliferated.

FIG. 7 is a Figure showing that pluripotent stem cells cultured in themedium composition of the present invention remained undifferentiated.

FIG. 8 is a Figure showing that pluripotent stem cells after suspensionstatic culture in the medium composition of the present inventionmaintained a normal karyotype.

FIG. 9 is a Figure showing that pluripotent stem cells cultured in themedium composition of the present invention remained undifferentiated.

FIG. 10 is a Figure showing that, when microcarriers attached with HepG2cells was cultured in the medium composition of the present invention,the HepG2 cells could be proliferated on the microcarrier.

FIG. 11 is a Figure showing that, when spheres of HeLa cells were addedto the medium composition of the present invention, the spheres wereuniformly dispersed and were in a suspended state.

FIG. 12 is a Figure showing that spheres of HeLa cells could be formedin the medium composition of the present invention.

FIG. 13 is a Figure showing a film, which is one embodiment of thestructure of the present invention, wherein the concentration of thedeacylated gellan gum in the medium composition was 0.02%(weight/volume).

FIG. 14 is a Figure showing that spheres of HepG2 cells could be formedin the medium composition of the present invention.

FIG. 15 is a Figure showing the suspended state of laminin-coated GEMattached with HepG2 cells, when it was cultured in the mediumcomposition of the present invention.

FIG. 16 is a Figure showing the suspended state of HepG2 cells embeddedin alginic acid beads, when they were cultured in the medium compositionof the present invention.

FIG. 17 is a Figure showing the suspended state of HepG2 cells embeddedin a collagen gel capsule, when they were cultured in the mediumcomposition of the present invention.

FIG. 18 is a Figure showing the suspended state of rice-derived calluswhen cultured in the medium composition of the present invention.

FIG. 19 is a Figure showing that, when spheres of HeLa cells werecultured in the medium composition of the present invention, the sphereswere uniformly dispersed and could be cultured in a suspended state.

FIG. 20 is a Figure showing that, when spheres of A549 cells and HCT116cells were cultured in the medium composition of the present invention,the spheres were uniformly dispersed and could be cultured in asuspended state.

FIG. 21 is a Figure showing that, when human primary hepatocytes werecultured in the medium composition of the present invention, sphereswere formed and could be cultured.

FIG. 22 is a Figure showing that, when Cynomolgus monkey primaryhepatocytes were cultured in the medium composition of the presentinvention, spheres were formed and could be cultured.

FIG. 23 is a Figure showing MCF-7 cell aggregates after culturing MCF-7cells for 5 days in the medium composition of the present invention.

FIG. 24 is a Figure showing aggregates after culturing A375 cells andMNNG/HOS cells for 4 days in the medium composition of the presentinvention.

FIG. 25 is a Figure showing aggregates after culturing MIAPaCa-2 cellsfor 6 days in the medium composition of the present invention.

DESCRIPTION OF EMBODIMENTS

The present invention is explained in more detail in the following.

The terms used in the present specification are defined as follows.

The cell in the present invention is a most basic unit constitutinganimals and plants, which has, as its elements, cytoplasm and variousorganelles inside the cellular membrane. In this case, the nucleusencapsulating the DNA may or may not be contained intracellularly. Forexample, the animal-derived cells in the present invention includereproductive cells such as spermatozoon, oocyte and the like, somaticcells constituting the living body, stem cells (pluripotent stem cellsetc.), progenitor cells, cancer celsl separated from the living body,cells separated from the living body, which acquired immortalizingability and is maintained stably in vitro (cell line), cells separatedfrom the living body and applied with artificial genetic modification,cells separated from the living body wherein the nucleus is artificiallyexchanged, and the like. Examples of the somatic cells constituting theliving body include, but are not limited to, fibroblast, bone marrowcells, B lymphocytes, T lymphocytes, neutrophils, red blood cells,platelets, macrophages, monocytes, osteocytes, bone marrow cells,pericytes, dendritic cells, keratinocytes, adipocytes, mesenchymalcells, epithelial cells, epidermal cells, endothelial cells, vascularendothelial cells, hepatocytes, chondrocytes, cumulus cells, nervesystem cells, glial cells, neurons, oligodendrocytes, microglial,astrocytes, heartcells, esophagus cells, myocytes (e.g., smooth musclecells or skeletal muscle cells), pancreas beta cells, melanincells,hematopoietic progenitor cells (e.g., cord blood derived CD34 positivecells), mononuclear cells and the like. The somatic cells include cellscollected from any tissue, for example, skin, kidney, spleen, adrenalgland, liver, lung, ovary, pancreas, uterus, stomach, colon, smallintestine, large intestine, bladder, prostate, testis, thymus, muscle,bond tissue, bone, joints, blood vessel tissue, blood (including cordblood), bone marrow, heart, eye, brain, nerve tissue and the like. Stemcells are cells concurrently having an ability to replicate itself, andan ability to differentiate into other plural lineages. Examples thereofinclude, but are not limited to, embryonic stem cells (ES cell),embryonic tumor cells, embryonic reproductive stem cells, artificialpluripotent stem cells (iPS cell), neural stem celsl, hematopoietic stemcells, mesenchymal stem cells, liver stem cells, pancreas stem cells,muscle stem cells, reproductive stem cells, intestinal stem cells,cancer stem cells, hair follicle stem cells and the like. Examples ofthe pluripotent stem cells include ES cells, embryonic reproductive stemcells and iPS cells, from among the aforementioned stem cells.Progenitor cells are cells on the way to differentiate from theaforementioned stem cell into a particular somatic cell or reproductivecell. Cancer cells are cells that are derived from a somatic cell andhave acquired infinite proliferative capacity. Cell lines are cells thathave acquired infinite proliferative capacity by an artificial operationin vitro.

Examples of the cancer tissue include, but are not limited to, tissuesfrom gastric cancer, esophagus cancer, large intestine cancer, coloncancer, rectal cancer, pancreatic cancer, breast cancer, ovarian cancer,prostate cancer, flat epithelial cell cancer, basal cell carcinoma,adenocarcinoma, bone marrow cancer, kidney cell cancer, urinary ductcancer, liver cancer, cholangiocarcinoma, cervical cancer, endometrialcancer, testis cancer, small cell lung cancer, non-small cell lungcancer, bladder cancer, epithelial cancer, craniopharyngioma, laryngealcancer, tongue cancer, fiber sarcoma, mucosasarcoma, liposarcoma,chondrosarcoma, osteogenic sarcoma, chordoma, blood vessel sarcoma,lymphangiosarcoma, lymphangioendothelial sarcoma, synovial sarcoma,mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, seminoma,Wilms' tumor, glioma, astrocytoma, bone marrow sarcoma, meningioma,melanoma, neuroblastoma, medulloblastoma, retina blastoma, malignantlymphoma, and blood derived from cancer patients and the like. Examplesof the cancer cell line include, but are not limited to, HBC-4, BSY-1,BSY-2, MCF-7, MCF-7/ADR RES, HS578T, MDA-MB-231, MDA-MB-435, MDA-N,BT-549, T47D as human breast cancer cell lines, HeLa as human cervicalcarcinoama cell line, A549, EKVX, HOP-62, HOP-92, NCI-H23, NCI-H226,NCI-H322M, NCI-H460, NCI-H522, DMS273, DMS114 as human lung cancer cellline, Caco-2, COLO-205, HCC-2998, HCT-15, HCT-116, HT-29, KM-12, SW-620,WiDr as human large intestine cancer cell line, DU-145, PC-3, LNCaP ashuman prostate cancer cell line, U251, SF-295, SF-539, SF-268, SNB-75,SNB-78, SNB-19 as human central nervous system cancer cell line,OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, SK-OV-3, IGROV-1 as human ovariancancer cell line, RXF-631L, ACHN, UO-31, SN-12C, A498, CAKI-1, RXF-393L,786-0, TK-10 as human kidney cancer cell line, MKN45, MKN28, St-4,MKN-1, MKN-7, MKN-74 as human gastric cancer cell line, LOX-IMVI, LOX,MALME-3M, SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62, UACC-257, M14 as skincancer cell line, CCRF-CRM, K562, MOLT-4, HL-60 TB, RPMI8226, SR,UT7/TPO, Jurkat as leukemia cell line, A431 as human epithelial likecancer cell line, A375 as human melanoma cell line, MNNG/HOS as humanosteosarcoma cell line, MIAPaCa-2 as human pancreatic cancer cell line,and the like. Examples of the cell line include, but are not limited to,HEK293 (human embryonic kidney cell), MDCK, MDBK, BHK, C-33A, AE-1, 3D9,Ns0/1, NIH3T3, PC12, S2, Sf9, Sf21, High Five (registered trade mark),Vero and the like.

Examples of the hepatocytes in the present invention include primaryhepatocytes collected from liver tissue, hepatocyte strain establishedby passage culture under conditions optimized for in vitro culture, andhepatocytes differentiated and induced in vitro from cells derived froma tissue other than the liver, pluripotent stem cells such as iPS cells,ES cells and the like, mesenchymal stem cells, stem cells derived fromperipheral blood, myeloid stem cells, adipose stem cells, liver stemcells, liver progenitor cells, and the like. The liver tissue is a livercollected from human, rat, mouse, guinea pig, hamster, rabbit, swine,bovine, horse, dog, cat, monkey etc., which may be a normal liver or acancerated liver. While the primary hepatocytes can be separated andrecovered from such liver by a perfusion method using collagenase, itmay be purchased from reagent companies such as Primarycell, JapanBecton Dickinson and Company, Takara Bio Inc., Hokkaido System ScienceCo., Ltd., Lonza Japan, Veritas Ltd., Life Technologies JapanCorporation and the like. The purchased hepatocytes may be in a frozenstate or attached to a carrier such as collagen and the like. Examplesof the hepatocyte cell lines include, but are not limited to, HepG2,Hep3B, HepaRG (registered trade mark), JHH7, HLF, HLE, PLC/PRF/5, WRL68,HB611, SK-HEP-1, HuH-4, HuH-7 and the like.

While the function of the hepatocytes in the present invention is notparticularly limited, it includes expression of the activity ofcytochrome P450 (also referred to as CYP) such as CYP1A1, CYP1A2,CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5and the like and metabolism of pharmaceutical products and the like bythese enzymes, conjugation of pharmaceutical products and the like byglucuronic acid, glutathione, sulfuric acid, glycine and the like,production of useful proteins such as albumin, apolipoproteins,thrombopoietin and the like, secretion of bilirubin, synthesis of urea,synthesis of bile acid and fatty acid, transport of pharmaceuticalproducts and the like by transporters, and the like. In the embodimentof the present invention, the hepatocytes preferably maintains, from theabove-mentioned functions, activity of cytochrome P450, production ofalbumin and/or transport of pharmaceutical products and the like bytransporters (for example, uptake of Carboxydichlorofluoresceindiacetate, Tetraethylammonium Bromide, Taurocholate, Rosvastatin andexcretion of Carboxydichlorofluorescein).

The pharmaceutical products in the present invention include anysubstance applied to medical use. The pharmaceutical product candidatedrug is a substance which has been the subject of search or developmentand research as a candidate for a pharmaceutical product, and includessynthesis compound, protein, nucleic acid, saccharides, naturallyoccurring substance and the like.

The anticancer drug in the present invention includes medicaments thatdirectly act on the cancer cells and suppress proliferation and functionof the cancer cell, as well as medicaments that do not directly act onthe cancer cell but suppress proliferation or function of the cancercell, or kill the cancer cell by a collaborative action with immunocytein vivo or other medicaments. Examples of the anticancer drug include,but are not limited to, alkylating agent, platinum derivative, metabolicantagonist represented by 5-FU's anticancer drug, topoisomeraseinhibitor, microtubule inhibitor, anticancer antibiotic represented byepirubicin, molecular target drug represented by gefitinib, trastuzumab,cetuximab, erlotinib, panitumumab, lapatinib, temsirolimus, everolimus,ipilimumab, vandetanib, crizotinib, ruxolitinib, trametinib, and thelike. Examples of the target molecule of the molecular target druginclude, but are not limited to, various kinases, Her2, EGFR (epidermalgrowth factor receptor), PI3K (phosphatidyl inositol 3-kinase), mTOR(mammals rapamycin target protein), Akt, CDK (cyclin dependent kinase),VEGFR (vascular endothelial cell proliferation factor receptor), PDGFR(platelet-derived growth factor receptor), FGFR (fibroblast growthfactor receptor), c-Met, Raf, p38 MAPK, CTLA-4, ALK, JAK, MEK (MAPK/ERKkinase), Hsp90, histone deacetylase and the like. Furthermore, syntheticcompounds, proteins, nucleic acids, saccharides, natural products to bethe candidates for medicaments having such effects are also included inthe anticancer drug in the present invention.

The plant-derived cell in the present invention also includes cellsseparated from each tissue of a plant body, as well as a protoplastobtained by artificially removing the cell wall from the cell.

The tissue in the present invention is a unit of a structure which is anassembly in a certain manner of cells having some kinds of differentproperties and functions, and examples of the animal tissue includeepithelial tissue, bond tissue, muscular tissue, nerve tissue and thelike. Examples of the plant tissue include meristem, epidermis tissue,assimilation tissue, mesophyll tissue, conductive tissue, mechanicaltissue, parenchyma tissue, dedifferentiated cell cluster (callus) andthe like.

When cells and/or tissues are cultivated by the method of the presentinvention, the cells and/or tissues to be cultivated can be selectedfreely from the cells and/or tissues described above and cultivated. Thecells and/or tissues can be directly recovered from an animal or plantbody. The cells and/or tissues may be induced, grown or transformed froman animal or plant body by applying a particular treatment and thencollected. In this case, the treatment may be in vivo or in vitro.Examples of the animal include insect, fish, amphibian, reptiles, birds,pancrustacea, hexapoda, mammals and the like. Examples of the mammalinclude, but are not limited to, rat, mouse, rabbit, guinea pig,squirrel, hamster, vole, platypus, dolphin, whale, dog, cat, goat,bovine, horse, sheep, swine, elephant, common marmoset, squirrel monkey,Macaca mulatta, chimpanzee and human. The plant is not particularlylimited as long as the collected cells and/or tissues can be applied toliquid culture. Examples thereof include, but are not limited to, plants(e.g., ginseng, periwinkle, henbane, coptis, belladonna etc.) producingcrude drugs (e.g., saponin, alkaloids, berberine, scopolin, phytosteroletc.), plants (e.g., blueberry, safflower, madder, saffron etc.)producing dye or polysaccharide (e.g., anthocyanin, safflower dye,madder dye, saffron dye, flavones etc.) to be a starting material forcosmetic or food, or plants producing a pharmaceutical drug substance,plants (rice, corn, wheat or barley etc.) to be feed or food and thelike.

Suspending of cells and/or tissues in the present invention refers to astate where cells and/or tissues do not adhere to a culture container(non-adhesive). Furthermore, in the present invention, when the cellsand/or tissues are proliferated, differentiated or maintained, the statewhere the cells and/or tissues are uniformly dispersed and suspended inthe liquid medium composition in the absence of a pressure on orvibration of the liquid medium composition from the outside or shaking,rotating operation and the like in the composition is referred to as“suspension standing”, and cultivation of the cells and/or tissues insuch condition is referred to as “suspension standing culture”. In the“suspension standing”, the period of suspending includes at least 5-60min, 1 hr-24 hr, 1 day-21 days, though the period is not limited theretoas long as the suspended state is maintained.

The medium composition of the present invention is a compositioncontaining a structure capable of culturing cells or tissues withsuspending (preferably capable of suspension standing culture) and amedium.

The medium composition of the present invention is preferably acomposition permitting an exchange treatment of the medium compositionduring culture, and recovery of the cells or tissues from the mediumcomposition after completion of the culture. More preferably, it is acomposition that does not require any of a temperature change, achemical treatment, an enzyme treatment and a shear force duringrecovery of the cells or tissues from the medium composition.

The structure in the present invention is formed from a particularcompound and shows an effect of uniformly suspending cells and/ortissues. More particularly, it includes an assembly of polymer compoundsvia an ion, a three-dimensional network formed by polymer compounds andthe like. It is known that polysaccharides form a microgel via a metalion (e.g., JP-A-2004-129596), and the structure of the present inventionalso includes such microgel as one embodiment.

One embodiment of the assembly of polymer compounds via an ion is a filmstructure. Such film is shown in FIG. 13 as an example.

The size of the structure in the present invention is preferably a sizethat passes a filter having a pore size of 0.2 μm to 200 μm when it ispassed through a filter. The lower limit of the pore size is morepreferably more than 1 μm and, in consideration of stable suspension ofcells or tissues, it more preferably exceeds 5 μm. The upper limit ofthe pore size is more preferably less than 100 μm and, in considerationof the size of the cells or tissues, it is more preferably less than 70μm.

The particular compound in the present invention refers to a compoundthat forms, upon mixing with a liquid medium, an indeterminate structurewhich is uniformly dispersed in the liquid, substantially retains thecells and/or tissues without substantially increasing the viscosity ofthe liquid, and shows an effect of preventing sediment thereof. The“without substantially increasing the viscosity of the liquid” meansthat the viscosity of the liquid does not exceed 8 mPa·s. In this case,the viscosity of the liquid (that is, the viscosity of the mediumcomposition of the present invention) is not more than 8 mPa·s,preferably not more than 4 mPa·s, more preferably not more than 2 mPa·s.Furthermore, the chemical structure, molecular weight, property etc. ofthe particular compound are not limited as long as it forms thestructure in a liquid medium, and shows an effect of uniformlysuspending (preferably suspension standing) the cells and/or tissueswithout substantially increasing the viscosity of the liquid.

The viscosity of the liquid containing the structure can be measured,for example, by the method described in the below-mentioned Examples.Specifically, it can be measured under 37° C. conditions and using anE-type viscosity meter (manufactured by Toki Sangyo Co., Ltd., TV-22type viscosity meter, model: TVE-22L, corn roter: standard roter 1°34′×R24, rotation number 100 rpm).

Examples of the particular compound to be used in the present inventioninclude, but are not limited to, polymer compounds, preferably a polymercompound having an anionic functional group.

As the anionic functional group, carboxy group, sulfo group, phosphategroup and a salt thereof can be mentioned, with preference given tocarboxy group or a salt thereof.

As a polymer compound to be used in the present invention, one havingone or more kinds selected from the aforementioned anionic functionalgroups can be used.

Preferable specific examples of the polymer compound to be used in thepresent invention include, but are not limited to, polysaccharideswherein not less than 10 single saccharides (e.g., triose, tetrose,pentose, hexsauce, heptose etc.) are polymerized, more preferably,acidic polysaccharides having an anionic functional group. The acidicpolysaccharides here is not particularly limited as long as it has ananionic functional group in the structure thereof, and includes, forexample, polysaccharides having a uronic acid (e.g., glucuronic acid,iduronic acid, galacturonic acid, mannuronic acid), polysaccharideshaving a sulfuric acid group or phosphate group in a part of thestructure thereof, and polysaccharides having the both structures, andincludes not only naturally-obtained polysaccharides but alsopolysaccharides produced by microorganisms, polysaccharides produced bygenetic engineering, and polysaccharides artificially synthesized usingan enzyme. More specifically, examples thereof include polymer compoundscomposed of one or more kinds selected from the group consisting ofhyaluronic acid, gellan gum, deacylated gellan gum (hereinaftersometimes to be referred to as DAG), rhamsan gum, diutan gum, xanthangum, carageenan, xanthan gum, hexuronic acid, fucoidan, pectin, pecticacid, pectinic acid, heparan sulfate, heparin, heparitin sulfate,keratosulfate, chondroitin sulfate, dermatan sulfate, rhamnan sulfateand a salt thereof. Polysaccharides are preferably hyaluronic acid, DAG,diutan gum, xanthan gum, carageenan or a salt thereof, most preferablyDAG since use thereof at a low concentration can suspend cells ortissues and in consideration of easy recovery of the cells or tissues.

The salt here includes, for example, alkali metal salts such as lithium,sodium, potassium, salts with alkaline earth metals such as calcium,barium, magnesium and salts with aluminum, zinc, copper, iron, ammonium,organic base and amino acid and the like salt.

The weight average molecular weight of these polymer compounds(polysaccharides etc.) is preferably 10,000 to 50,000,000, morepreferably 100,000 to 20,000,000, still more preferably 1,000,000 to10,000,000. For example, the molecular weight can be measured based onpullulan by gel penetration chromatography (GPC).

As described in the below-mentioned Examples, phosphorylated DAG canalso be used. The phosphorylation can be performed by a known method.

In the present invention, plural kinds (preferably two kinds) of theabove-mentioned polysaccharides can be used in combination. The kind ofthe combination of the polysaccharides is not particularly limited aslong as the aforementioned structure is formed in a liquid medium, andthe cells and/or tissues can be uniformly suspended (preferablysuspension stood) without substantially increasing the viscosity of theliquid. Preferably, the combination includes at least DAG or a saltthereof. That is, a preferable combination of polysaccharides containsDAG or a salt thereof, and polysaccharides other than DAG and a saltthereof (e.g., xanthan gum, alginic acid, carageenan, diutan gum,methylcellulose, locust bean gum or a salt thereof). Examples ofspecific combination of polysaccharides include, but are not limited to,DAG and rhamsan gum, DAG and diutan gum, DAG and xanthan gum, DAG andcarageenan, DAG and xanthan gum, DAG and locust bean gum, DAG andκ-carageenan, DAG and sodium alginate, DAG and methylcellulose and thelike.

More preferable specific examples of the particular compound to be usedin the present invention include hyaluronic acid, deacylated gellan gum,diutan gum, carageenan and xanthan gum and a salt thereof. Mostpreferable examples include deacylated gellan gum and a salt thereof,since the viscosity of the medium composition can be made low and thecells or tissues can be easily recovered.

The deacylated gellan gum in the present invention is a linear polymerpolysaccharide containing 4 molecules of sugars of 1-3 bonded glucose,1-4 bonded glucuronic acid, 1-4 bonded glucose and 1-4 bonded rhamnoseas the constituent unit, which is a polysaccharide of the followingformula (I) wherein R1, R2 are each a hydrogen atom, and n is an integerof two or more. R1 may contain a glyceryl group, R2 may contain anacetyl group, and the content of the acetyl group and glyceryl group ispreferably not more than 10%, more preferably not more than 1%.

The structure in the present invention takes various forms depending onthe particular compound. In the case of deacylated gellan gum, ituptakes a metal ion (e.g., calcium ion) in a liquid medium when mixedwith the liquid medium, forms an indeterminate structure via the metalion, and suspends the cells and/or tissues. The viscosity of the mediumcomposition of the present invention prepared from deacylated gellan gumis not more than 8 mPa·s, preferably not more than 4 mPa·s, and morepreferably not more than 2 mPa·s for easy recovery of the cells ortissues.

The particular compound in the present invention can be obtained by achemical synthesis method. When the compound is a naturally-occurringsubstance, it is preferably obtained from various plants, variousanimals, various microorganisms containing the compound by extraction,separation and purification by conventional techniques. For extraction,the compound can be extracted efficiently by using water andsupercritical gas. For example, as a production method of gellan gum, aproducing microorganism is cultured in a fermentation medium, a mucosalsubstance produced outside fungus is recovered by a general purificationmethod and, after the steps of drying, pulverizing and the like,powderized. When it is deacylated gellan gum, an alkali treatment isapplied when a mucous substance is recovered, the glyceryl group and theacetyl group bonded to 1-3 bonded glucose residue are deacylated andrecovered. Examples of the purification method include liquid-liquidextraction, fractional precipitation, crystallization, various kinds ofion exchange chromatography, gel filtration chromatography usingSephadex LH-20 and the like, adsorption chromatography using activatedcarbon, silica gel and the like, adsorption and desorption treatment ofactive substance by thin layer chromatography, high performance liquidchromatography using reversed-phase column and the like, and impuritycan be removed and the compound can be purified by using them singly orin combination in any order, or repeatedly. Examples of the gellangum-producing microorganism include, but are not limited to,Sphingomonas elodea and microorganism obtained by altering the gene ofSphingomonas elodea.

When it is deacylated gellan gum, commercially available products, forexample, “KELCOGEL (registered trade mark of CP Kelco) CG-LA”manufactured by SANSHO Co., Ltd., “KELCOGEL (registered trade mark of CPKelco)” manufactured by San-Ei Gen F.F.I., Inc. and the like can beused. As native-type gellan gum, “KELCOGEL (registered trade mark of CPKelco) HT” manufactured by San-Ei Gen F.F.I., Inc. and the like can beused.

The concentration of the particular compound in a medium depends on thekind of the particular compound, and can be appropriately determinedwithin the range where the particular compound can form theaforementioned structure in a liquid medium, and can uniformly suspend(preferably suspension stand) the cells and/or tissues withoutsubstantially increasing the viscosity of the liquid. It is generally0.0005% to 1.0% (weight/volume), preferably 0.001% to 0.4%(weight/volume), more preferably 0.005% to 0.1% (weight/volume), stillmore preferably 0.005% to 0.05% (weight/volume). For example, in thecase of deacylated gellan gum, it is added to a medium at 0.001% to 1.0%(weight/volume), preferably 0.003% to 0.5% (weight/volume), morepreferably 0.005% to 0.1% (weight/volume), more preferably 0.01% to0.05% (weight/volume), most preferably, 0.01% to 0.03% (weight/volume).In the case of xanthan gum, it is added to a medium at 0.001% to 5.0%(weight/volume), preferably 0.01% to 1.0% (weight/volume), morepreferably 0.05% to 0.5% (weight/volume), most preferably 0.1% to 0.2%(weight/volume). In the case of a K-carageenan and locust bean gummixture, it is added to a medium at 0.001% to 5.0% (weight/volume),preferably 0.005% to 1.0% (weight/volume), more preferably 0.01% to 0.1%(weight/volume), most preferably 0.03% to 0.05% (weight/volume). In thecase of native-type gellan gum, it is added to a medium at 0.05% to 1.0%(weight/volume), preferably 0.05% to 0.1% (weight/volume).

When plural kinds (preferably two kinds) of the above-mentionedpolysaccharides are used in combination, the concentration of thepolysaccharides can form the aforementioned structure in a liquidmedium, and can uniformly suspend (preferably suspension stand) thecells and/or tissues without substantially increasing the viscosity ofthe liquid. For example, when a combination of DAG or a salt thereof andpolysaccharide other than DAG and a salt thereof is used, theconcentration of DAG or a salt thereof is, for example, 0.005-0.02%(weight/volume), preferably 0.01-0.02% (weight/volume), and theconcentration of polysaccharide other than DAG and a salt thereof is,for example, 0.005-0.4% (weight/volume), preferably 0.1-0.4%(weight/volume). Specific examples of the combination of theconcentration range include the following. DAG or a salt thereof:0.005-0.02% (preferably 0.01-0.02%) (weight/volume)

polysaccharide other than DAG

xanthan gum: 0.1-0.4% (weight/volume)

sodium alginate: 0.1-0.4% (weight/volume)

locust bean gum: 0.1-0.4% (weight/volume)

methylcellulose: 0.1-0.4% (weight/volume) (preferably 0.2-0.4%(weight/volume))

carageenan: 0.05-0.1% (weight/volume)

diutan gum: 0.05-0.1% (weight/volume)

The concentration can be calculated by the following formula.Concentration (%)=weight (g) of particular compound/volume (ml) ofmedium composition×100

The aforementioned compound can also be further converted to a differentderivative by a chemical synthesis method, and the thus-obtainedderivative can also be used effectively in the present invention.Specifically, in the case of deacylated gellan gum, a derivative of acompound represented by the formula (I) wherein a hydroxyl group for R1and/or R2 is substituted by C1-3 alkoxy group, C1-3 alkylsulfonyl group,a monosaccharide residue such as glucose, fructose and the like,oligosaccharide residue such as sucrose, lactose and the like, or aminoacid residue such as glycine, arginine and the like can also be used inthe present invention. In addition, the compound can also be crosslinkedusing a crosslinking agent such as1-ethyl-3-(3-di-methylaminopropyl)carbodiimide (EDC) and the like.

The particular compound or a salt thereof to be used in the presentinvention can be present in any crystal form depending on the productionconditions, and can be present as any hydrate. Such crystal form,hydrate and mixtures thereof are also encompassed in the scope of thepresent invention. In addition, they may be present as a solvatecontaining an organic solvent such as acetone, ethanol, tetrahydrofuranand the like. Such forms are all encompassed in the scope of the presentinvention.

The particular compound to be used in the present invention may bepresent in the form of tautomer formed by isomerization in the ring oroutside the ring, geometric isomer or tautomer, or a mixture ofgeometric isomers, or mixtures thereof. When the compound of the presentinvention has an asymmetric center, irrespective of whether the compoundis formed by isomerization, it may be present in the form of a resolvedoptical isomer or a mixture containing same at any ratio.

The medium composition of the present invention may contain a metal ion,for example, a divalent metal ion (calcium ion, magnesium ion, zinc ion,ferrous ion, copper ion etc.), and preferably contains calcium ion. Twoor more kinds of metal ions can be used in combination, for example,calcium ion and magnesium ion, calcium ion and zinc ion, calcium ion andferrous ion, and calcium ion and copper ion. Those of ordinary skill inthe art can appropriately determine the combination. In one embodiment,since the medium composition contains a metal ion, polymer compoundsgather via a metal ion and form a three-dimensional network (e.g.,polysaccharides form a microgel via a metal ion), whereby the structureof the present invention can be formed. The concentration of the metalion can be appropriately determined within the range where theparticular compound can form the aforementioned structure in a liquidmedium, and can uniformly suspend (preferably suspension stand) thecells and/or tissues without substantially increasing the viscosity ofthe liquid medium. The salt concentration is, but is not limited to, 0.1mM-300 mM, preferably 0.5 mM-100 mM. The metal ion may be mixed with amedium, or a salt solution is separately prepared and added to themedium. The medium composition of the present invention may contain thebelow-mentioned extracellular matrix, adhesion molecule and the like.

The present invention also includes a culture method for proliferatingcells or tissues by using the medium composition, a method of recoveringthe obtained cells or tissues by, for example, filtration,centrifugation or magnetic separation, and a production method of asphere by using the medium composition.

When cells and/or tissues are cultured in vitro, a structure composed ofthe particular compound to be used in the present invention shows aneffect of suspending (preferably effect of suspension standing) thecells and/or tissues in a liquid containing the structure of theparticular compound. By the suspending effect, a more increased amountof the cells and/or tissues per a given volume can be cultivated ascompared to a single layer culture. When a conventional floating culturemethod accompanies rotation or shaking operation, the proliferation rateand recovery rate of the cells and/or tissues may become low, or thefunction of the cell may be impaired since a shear force acts on thecells and/or tissues. Using the medium composition of the presentinvention, which contains a structure of the particular compound, canuniformly disperse the cells and/or tissues without an operation such asshaking and the like, and can obtain the object cells and/or tissueseasily in a large amount without loss of the cell function. In addition,when cells and/or tissues are suspension cultured in a conventionalmedium containing a gel substrate, observation and recovery of the cellsand/or tissues are sometimes difficult, and the function thereof issometimes impaired during recovery. However, using the mediumcomposition containing the structure of the particular compound of thepresent invention, the cells and/or tissues can be subjected tosuspension culture, observed without impairment of the function thereof,and can be recovered. In addition, a conventional medium containing agel substrate sometimes shows high viscosity that makes it difficult toexchange the medium. However, since the medium composition containingthe structure of the particular compound of the present invention haslow viscosity, it can be exchanged easily with a pipette, pump and thelike.

The human-derived cells and/or tissues cultured by the method of thepresent invention can be transplanted for a treatment object to patientshaving a disease or disorder. In this case, treatment target disease,the kind of disorder, a pre-treatment method and a cell transplantationmethod are appropriately selected by those of ordinary skill in the art.The engraftment of the transplanted cells in the recipient, recoveryfrom the disease or disorder, the presence or absence of side effectsassociated with transplantation, and treatment effect are appropriatelyexamined and judged by general methods for transplantation therapy.

Moreover, since the cells and/or tissues are efficiently proliferated bythe method of the present invention, a medium composition containing theparticular compound and a structure thereof of the present invention canbe used as a reagent for cell research. For example, when a factorcontrolling the differentiation and proliferation of cells and tissuesis to be elucidated, cells and the object factor are cocultured, and thenumber and kind of the cell, and changes in the cell surfacedifferentiation marker and expressed gene are analyzed. In this case,using the medium composition of the present invention, the number of theanalysis target cells can be efficiently amplified, and efficientlyrecovered as well. When the object factor is elucidated, the cultureconditions, culture apparatus, the kind of medium, the kind of thecompound of the present invention, the content of the particularcompound, the kind of the additive, the content of the additive, cultureperiod, culture temperature and the like are appropriately selected bythose of ordinary skill in the art from the range described in thepresent specification. The cell that was proliferated or emerged byculture can be observed using a standard microscope in the pertinentfield. In this case, cultured cells may be stained with a specificantibody. The expressed gene that has changed due to the object factorcan be found by extracting the DNA (deoxyribonucleic acid) or RNA(ribonucleic acid) from the cultured cells and detecting by SouthernBlotting, Northern Blotting, RT-PCR and the like. In addition, a cellsurface differentiation marker is detected by ELISA and flow cytometryusing a specific antibody, and the effect of the object factor on thedifferentiation and proliferation can be observed.

When cells and/or tissues are cultivated by the culture method of thepresent invention, culture tools generally used for cell culture such asschale, flask, plastic bag, Teflon (registered trade mark) bag, dish,schale, dish for tissue culture, multidish, microplate, microwell plate,multiplate, multiwall plate, chamber slide, cell culture flask, spinnerflask, tube, tray, culture bag, roller bottle and the like can be usedfor cultivation. While the materials of these culture tools are notparticularly limited, for example, glass, plastics such as polyvinylchloride, cellulosic polymers such as ethylcellulose, acetylcelluloseand the like, polystyrene, polymethylmethacrylate, polycarbonate,polysulfone, polyurethane, polyester, polyamide, polystyrene,polypropylene, polyethylene, polybutadiene, poly(ethylene-vinylacetate)copolymer, poly(butadiene-styrene) copolymer,poly(butadiene-acrylonitrile) copolymer, poly(ethylene-ethylacrylate)copolymer, poly(ethylene-methacrylate) copolymer, polychloroprene,styrol resin, chlorosulfonated polyethylene, ethylenevinyl acetate,acrylic block copolymer, and the like can be mentioned. These plasticsare not only superior in gas permeability with oxygen, carbon dioxideand the like, but also superior in industrial molding processability,can stand various sterilization treatments, and are preferablytransparent materials permitting observation of the inside of culturetools. Here, the method for sterilization treatment is not particularlylimited and, for example, radiation sterilization, ethylene oxide gassterilization, autoclave sterilization and the like can be mentioned.Moreover, these plastics may be applied with various surface treatments(e.g., plasma treatment, corona treatment etc.). Furthermore, theseculture tools may be coated in advance with an extracellular matrix, acell adhesion molecule and the like. Examples of the coating materialinclude collagen I to XIX, gelatin, fibronectin, vitronectin, laminin-1to 12, nitogen, tenascin, thrombospondin, von Willebrand factor,osteopontin, fibrinogen, various elastins, various proteoglycans,various cadherins, desmocolin, desmoglein, various integrins,E-selectin, P-selectin, L-selectin, immunoglobulin, hyaluronic acid,superfamily, Matrigel, poly-D-lysine, poly-L-lysine, chitin, chitosan,sepharose, alginic acid gel, hydrogel, cleavage fragments thereof andthe like. These coating materials having an amino acid sequenceartificially altered by gene recombination techniques can also be used.A coating material for inhibiting adhesion of the cells and/or tissuesto culture tools can also be used. Examples of the coating materialinclude, but are not limited to, silicon,poly(2-hydroxymethylmethacrylate), poly(2-methoxymethylacrylate),poly(2-methacryloyloxyethylphosphoryl choline),poly-N-isopropylacrylamide, mebiol gel (registered trade mark) and thelike.

The cells and/or tissues can also be cultured by automaticallyconducting cell seeding, medium exchange, cell image obtainment, andrecovery of cultured cells, under a mechanical control and under aclosed environment while controlling pH, temperature, oxygenconcentration and the like and using a bioreactor and an automaticincubator capable of high density culture. As a method for supplying anew medium and feeding the required substances to the cells and/ortissues during the culture using such apparatuses, fed-batch culture,continuous culture and perfusion culture are available, and all thesemethods can be used for the culture method of the present invention.Culture containers used for bioreactors and automatic incubators includeopen culture containers with easy opening-closing and a large contactarea with the outside world (for example, culture containers having alid), and closed culture containers with difficult ending-closing and asmall contact area with the outside world (for example, cartridge typeculture containers). Both culture containers can be used for the culturemethod of the present invention.

When cells and/or tissues are cultivated using the particular compoundin the present invention, a medium composition can be prepared by mixinga medium used for cultivating the cells and/or tissues and theparticular compound. According to the classification by such compositionof the medium, natural medium, semisynthetic medium and synthetic mediumcan be mentioned. According to the classification by the shape,semi-solid medium, liquid medium, powder medium (hereinafter sometimesto be referred to as powder medium) and the like can be mentioned. Whenthe cells and/or tissues are derived from an animal, any medium used forculturing animal cells can be used. Examples of the medium includeDulbecco's Modified Eagle's Medium (DMEM), hamF12 medium (Ham's NutrientMixture F12), DMEM/F12 medium, McCoy's 5A medium, Eagle MEM medium(Eagle's Minimum Essential Medium; EMEM), αMEM medium (alpha ModifiedEagle's Minimum Essential Medium; αMEM), MEM medium (Minimum EssentialMedium), RPMI1640 medium, Iscove's Modified Dulbecco's Medium (IMDM),MCDB131 medium, William medium E, IPL41 medium, Fischer's medium,StemPro34 (manufactured by Invitrogen), X-VIVO 10 (manufactured byCambrex Corporation), X-VIVO 15 (manufactured by Cambrex Corporation),HPGM (manufactured by Cambrex Corporation), StemSpan H3000 (manufacturedby STEMCELL Technologies), StemSpanSFEM (manufactured by STEMCELLTechnologies), Stemlinell (manufactured by Sigma Aldrich), QBSF-60(manufactured by Qualitybiological), StemPro hESC SFM (manufactured byInvitrogen), Essential8 (registered trade mark) medium (manufactured byGibco), mTeSR1 or 2 medium (manufactured by STEMCELL Technologies),ReproFF or ReproFF2 (manufactured by ReproCELL), PSGro hESC/iPSC medium(manufactured by System Biosciences), NutriStem (registered trade mark)medium (manufactured by Biological Industries), CSTI-7 medium(manufactured by Cell Science & Technology Institute, Inc.), MesenPRO RSmedium (manufactured by Gibco), MF-Medium (registered trade mark)mesenchymal stem cell proliferation medium (manufactured by TOYOBO CO.,LTD.), Sf-900II (manufactured by Invitrogen), Opti-Pro (manufactured byInvitrogen), and the like.

The medium to be used for culture of cancer cells can be theabove-mentioned medium added with a cell adhesion factor, and examplesthereof include Matrigel, collagen gel, gelatin, poly-L-lysine,poly-D-lysine, laminin and fibronectin. It is possible to add two ormore kinds of these cell adhesion factors in combination. Furthermore, amedium to be used for culture of cancer cell sphere can be further mixedwith a thickener such as guargum, tamarind gum, alginic acidpropyleneglycol, locust bean gum, gum arabic, tara gum, tamarind gum,methylcellulose and the like.

Examples of the medium to be used for culture of hepatocytes include, inaddition to the above-mentioned media, HepatoZYME-SFM (manufactured byLife Technologies), HCM (registered trade mark)-hepatocyte culturemedium Bullet Kit (registered trade mark, manufactured by Lonza), HBM(registered trade mark)-hepatocyte basic medium (manufactured by Lonza),HMM (registered trade mark)-hepatocyte maintenance medium (manufacturedby Lonza), modified Lanford's medium (manufactured by NISSUIPHARMACEUTICAL CO., LTD.), ISOM's medium, liver cell proliferationmedium (manufactured by Takara Bio Inc.), hepatocyte maintenance medium(manufactured by Takara Bio Inc.), hepatocyte basic medium (manufacturedby Takara Bio Inc.), activity maintenance super medium (manufactured byIn Vitro ADMET Laboratories) and the like. These media can contain acell adhesion factor, and examples thereof include Matrigel, collagengel, gelatin, poly-L-lysine, poly-D-lysine, laminin and fibronectin. Itis also possible to add two or more kinds of these cell adhesion factorsin combination. Furthermore, a medium to be used for culture of cancercell sphere or hepatocyte sphere can be further mixed with a thickenersuch as guargum, tamarind gum, alginic acid propyleneglycol, locust beangum, gum arabic, tara gum, tamarind gum, methylcellulose and the like.

When the cells and/or tissues are derived from a plant, a mediumobtained by adding auxins and, where necessary, a plant growth controlsubstance (plant hormone) such as cytokines and the like at a suitableconcentration to a basic medium such as Murashige Skoog (MS) medium,Linsmaier Skoog (LS) medium, White medium, Gamborg's B5 medium, nichemedium, hela medium, Morel medium and the like generally used forculture of plant tissues, or a modified medium wherein these mediumcomponents are modified to an optimal concentration (e.g., ammonianitrogen at a half concentration etc.) can be mentioned as the medium.These media can be further supplemented, where necessary, with caseindegrading enzyme, corn steep liquor, vitamins and the like. Examples ofthe auxins include, but are not limited to, 3-indoleacetic acid (IAA),3-indolebutyric acid (IBA), 1-naphthaleneacetic acid (NAA),2,4-dichlorophenoxyacetic acid (2,4-D) and the like. For example, auxinscan be added to a medium at a concentration of about 0.1-about 10 ppm.Examples of the cytokines include, but are not limited to, kinetin,benzyladenine (BA), zeatin and the like. For example, cytokines can beadded to a medium at a concentration of about 0.1-about 10 ppm.

Those of ordinary skill in the art can freely add, according to theobject, sodium, potassium, calcium, magnesium, phosphorus, chlorine,various amino acids, various vitamins, antibiotic, serum, fatty acid,sugar and the like to the above-mentioned medium. For culture ofanimal-derived cells and/or tissues, those of ordinary skill in the artcan also add, according to the object, one or more kinds of otherchemical components and biogenic substances in combination.

Examples of the components to be added to a medium for animal-derivedcells and/or tissues include fetal bovine serum, human serum, horseserum, insulin, transferrin, lactoferrin, cholesterol, ethanolamine,sodium selenite, monothioglycerol, 2-mercaptoethanol, bovine serumalbumin, sodium pyruvate, polyethylene glycol, various vitamins, variousamino acids, agar, agarose, collagen, methylcellulose, variouscytokines, various hormones, various proliferation factors, variousextracellular matrices, various cell adhesion molecules and the like.Examples of the cytokine to be added to a medium include, but are notlimited to, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3(IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6(IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9(IL-9), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12(IL-12), interleukin-13 (IL-13), interleukin-14 (IL-14), interleukin-15(IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), interferon-α(IFN-α), interferon-β (IFN-β), interferon-γ (IFN-γ), granulocyte colonystimulating factor (G-CSF), monocyte colony stimulating agent (M-CSF),granulocyte-macrophage colony stimulating agent (GM-CSF), stem cellfactor (SCF), flk2/flt3 ligand (FL), leukemia cell inhibitory factor(LIF), oncostatin M (OM), erythropoietin (EPO), thrombopoietin (TPO) andthe like.

Examples of the hormone to be added to a medium include, but are notlimited to, melatonin, serotonin, thyroxine, triiodothyronine,epinephrine, norepinephrine, dopamine, anti-Mullerian hormone,adiponectin, adrenocorticotropic hormone, angiotensinogen andangiotensin, antidiuretic hormone, atrial natriuretic peptide,calcitonin, cholecystokinin, corticotropin release hormone,erythropoietin, follicle stimulating hormone, gastrin, ghrelin,glucagon, gonadotropin release hormone, growth hormone release hormone,human chorionic gonadotropin, human placental lactogen, growth hormone,inhibin, insulin, insulin-like growth factor, leptin, luteinizinghormone, melanocyte stimulating hormone, oxytocin, parathyroid hormone,prolactin, gastrin-releasing peptide, somatostatin, thrombopoietin,thyroid gland stimulation hormone, thyrotropin releasing hormone,cortisol, androstenedione, testosterone, dehydroepiandrosterone,androstenedione, dihydrotestosterone, estradiol, estrone, estriol,progesterone, calcitriol, calcidiol, prostaglandin, leukotriene,prostacyclin, thromboxane, prolactin releasing hormone, lipotropin,brain natriuretic peptide, neuropeptide Y, histamine, endothelin,pancreas polypeptide, rennin and enkephalin.

Examples of the growth factor to be added to a medium include, but arenot limited to, transforming growth factor-α (TGF-α), transforminggrowth factor-β (TGF-β), macrophage inflammatory protein-1a (MIP-1α),epithelial cell growth factor (EGF), fibroblast growth factor-1, 2, 3,4, 5, 6, 7, 8 or 9 (FGF-1, 2, 3, 4, 5, 6, 7, 8, 9), nerve cell growthfactor (NGF) hepatocyte growth factor (HGF), leukemia inhibitory factor(LIF), protease nexin I, protease nexin II, platelet-derived growthfactor (PDGF), choline vasoactive differentiation factor (CDF),chemokine, Notch ligand (Deltal and the like), Wnt protein,angiopoietin-like protein 2, 3, 5 or 7 (Angpt2, 3, 5, 7), insulin likegrowth factor (IGF), insulin-like growth factor binding protein-1(IGFBP), Pleiotrophin and the like.

In addition, these cytokines and growth factors having amino acidsequences artificially altered by gene recombinant techniques can alsobe added. Examples thereof include IL-6/soluble IL-6 receptor complex,Hyper IL-6 (fusion protein of IL-6 and soluble IL-6 receptor) and thelike.

Examples of the various extracellular matrices and various cell adhesionmolecules include collagen I to XIX, fibronectin, vitronectin, laminin-1to 12, nitogen, tenascin, thrombospondin, von Willebrand factor,osteopontin, fibrinogen, various elastins, various proteoglycans,various cadherins, desmocolin, desmoglein, various integrins,E-selectin, P-selectin, L-selectin, immunity globulin superfamily,Matrigel, poly-D-lysine, poly-L-lysine, chitin, chitosan, sepharose,hyaluronic acid, alginate gel, various hydrogels, cleavage fragmentsthereof and the like.

Examples of the antibiotic to be added to a medium include Sulfonamidesand preparations, penicillin, phenethicillin, methicillin, oxacillin,cloxacillin, dicloxacillin, flucloxacillin, nafcillin, ampicillin,penicillin, amoxicillin, ciclacillin, carbenicillin, ticarcillin,piperacillin, azlocillin, mezlocillin, mecillinam, andinocillin,cephalosporin and a derivative thereof, oxolinic acid, amifloxacin,temafloxacin, nalidixic acid, Piromidic acid, ciprofloxacin, cinoxacin,norfloxacin, perfloxacin, Rosaxacin, ofloxacin, enoxacin, pipemidicacid, sulbactam, clavulanic acid, β-bromopenisillanic acid,β-chloropenisillanic acid, 6-acetylmethylene-penisillanic acid,cephoxazole, sultampicillin, adinoshirin and sulbactam formaldehydehudrate ester, tazobactam, aztreonam, sulfazethin, isosulfazethin,norcardicin, m-carboxyphenyl, phenylacetamidophosphonic acid methyl,Chlortetracycline, oxytetracycline, tetracycline, demeclocycline,doxycycline, methacycline, and minocycline.

When the particular compound in the present invention is added to theabove-mentioned medium, the particular compound is dissolved ordispersed in an appropriate solvent when in use (this is used as amedium additive). Thereafter, the medium additives can be added to amedium such that the concentration of the particular compound in themedium is, as detailedly described above, a concentration at which thecells and/or tissues can be uniformly suspended (preferably suspensionstood) without substantially increasing the viscosity of the liquidmedium, for example, 0.0005% to 1.0% (weight/volume), preferably 0.001%to 0.4% (weight/volume), more preferably 0.005% to 0.1% (weight/volume),further preferably 0.005% to 0.05% (weight/volume). For example, in thecase of deacylated gellan gum, it is added to a medium at 0.001% to 1.0%(weight/volume), preferably 0.003% to 0.5% (weight/volume), morepreferably 0.005% to 0.1% (weight/volume), most preferably 0.01% to0.03% (weight/volume). In another aspect, in the case of deacylatedgellan gum, it is added to a medium at 0.0005% to 1.0% (weight/volume),preferably 0.001% to 0.5% (weight/volume), more preferably 0.003% to0.1% (weight/volume), most preferably 0.005% to 0.03% (weight/volume).In the case of xanthan gum, it is added to a medium at 0.001% to 5.0%(weight/volume), preferably 0.01% to 1.0% (weight/volume), morepreferably 0.05% to 0.5% (weight/volume), most preferably 0.1% to 0.2%(weight/volume). In the case of a K-carageenan and locust bean gummixture, it is added to a medium at 0.001% to 5.0% (weight/volume),preferably 0.005% to 1.0% (weight/volume), more preferably 0.01% to0.1%, most preferably 0.03% to 0.05% (weight/volume). In the case of adeacylated gellan gum and diutan gum mixture, it is added to a medium at0.001% to 1.0% (weight/volume), most preferably 0.005% to 0.01%(weight/volume). In the case of a deacylated gellan gum andmethylcellulose mixture, it is added to a medium at 0.001% to 1.0%(weight/volume), most preferably 0.005% to 0.2% (weight/volume). In thecase of a deacylated gellan gum and locust bean gum mixture, it is addedto a medium at 0.001% to 1.0% (weight/volume), most preferably 0.01% to0.1% (weight/volume). In the case of a deacylated gellan gum and sodiumalginate mixture, it is added to a medium at 0.001% to 1.0%(weight/volume), most preferably 0.01% to 0.1% (weight/volume). In thecase of a deacylated gellan gum and xanthan gum mixture, it is added toa medium at 0.001% to 1.0% (weight/volume), most preferably 0.01% to0.1% (weight/volume). deacylated gellan gum and κ-carageenan mixture, itis added to a medium at 0.001% to 1.0% (weight/volume), most preferably0.01% to 0.1% (weight/volume). The concentration can be calculated bythe following formula.Concentration (%)=weight (g) of particular compound/volume (ml) ofmedium composition×100

Here, examples of appropriate solvent used for the medium additiveinclude, but are not limited to, aqueous solvents such as water,dimethyl sulfoxide (DMSO), various alcohols (e.g., methanol, ethanol,butanol, propanol, glycerol, propylene glycol, butyleneglycol and thelike), and the like. In this case, the concentration of the particularcompound is 0.001% to 5.0% (weight/volume), preferably 0.01% to 1.0%(weight/volume), more preferably 0.1% to 0.6% (weight/volume). It isalso possible to further add an additive to enhance the effect of theparticular compound, or lower the concentration when in use. As anexample of such additive, one or more kinds of guargum, tamarind gum,alginic acid propyleneglycol ester, locust bean gum, gum arabic, taragum, tamarind gum, methylcellulose, carboxymethylcellulose, agarose,tamarind seed gum, polysaccharides such as pullulan and the like can bemixed. It is also possible to immobilize the particular compound on thesurface of a carrier or carry the particular compound inside a carrierduring culture. The particular compound can have any shape duringprovision or preservation. The particular compound may be in the form ofa formulated solid such as tablet, pill, capsule, granule, or a liquidsuch as a solution obtained by dissolving in an appropriate solventusing a solubilizer or a suspension, or may be bonded to a substrate ora single substance. Examples of the additive used for formulatinginclude preservatives such as p-oxybenzoic acid esters and the like;excipients such as lactose, glucose, sucrose, mannit and the like;lubricants such as magnesium stearate, talc and the like; binders suchas polyvinyl alcohol, hydroxypropylcellulose, gelatin and the like;surfactants such as fatty acid ester and the like; plasticizers such asglycerol and the like; and the like. These additives are not limited tothose mentioned above, and can be selected freely as long as they areutilizable for those of ordinary skill in the art. The particularcompound of the present invention may be sterilized as necessary. Thesterilization method is not particularly limited, and, for example,radiation sterilization, ethylene oxide gas sterilization, autoclavesterilization, filter sterilization and the like can be mentioned. Whenfilter sterilization (hereinafter sometimes to be referred to asfiltration sterilization) is to be performed, the material of the filterpart is not particularly limited and, for example, glass fiber, nylon,PES (polyethersulfone), hydrophilic PVDF (polyvinylidene fluoride),cellulose mixed ester, celluloseacetate, polytetrafluoroethylene and thelike can be mentioned. While the size of the pore in the filter is notparticularly limited, it is preferably 0.1 μm to 10 μm, more preferably0.1 μm to 1 μm, most preferably 0.1 μm to 0.5 μm. The sterilizationtreatment may be applied when the particular compound is in a solidstate or a solution state.

The medium composition of the present invention can be obtained byforming the above-mentioned structure in a liquid medium by adding asolution or dispersion of the particular compound prepared above to theliquid medium. Since a medium generally contains a sufficientconcentration of metal ions to assemble polymer compounds through ionsor form a three-dimensional network of polymer compounds, the mediumcomposition of the present invention can be obtained by simply adding asolution or dispersion of the particular compound of the presentinvention to a liquid medium. Alternatively, a medium may be added to amedium additive (a solution or dispersion of the particular compound).Furthermore, the medium composition of the present invention can also beprepared by mixing the particular compound and a medium component in anaqueous solvent (for example, water including ion exchange water,ultrapure water and the like). Examples of the embodiment of mixinginclude, but are not limited to, (1) mixing a liquid medium and a mediumadditive (solution), (2) mixing a liquid medium and the above-mentionedpolymer compound (solid such as powder etc.), (3) mixing a mediumadditive (solution) and a powder medium, (4) mixing a powder medium andthe above-mentioned polymer compound (solid such as powder etc.) with anaqueous solvent, and the like. To prevent the particular compound in themedium composition of the present invention from being non-uniformlydistributed, the embodiment of (1) or (4), or (1) or (3) is preferable.

When the particular compound is dissolved in a solvent (e.g., aqueoussolvent such as water, liquid medium) or the particular compound and apowder medium are dissolved in a solvent, the mixture is preferablyheated to promote dissolution. The heating temperature is, for example,80° C.-130° C., preferably 100° C.-125° C. (e.g., 121° C.) at whichheating sterilization is performed.

After heating, the obtained solution of the particular compound iscooled to room temperature. The above-mentioned structure composed ofthe particular compound can be formed by adding the aforementioned metalion to the solution (e.g., by adding the solution to a liquid medium).Alternatively, the above-mentioned structure composed of the particularcompound can also be formed by heating (for example, 80° C.-130° C.,preferably 100° C.-125° C. (e.g., 121° C.)) the particular compound whendissolved in a solvent (e.g., an aqueous solvent such as water andliquid medium) containing the aforementioned metal ion, and cooling theobtained solution to room temperature.

Examples of the preparation method of the medium composition of thepresent invention are shown below, which are not to be construed aslimitative. The particular compound is added to ion exchange water orultrapure water. Then, the mixture is stirred with heating at atemperature at which the particular compound can be dissolved (e.g., notless than 60° C., not less than 80° C., not less than 90° C.) to allowfor dissolution to a transparent state.

After dissolving, the mixture is allowed to cool with stirring, andsterilized (e.g., autoclave sterilization at 121° C. for 20 min). Aftercooling to room temperature, the aforementioned sterilized aqueoussolution is added with stirring (e.g., homomixer etc.) to a given mediumto be used for static culture to uniformly mix the solution with themedium. The mixing method of the aqueous solution and the medium is notparticularly limited, and may be manual mixing such as pipetting etc.,or mixing with an instrument such as magnetic stirrer, mechanicalstirrer, homomixer and homogenizer. Furthermore, the medium compositionof the present invention can be filtrated through a filter after mixing.The size of the pore of the filter to be used for the filtrationtreatment is 5 μm to 100 μm, preferably 5 μm to 70 μm, more preferably10 μm to 70 μm.

Alternatively, a powder medium and the above-mentioned polymer compound(solid such as powder etc.) is mixed with an aqueous solvent, and themixture is heated at the above-mentioned temperature to prepare themedium composition of the present invention.

For example, when deacylated gellan gum is prepared, deacylated gellangum is added to ion exchange water or ultrapure water to 0.1% to 1%(weight/volume), preferably 0.2% to 0.5% (weight/volume), morepreferably 0.3% to 0.4% (weight/volume). Furthermore, in another aspect,when deacylated gellan gum is prepared, deacylated gellan gum is add toion exchange water or ultrapure water to 0.1% to 1% (weight/volume),preferably 0.2% to 0.8% (weight/volume), more preferably 0.3% to 0.6%(weight/volume).

Then, the aforementioned deacylated gellan gum is dissolved to atransparent state by stirring with heating at any temperature as long asdissolution is possible, which may be not less than 60° C., preferablynot less than 80° C., more preferably not less than 90° C. (e.g.,80-130° C.). After dissolution, the mixture is allowed to cool withstirring, and sterilized with autoclave at, for example, 121° C. for 20min. After cooling to room temperature, the aqueous solution is addedto, for example, DMEM/F-12 medium with stirring by a homomixer and thelike to a desired final concentration (for example, when the finalconcentration is 0.015%, the ratio of 0.3% aqueous solution:medium is1:19), and the mixture is uniformly mixed.

The mixing method of the aqueous solution and the medium is notparticularly limited, and may be manual mixing such as pipetting etc.,or mixing with an instrument such as magnetic stirrer, mechanicalstirrer, homomixer and homogenizer. Furthermore, the medium compositionof the present invention can be filtrated through a filter after mixing.The size of the pore of the filter to be used for the filtrationtreatment is 5 μm to 100 μm, preferably 5 μm to 70 μm, more preferably10 μm to 70 μm.

Furthermore, after preparation of the medium composition of the presentinvention, the structure can be sedimented by a centrifugationtreatment.

Those of ordinary skill in the art can freely select the form and stateof the cells and/or tissues to be cultured by the method of the presentinvention. Preferable specific examples thereof include, but are notparticularly limited to, a state in which the cells and/or tissues aresingly dispersed in the medium composition, a state in which the cellsand/or tissues are attached to the surface of a carrier, a state inwhich the cells and/or tissues are embedded inside a carrier, a state inwhich plural cells assemble and form cell aggregations (spheres), or astate in which two or more kinds of cells assemble and form cellaggregations (spheres), and the like. More preferred are a state inwhich the cells and/or tissues are attached to the surface of a carrier,a state in which the cells and/or tissues are embedded inside a carrier,a state in which plural cells assemble and form cell aggregations(spheres), and a state in which two or more kinds of cells assemble andform cell aggregations (spheres). Further preferred are a state in whichthe cells and/or tissues are attached to the surface of a carrier, astate in which plural cells assemble and form cell aggregations(spheres), and a state in which two or more kinds of cells assemble andform cell aggregations (spheres). Among these states, the state withforming cell aggregations (spheres) can be mentioned as the mostpreferable state to be cultured by the culture method of the presentinvention, since cell-cell interactions and cell structures close tothose in the in vivo environment are reconstructed, long-term culturecan be performed while maintaining the cell function, and also cellrecovery is relatively easy.

As a carrier to support the cells and/or tissues on the surface,microcarrier and glass bead composed of various polymers, ceramic bead,polystyrene bead, dextran bead and the like can be mentioned. Asexamples of the polymers, vinyl resin, urethane resin, epoxy resin,polystyrene, polymethylmethacrylate polyester, polyamide, polyimide,silicon resin, phenol resin, melamine resin, urea resin, aniline resin,ionomer resin, polycarbonate, collagen, dextran, gelatin, cellulose,alginates, mixtures thereof, and the like can be used. The carrier maybe coated with a compound that enhances cell adhesion or release ofsubstance from the cells. As examples of such coating materials,poly(monostearoylglycerides succinic acid),poly-D,L-lactid-co-glycolide, sodium hyaluronate, n-isopropylacrylamide,collagen I to XIX, fibronectin, vitronectin, laminin-1 to 12, nitogen,tenascin, thrombospondin, von Willebrand factor, osteopontin,fibrinogen, various elastins, various proteoglycans, various cadherins,desmocolin, desmoglein, various integrins, E-selectin, P-selectin,L-selectin, immunoglobulin superfamily, Matrigel, poly-D-lysine,poly-L-lysine, chitin, chitosan, sepharose, alginic acid gel, varioushydrogels, further, cleavage fragments thereof, and the like can bementioned. Here, two or more kinds of the coating materials may becombined. Furthermore, one or more kinds of polysaccharides such asguargum, tamarind gum, locust bean gum, gum arabic, tara gum, tamarindgum, methylcellulose, carboxymethylcellulose, agarose, tamarind seedgum, pullulan and the like can also be mixed with a medium to be usedfor culture of a carrier supporting the cells and/or tissues on thesurface. The carrier may also contain a magnetic material, for example,ferrite. The diameter of the carrier is several tens of micrometers toseveral hundreds of micrometers, more preferably 100 μm to 200 μm, andits specific gravity is preferably close to 1, more preferably 0.9-1.2,particularly preferably about 1.0. Examples of the carrier include, butare not limited to, Cytodex 1 (registered trade mark), Cytodex 3(registered trade mark), Cytoline 1 (registered trade mark), Cytoline 2(registered trade mark), Cytopore 1 (registered trade mark), Cytopore 2(registered trade mark), (above, GE Healthcare Life Sciences), Biosilon(registered trade mark) (NUNC), Cultispher-G (registered trade mark),Cultispher-S (registered trade mark) (above, Thermo SCIENTIFIC),HILLEXCT (registered trade mark), ProNectinF-COATED (registered trademark), and HILLEXII (registered trade mark) (Solo Hill Engineering), GEM(registered trade mark) (Global Eukaryotic Microcarrier) and the like.The carrier may be sterilized as necessary. The sterilization method isnot particularly limited and, for example, radiation sterilization,ethylene oxide gas sterilization, autoclave sterilization, dry heatsterilization, and the like can be mentioned. The method for culturinganimal cells using the carrier is not particularly limited, and aculture method using a general flow layer-type culture vessel or fillinglayer-type culture vessel, and the like can be used. Here, a carriersupporting cells and/or tissues on the surface and using a mediumcomposition comprising the structure of the particular compound of thepresent invention allows for uniform dispersion even without anoperation of shaking and the like. As a result, the object cells and/ortissues can be cultured without losing cell function.

The cells and/or tissues cultured by this method can be collected byperforming centrifugation and filtration treatment while the cellsand/or tissues are supported by the carrier after the culture. In thiscase, centrifugation and filtration treatment may be performed afteradding the liquid medium used. For example, unlimitatively, thegravitational acceleration (G) of centrifugation is 50G to 1000G, morepreferably 100G to 500G, and the size of the pore of the filter used forthe filtration treatment is 10 μm to 100 μm. Furthermore, culturedcarriers can be recovered with a magnetic force by encapsulating amaterial having magnetism, such as ferrite, in the carrier. The cellsand/or tissues cultured by this method can be collected by releasing thecarrier by using various chelating agents, a heat treatment, or anenzyme.

When cells and/or tissues are embedded inside a carrier, materialscomposed of various polymers can be selected as the carrier. As examplesof such polymers, collagen, gelatin, alginates, chitosan, agarose, polyglycolic acid, polylactic acid, fibrin adhesive, polylacticacid-polyglycolic acid copolymer, proteoglycan, glycosaminoglycan,sponge such as polyurethane foam, DseA-3D (registered trade mark), polyN-substituted acrylamide derivative, poly N-substituted methacrylamidederivative, and copolymers thereof, polyvinyl methylether, polypropyleneoxide, polyethylene oxide, temperature sensitive polymers such aspartially acetified polyvinyl alcohol, polyacrylamide, polyvinylalcohol, methylcellulose, nitrocellulose, cellulose butyrate,polyethylene oxide, and hydrogels such aspoly(2-hydroxyethylmethacrylate)/polycaprolactone and the like can bementioned. In addition, it is possible to prepare a carrier forembedding cells by using two or more kinds of these polymers.Furthermore, the carrier may have a physiologically active substancebesides these polymers. As examples of the physiologically activesubstance, cell growth factors, differentiation inducing factors, celladhesion factors, antibodies, enzymes, cytokines, hormones, lectins,extracellular matrices and the like can be mentioned, and a plurality ofthese can also be contained. Examples of the cell adhesion factorinclude poly(monostearoylglycerides succinic acid),poly-D,L-lactid-co-glycolide, sodium hyaluronate, n-isopropylacrylamide,collagen I to XIX, gelatin, fibronectin, vitronectin, laminin-1 to 12,nitogen, tenascin, thrombospondin, von Willebrand factor, osteopontin,fibrinogen, various elastins, various proteoglycans, various cadherins,desmocolin, desmoglein, various integrins, E-selectin, P-selectin,L-selectin, immunoglobulin superfamily, Matrigel, poly-D-lysine,poly-L-lysine, chitin, chitosan, sepharose, alginic acid gel, varioushydrogels, further, cleavage fragments thereof, and the like. In thiscase, two or more kinds of cell adhesion factors may be combined.

Furthermore, one or more kinds of thickeners such as guargum, tamarindgum, alginic acid propyleneglycol, locust bean gum, gum arabic, taragum, tamarind gum, methylcellulose, carboxymethylcellulose, agarose,tamarind seed gum, pullulan, and the like can also be mixed with amedium used for culture of a carrier embedding cells and/or tissues.

The method for embedding the cells and/or tissues in these carriers isnot particularly limited and, for example, a method including aspiratinga mixture of the cells and the aforementioned polymers with a syringeand dropwise adding them to a medium from around 25G-19G injectionneedle, or dropwise adding to a medium using a micropipette, and thelike can be used.

The size of the bead-like carrier formed here is determined by the shapeof the tip of a tool used for the dropwise addition of a mixture of thecell and the aforementioned polymers, which is preferably several tensof micrometers to several thousands of micrometers, more preferably 100μm to 2000 μm. The number of cells that can be cultured on a bead-likecarrier is not particularly limited, and can be freely selectedaccording to the bead size. For example, 5 million cells can be embeddedin a bead-like carrier with a diameter of about 2000 μm. The cells maybe singly dispersed within the carrier or plural cells may assemble toform a cell aggregate. Here, a carrier having the cells and/or tissuesembedded therein and using a medium composition comprising the structureof the particular compound of the present invention allows for uniformdispersion even without an operation of stirring and the like. As aresult, the object cells and/or tissues can be cultured without losingcell function. The cells and/or tissues cultured by this method can becollected by performing centrifugation and filtration treatment whilethe cells and/or tissues are embedded in the carrier after the culture.In this case, centrifugation and filtration treatment may be performedafter adding the liquid medium used. For example, unlimitatively, thegravitational acceleration (G) of centrifugation is 50G to 1000G, morepreferably 100G to 500G, and the size of the pore of the filter used forthe filtration treatment is 10 μm to 100 μm. The cells and/or tissuescultured by this method can be collected by dispersing them bydecomposing the carrier by a treatment using various chelating agents,heat, an enzyme and the like.

A method for forming a cell aggregate (sphere) is not particularlylimited, and can be appropriately selected by those of ordinary skill inthe art. Examples thereof include a method using a container having acell non-adhesive surface, hanging drop method, gyratory culture method,three-dimensional scaffold method, centrifugation method, a method usingcoagulation by an electric field or magnetic field and the like. Forexample, using a method using a container having a cell non-adhesivesurface, the object cells are cultured in a culture container such asschale and the like applied with a surface treatment to inhibit celladhesion, whereby a sphere can be formed. Such cell non-adhesive culturecontainer is used, the object cells are first collected, a cellsuspension thereof is prepared and plated in the culture container toperform culture. When culture is continued for about 1 week, the cellsspontaneously form a sphere. As a cell non-adhesive surface used here, asurface of a culture container generally used such as schale and thelike, which is coated with a substance inhibiting cell adhesion and thelike can be used. Examples of such substance include agarose, agar,copolymer ofpoly-HEMA(poly-(2-hydroxl-ethylmethacrylate)2-methacryloyloxyethylphosphorylcholine and other monomer (for example, butylmethacrylate etc.),poly(2-methoxymethylacrylate), poly-N-isopropylacrylamide, mebiol gel(registered trade mark) and the like. When cytotoxicity is absent, thesubstance is not limited thereto.

As a method for forming a cell aggregate (sphere), the methods describedin NATURE BIOTECHNOLOGY, VOL. 28, NO. 4, April 2010, 361-366, NATUREPROTOCOLS, VOL. 6, NO. 5, 2011, 689-700, NATURE PROTOCOLS, VOL. 6, NO.5, 2011, 572-579, Stem Cell Research, 7, 2011, 97-111, Stem Cell Rev andRep, 6, 2010, 248-259 and the like can also be used.

In addition, a medium used for culture for forming a sphere can alsocontain a component that promotes formation of a sphere or promotesmaintenance thereof. Examples of the component having such effectinclude dimethyl sulfoxide, superoxide dismutase, caeruloplasmin,catalase, peroxidase, L-ascorbic acid, L-ascorbic acid phosphate ester,tocopherol, flavonoid, uric acid, bilirubin, selenium-containingcompound, transferrin, unsaturated fatty acid, albumin, theophylline,forskolin, glucagon, dibutyryl cAMP and the like. As theselenium-containing compound, ROCK inhibitors such as sodium selenite,sodium selenate, dimethyl selenide, hydrogen selenide, Selenomethionine,Se-Methylselenocysteine, Selenocystathionine, Selenocysteine,Selenohomocysteine, adenosine-5′-triphosphoric acid,Se-Adenosylselenomethionine, Y27632, Fasudil (HA1077), H-1152, Wf-536and the like can be mentioned. To obtain the object cell aggregatehaving a uniform size, plural concaves having the same diameter as theobject cell aggregate can also be introduced onto a cell non-adhesiveculture container to be used. When these concaves are in contact witheach other or within the range of the diameter of the object cellaggregate, and cells are plated, the plated cells do not form a cellaggregate between concaves but certainly form a cell aggregate with asize corresponding to the volume thereof in the concave, thus affordinga cell aggregate population having a uniform size. As the shape of theconcave in this case is preferably a hemisphere or cone.

Alternatively, a sphere can also be formed based on a support showingcell adhesiveness. Examples of such support include collagen,polyrotaxane, polylactic acid (PLA), polylactic acid glycolic acid(PLGA) copolymer, hydrogel and the like.

In addition, a sphere can also be formed by co-cultivating with a feedercell. As a feeder cell to promote sphere formation, any adhesive cellcan be used. Preferably, a feeder cell for each kind of cell isdesirable. Although not limited, for example, when a sphere of cellsderived from the liver or cartilage is formed, examples of the feedercell include COS-1 cell and vascular endothelial cell as preferable celltypes.

Furthermore, a sphere can also be formed using the culture compositioncontaining the structure of the particular compound of the presentinvention. In this case, the particular compound can be added to amedium used for sphere formation, such that the concentration of theparticular compound is, as detailedly described above, a concentrationat which the cells and/or tissues can be uniformly suspended (preferablysuspension stood) without substantially increasing the viscosity of theliquid medium, for example, 0.0005% to 1.0% (weight/volume), preferably0.001% to 0.3% (weight/volume), more preferably 0.005% to 0.1%(weight/volume), further preferably 0.01% to 0.05% (weight/volume). Inanother aspect, the particular compound can be added to a medium usedfor sphere formation, such that the concentration of the particularcompound is, as detailedly described above, a concentration at which thecells and/or tissues can be uniformly suspended (preferably suspensionstood) without substantially increasing the viscosity of the liquidmedium, for example, 0.0005% to 1.0% (weight/volume), preferably 0.001%to 0.3% (weight/volume), more preferably 0.003% to 0.1% (weight/volume),further preferably 0.005% to 0.05% (weight/volume).

The sphere is prepared by uniformly dispersing the object cells in amedium containing the structure of the particular compound, and allowingthem to cultivate by standing still for 3 days to 10 days. The preparedsphere can be recovered by centrifugation and filtration treatment. Forexample, unlimitatively, the gravitational acceleration (G) ofcentrifugation is 50G to 1000G, more preferably 100G to 500G, and thesize of the pore of the filter used for the filtration treatment is 10μm to 100 μm. In addition, using magnetic fine particles coated, on thesurface, with an antibody that specifically binds to the object cell,cultured sphere can be recovered by magnetic force. Examples of suchmagnetic fine particles include Dynabeads (manufactured by VeritasLtd.), MACS microbead (manufactured by Miltenyi Biotec), BioMag(manufactured by Techno Chemicals Corporation) and the like.

The size of the sphere varies depending on the cell type and cultureperiod and is not particularly limited. When it has a spherical shape orellipse spherical shape, the diameter thereof is 20 μm to 1000 μm,preferably 40 μm to 500 μm, more preferably 50 μm to 300 μm, mostpreferably 80 μm to 200 μm.

Such sphere can maintain proliferative capacity for not less than 10days, preferably not less than 13 days, more preferably not less than 30days, by continuing the standing culture. By regularly furtherperforming, during the standing culture, mechanical division, or asingle cell-forming treatment and coagulation, the proliferativecapacity can be maintained substantially infinitely.

The culture container to be used for culturing sphere is notparticularly limited as long as it generally permits animal cellculture. For example, flask, dish, schale, tissue culture dish,multidish, microplate, microwell plate, multiplate, multiwall plate,chamber slide, cell culture flask, spinner flask, schale, tube, tray,culture bag, roller bottle, EZ SPHERE (manufactured by ASAHI GLASS CO.,LTD.), Sumilon cell tight plate (manufactured by SUMITOMO BAKELITE) andthe like can be mentioned.

Of these culture containers, microplate, microwell plate, multiplate andmultiwall plate are preferably used when evaluation of many anticancerdrugs, pharmaceutical product candidate compounds or pharmaceuticalproducts is performed. While the well bottom shape of these plates isnot particularly limited, flat bottom, U-shaped bottom and V-shapedbottom can be used, and U-shaped bottom is preferably used. While thematerials of these culture tools are not particularly limited, forexample, glass, plastics such as polyvinyl chloride, cellulosicpolymers, polystyrene, polymethylmethacrylate, polycarbonate,polysulfone, polyurethane, polyester, polyamide, polystyrene,polypropylene and the like, and the like can be mentioned.

The medium to be used for standing culture of sphere can contain a celladhesion factor, examples thereof include Matrigel, collagen gel,gelatin, poly-L-lysine, poly-D-lysine, laminin and fibronectin. Two ormore kinds of these cell adhesion factors can also be added incombination. Furthermore, the medium to be used for culturing sphere canbe mixed with a thickener such as guargum, tamarind gum, alginic acidpropyleneglycol, locust bean gum, gum arabic, tara gum, tamarind gum,methylcellulose, carboxymethylcellulose, agarose, tamarind seed gum,pullulan and the like.

Using a medium composition comprising the structure of the particularcompound of the present invention, uniform dispersion in a medium can beafforded even without an operation of shaking and the like. As a result,the object cells and/or tissues can be cultured as a sphere withoutlosing cell function.

The sphere standing cultured by this method can be collected byperforming centrifugation and filtration treatment after the culture. Inthis case, centrifugation and filtration treatment may be performedafter adding the liquid medium used. For example, unlimitatively, thegravitational acceleration (G) of centrifugation is 50G to 1000G, morepreferably 100G to 500G, and the size of the pore of the filter used forthe filtration treatment is 10 μm to 100 μm. In addition, using magneticfine particles coated, on the surface, with an antibody thatspecifically binds to the object cell, cultured sphere can be recoveredby magnetic force. Examples of such magnetic fine particles includeDynabeads (manufactured by Veritas Ltd.), MACS microbead (manufacturedby Miltenyi Biotec), BioMag (manufactured by Techno ChemicalsCorporation) and the like. The recovered sphere can be dispersed as asingle cell by further decomposing by a treatment with various chelatingagents, heat, filter, enzyme and the like. Cell recovery and exchange ofthe medium composition can also be achieved by performingcentrifugation, a filtration treatment or a recovery treatment bymagnetism by using a bioreactor and an automatic incubator capable ofconducting under a mechanical control and under a closed environment.

As a method for standing culture of plant-derived cells and/or tissues,callus, which is an undifferentiated plant cell aggregate, can becultivated. Callus can be induced by a method known for each plantspecies to be used. For example, a surface of a part of a tissue of adifferentiated plant body (e.g., root, stalk, leaf section, seed,growing point, embryo, pollen etc.) is sterilized, where necessary, with70% alcohol, 1% sodium hypochlorite solution and the like, a tissuesection with a suitable size (e.g., about 1-about 5 mm square rootsection) is cut out with a knife and the like as necessary, the tissuesection is plated on a callus induction medium sterilized in advance byan aseptic operation using a clean bench and the like, and asepticallycultivated under suitable conditions. The callus induced here may besubjected to liquid culture for mass proliferation, or may also bemaintained as a seed strain by passaging in a passage medium. Thepassage culture may be performed using any of liquid medium and solidmedium.

The amount of the plant cell aggregate inoculated when starting thestanding culture using the medium composition of the present inventionvaries depending on the proliferation rate of the object cell, culturemanner (batch culture, fed-batch culture, continuous culture etc.),culture period and the like. For example, when a plant cell aggregatesuch as callus and the like is to be cultivated, it is inoculated to themedium composition of the present invention such that the wet weight ofthe cell aggregate relative to the medium composition of the presentinvention is 4-8 (weight/volume (w/v)) %, preferably 5-7 (w/v) %. Theparticle size of the plant cell aggregate during culture is 1 mm to 40mm, preferably 3 mm to 20 mm, more preferably 5 mm to 15 mm. As usedherein, the “particle size” means a diameter when, for example, theplant cell aggregate has a spherical shape, a long diameter when it hasan ellipse spherical shape, and the maximum length possible when it hasother shape.

The temperature when cells and/or tissues are cultivated is generally 25to 39° C., preferably 33 to 39° C., for animal cells. The CO₂concentration is generally 4 to 10% by volume in the culture atmosphere,and 4 to 6% volume is preferable. The culture period is generally 3 to35 days, which may be freely set according to the object of the culture.The culture temperature for plant cells is generally 20 to 30° C. and,when light is necessary, they can be cultured under illuminanceconditions of illuminance 2000-8000 lux.

While the culture period is generally 3 to 70 days, which may be freelyset according to the object of the culture.

When cells and/or tissues are cultivated by the method of the presentinvention, cells and/or tissues prepared separately are added to theculture composition of the present invention and mixed to give a uniformdispersion. In this case, the mixing method is not particularly limitedand, for example, manual mixing using pipetting and the like, mixingusing instrument such as stirrer, vortex mixer, microplate mixer,shaking machine and the like can be mentioned. After mixing, the culturemedium may be stood still, or the culture medium may be rotated, shakenor stirred as necessary. The rotation number and frequency can beappropriately set according to the object of those of ordinary skill inthe art. When the medium composition needs to be exchanged during thestanding culture period, the cells and/or tissues and the mediumcomposition are separated by centrifugation or filtration treatment, anda new medium composition can be added of the cells and/or tissues.Alternatively, the cells and/or tissues are appropriately concentratedby centrifugation or filtration treatment, and a new medium compositioncan be added to the concentrated liquid.

For example, unlimitatively, the gravitational acceleration (G) ofcentrifugation is 50G to 1000G, more preferably 100G to 500G, and thesize of the pore of the filter used for the filtration treatment is 10μm to 100 μm. In addition, using magnetic fine particles coated, on thesurface, with an antibody that specifically binds to the object cell,the cultured cells and/or tissues can be separated by magnetic force.Examples of such magnetic fine particles include Dynabeads (manufacturedby Veritas Ltd.), MACS microbead (manufactured by Miltenyi Biotec),BioMag (manufactured by Techno Chemicals Corporation), magneticmicrosphere (manufactured by Polysciences Inc.) and the like. Exchangeof the medium composition can also be performed by using a bioreactorand an automatic incubator capable of conducting under a mechanicalcontrol and under a closed environment.

Since cancer cell can be efficiently proliferated by the method of thepresent invention, a medium composition containing the particularcompound of the present invention can be used for the evaluation of ananticancer drug for the cancer cell. For example, when an anticancerdrug that inhibits proliferation of cancer cell is to be elucidated,cancer cell and an anticancer drug are cocultured, and the number andkind of the cell, and changes in the cell surface differentiation markerand expressed gene are analyzed. In this case, using the mediumcomposition of the present invention, the number of the target cells tobe analyzed can be efficiently amplified, and efficiently recovered aswell. In the present invention, particularly, a medium additive forcancer cell that contains deacylated gellan gum or a salt thereof and amedium composition for cancer cell containing the additive can be usedfor the evaluation of cancer cell proliferation or anticancer activityand the like. In this case, the concentration of deacylated gellan gumor a salt thereof is as mentioned above.

While cancer cell is also proliferated even by using diutan gum,deacylated gellan gum is more preferable, since a proliferation effecton the cancer cell is particularly superior, and it can be used at a lowconcentration (the aforementioned preferable concentration), which inturn prevents easy development of bubbles in the culture medium andfacilitates recovery of the cancer cells.

More specific screening method for an anticancer drug includes, forexample, a method comprising (a) a step of cultivating cancer cell inthe medium composition of the present invention in the presence of atest substance and in the absence thereof, and (b) a step of analyzingchanges in cancer cell proliferation. The method can further comprise astep of selecting a substance that suppresses proliferation of cancercell as compared to that in the absence of the test substance and/or astep of recovering the cancer cell. The changes mean an increase ordecrease in the proliferation of cancer cell. For the analysis, theabove-mentioned method can be performed, but the method is not limitedthereto.

When the activity of an anticancer drug is evaluated, the cultureconditions, culture tools, culture apparatus, the kind of medium, thekind of the particular compound, the content of the particular compound,the kind of the additive, the content of the additive, culture period,culture temperature, the kind of the anticancer drug, the content of theanticancer drug and the like can be appropriately determined by those ofordinary skill in the art from the range described in the presentspecification. The cell that was proliferated or emerged by culture canbe observed using a standard microscope in the pertinent field. When thecell number is measured, colony formation method, crystal violet method,thymidine uptake method, Trypan Blue staining method, ATP (adenosine 3phosphoric acid) measurement method,3-(4,5-dimethylthial-2-yl)-2,5-diphenyltetrazalium bromide (MTT)staining method, WST-1 (registered trade mark) staining method, WST-8(registered trade mark) staining method, flow cytometry, a method usinga cell number automatic measuring apparatus and the like can be used.Among these, WST-8 (registered trade mark) staining method can be mostpreferably utilized. When the cytotoxicity is evaluated, lactic aciddehydrogenase (LDH) activity measurement method, CytoTox-ONE (registeredtrade mark) method and the like can be used. Alternatively, culturedcell is stained with a specific antibody, cell surface differentiationmarker is detected by ELISA or flow cytometry, and the effect of theanticancer drug on the proliferation and apoptosis can be observed.Furthermore, the gene that showed different expression due to the cancerfighting can be found by extracting the DNA (deoxyribonucleic acid) orRNA (ribonucleic acid) from the cultured cells and detecting by SouthernBlotting, Northern Blotting, RT-PCR and the like.

Since the method of the present invention maintains survival andfunction of hepatocytes, a medium composition containing the particularcompound of the present invention can be used for the evaluation ofvarious effects of a pharmaceutical product or a medicament candidatesubstance on the hepatocytes. For example, when the toxicity effect of amedicament candidate substance is to be elucidated, hepatocytes and anevaluation target test substance are cocultured, and the number and kindof the cell, and changes in the cell surface differentiation marker andexpressed gene are analyzed. In this case, using the medium compositionof the present invention, the survival and function of the analysistarget hepatocytes can be maintained, and the hepatocytes can beefficiently recovered as well.

As a method of screening for a pharmaceutical product candidatesubstance that acts on hepatocytes, a method comprising (a) a step ofcultivating hepatocytes in the presence of a test substance and in theabsence thereof in the medium composition of the present invention, and(b) a step of analyzing changes in the physiological function of thehepatocytes can be mentioned.

As a method of evaluating the efficacy or toxicity of a pharmaceuticalproduct candidate substance that acts on hepatocytes, a methodcomprising (a) a step of cultivating hepatocytes in the presence of atest substance and in the absence thereof in the medium composition ofthe present invention, and (b) a step of analyzing changes in thephysiological function of the hepatocytes can be mentioned. Thesemethods can further comprise a step of selecting a substance thatsuppresses or increases the physiological function of the hepatocytesthan in the absence of the test substance, and/or a step of recoveringthe hepatocytes. The changes refer to an increase or decrease in thephysiological function of the hepatocytes (e.g., liver cellproliferation, enzyme activity of cytochrome P450 and the like). Anincrease in the physiological function of the hepatocytes can beevaluated to show low efficacy or toxicity, and a decrease in thephysiological function of the hepatocytes can be evaluated to show highefficacy or toxicity, and the like.

When the activity of a medicament candidate substance is evaluated, theculture conditions, culture tools, culture apparatus, the kind ofmedium, the kind of the particular compound, the content of theparticular compound, the kind of the additive, the content of theadditive, culture period, culture temperature, the kind and the contentof the pharmaceutical product or medicament candidate substance and thelike can be appropriately selected by those of ordinary skill in the artfrom the range described in the present specification. The cell that wasmaintained or emerged by culture can be observed using a standardmicroscope in the pertinent field. When the cell number is measured,colony formation method, crystal violet method, thymidine uptake method,Trypan Blue staining method, ATP (adenosine 3 phosphoric acid)measurement method, 3-(4,5-dimethylthial-2-yl)-2,5-diphenyltetrazaliumbromide (MTT) staining method, WST-1 (registered trade mark) stainingmethod, WST-8 (registered trade mark) staining method, flow cytometry, amethod using a cell number automatic measuring apparatus and the likecan be used. Among these, WST-8 (registered trade mark) staining methodcan be most preferably utilized. When the cytotoxicity is evaluated,lactic acid dehydrogenase (LDH) activity measurement method, CytoTox-ONE(registered trade mark) method and the like can be used. Alternatively,cultured cell is stained with a specific antibody, cell surfacedifferentiation marker is detected by ELISA (Enzyme-linked immunosorbentassay) or flow cytometry, and the effect of the pharmaceutical productor medicament candidate substance on the proliferation and apoptosis canbe observed. Furthermore, the gene that showed different expression dueto the pharmaceutical product or medicament candidate substance can befound by extracting the DNA (deoxyribonucleic acid) or RNA (ribonucleicacid) from the cultured cells and detecting by Southern Blotting,Northern Blotting, RT-PCR and the like. Moreover, the protein thatshowed different expression due to the pharmaceutical product ormedicament candidate substance can be detected by ELISA, WesternBlotting, flow cytometry and the like. Furthermore, the enzyme activityof cytochrome P450 can be detected by measuring the activity of theenzyme to convert the substrate structure by radioactive isotope method,high performance liquid chromatography method, luminescence method,color development method and the like.

EXAMPLES

The present invention is explained in more detail in the following byconcretely describing the Analysis Examples and Experimental Examples ofthe medium composition of the present invention as Examples; however,the present invention is not limited thereto.

Analysis Example 1: Viscosity Measurement and Cell Suspension Test ofMedium Containing Deacylated Gellan Gum

Preparation and Viscosity Measurement of Deacylated GellanGum-Containing Medium

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in pure water to 0.4% (w/v), and dissolved by stirringwith heating at 90° C. This aqueous solution was allowed to cool to roomtemperature with stirring, and sterilized at 121° C. for 20 min in anautoclave. A 2-fold concentration of DMEM/F-12 medium (manufactured byAldrich, 50 mL) and sterilization water (47.5 mL) were placed in a 300mL tall beaker with stirring by a homomixer (3000 rpm) at roomtemperature, aqueous deacylated gellan gum solution (2.5 mL) was added,and the mixture was continuously stirred for 1 min to prepare adeacylated gellan gum medium composition with a final concentration of0.01%. Medium compositions added with aqueous deacylated gellan gumsolution with final concentrations of 0.02, 0.03 and 0.05% (w/v) weresimilarly prepared. The viscosity of the medium compositions wasmeasured using an E type viscometer (manufactured by Toki Sangyo Co.,Ltd., Viscometer TVE-22L, standard roter 1° 34′×R24) under 37° C.condition at 100 rpm for 5 min.

Cell Suspension Test of Deacylated Gellan Gum-Containing Medium

Human cervical cancer cell line HeLa (manufactured by DS PHARMABIOMEDICAL CO., LTD.) was suspended in EMEM medium containing 10% (v/v)fetal bovine serum (manufactured by WAKO) at 250000 cells/mL, thesuspension (10 mL) was plated on EZ SPHERE (manufactured by ASAHI GLASSCO., LTD.), and cultured in a CO₂ incubator (5% CO₂) for 3 days. Theobtained suspension (10 mL) of spheres (diameter 100-200 μm) wascentrifuged (200G, 5 min) to allow for sphere sedimentation, and thesupernatant was removed to give a sphere suspension (1.0 mL).Successively, the deacylated gellan gum-containing medium prepared abovewas placed in a 1.5 mL Eppendorf tube by 1.0 mL, and a HeLa cell spheresuspension (10 μL) was further added. The cell aggregate was dispersedby tapping, incubated at 37° C., and the dispersion state of the cells 1hr later was visually observed.

(Comparative Example) Preparation of Methylcellulose andCollagen-Containing Medium

Preparation of Methylcellulose-Containing Medium

DMEM/F-12 medium (manufactured by Aldrich, 100 mL) was placed in a 200mL pear-shaped flask, and methylcellulose (M0387, manufactured byAldrich, 0.1 g) was added. The mixture was stirred while cooling in anice bath to dissolve methylcellulose. Using this solution, mediumcompositions added with the aqueous methylcellulose solution at a finalconcentration of 0.1, 0.3, 0.6 or 1.0% (w/v) were prepared.

Preparation of Collagen-Containing Medium

A 10-fold concentration of DMEM/F-12 medium (manufactured by Aldrich, 1mL), a buffer for reconstitution (manufactured by Nitta Gelatin Inc., 1mL) and pure water (1.5 mL) were added to 0.3% cell matrix type I-A(manufactured by Nitta Gelatin Inc., 6.5 mL), and the mixture wasstirred in an ice to give a 0.2% collagen-containing medium. Similarly,medium compositions added with collagen at a final concentration of0.01, 0.05, 0.1 or 0.2% (w/v) were prepared.

The medium compositions prepared above were subjected to a suspensiontest of HeLa cell spheres and a viscosity measurement, in the samemanner as with the deacylated gellan gum-containing medium. Theviscosity of 1.0% (w/v) methylcellulose was measured at 50 rpm due tothe measurement range of the apparatus.

TABLE 1 deacylated gellan gum HeLa cell concentration viscositysuspension/ % (w/v) state (mPa · s) sedimentation 0.01 liquid 1.31suspension 0.02 liquid 1.92 suspension 0.03 liquid 2.38 suspension 0.05liquid 3.34 suspension

TABLE 2 methylcellulose HeLa cell concentration viscosity suspension/ %(w/v) state (mPa · s) sedimentation 0.1 liquid 2.31 sedimentation 0.3liquid 8.15 sedimentation 0.6 liquid 13.0 sedimentation 1.0 liquid 48.2sedimentation

TABLE 3 collagen HeLa cell concentration viscosity suspension/ % (w/v)state (mPa · s) sedimentation 0.01 liquid 1.18 sedimentation 0.05liquid/solid unmeasurable suspension (gel) 0.1 solid (gel) unmeasurablesuspension 0.2 solid (gel) unmeasurable suspension

EXPERIMENTAL EXAMPLES

While the usefulness of the medium composition of the present inventionin cell culture is concretely explained in the following ExperimentalExamples, the present invention is not is limited thereto alone. The CO₂concentration (%) in a CO₂ incubator was shown by % volume of CO₂ in theatmosphere. PBS means phosphate buffered saline (manufactured by SigmaAldrich Japan), and FBS means fetal bovine serum (manufactured byBiological Industries). In addition, (w/v) shows weight per volume.

Experimental Example 1: Cell Proliferation Test by Dispersing SingleCell

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to IMDM medium (manufactured byGibco) containing 10% (v/v) fetal bovine serum and 10 ng/mLthrombopoietin (manufactured by WAKO). Successively, human is leukemiacell line UT7/TPO was plated on a medium composition added with theabove-mentioned deacylated gellan gum to 20000 cells/mL, and dispensedto a 6-well flat bottom microplate (manufactured by CorningIncorporated) at 5 mL/well. Similarly, human cervical cancer cell lineHeLa (manufactured by DS PHARMA BIOMEDICAL CO., LTD.) was plated at20000 cell/mL on a medium composition obtained by adding 0.015% (w/v)deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)to EMEM medium containing 10% (v/v) fetal bovine serum (manufactured byWAKO), and the composition was dispensed to a 6-well flat bottommicroplate (manufactured by Corning Incorporated) at 5 mL/well. The cellsuspensions were cultured while being stood still in a CO₂ incubator (5%CO₂) for 3 days. Thereafter, a part of the culture medium was recovered,the same amount of Trypan Blue staining solution (manufactured byInvitrogen Corporation) was added, and the number of viable cells wasmeasured by blood cell meter (manufactured by ERMA INC.)

As a result, it was confirmed that, using the medium composition of thepresent invention, UT7/TPO cells and HeLa cells can be uniformlycultivated in a suspended state, and efficiently proliferate in themedium composition. The cell numbers of UT7/TPO cells and HeLa cellsafter static suspension culture for 3 days are shown in Table 4.

TABLE 4 UT7/TPO cells HeLa cells cell number (×10000/mL) 38 40

Experimental Example 2: Cell Proliferation Test by Culturing CellLine-Derived Sphere

Human liver cancer cell line HepG2 (manufactured by DS PHARMA BIOMEDICALCO., LTD.) was suspended in DMEM medium containing 10% (v/v) fetalbovine serum (manufactured by WAKO) at 250000 cells/mL, and thissuspension (10 mL) was plated on EZ is SPHERE (manufactured by ASAHIGLASS CO., LTD.) and cultured for 7 days in a CO₂ incubator (5% CO₂).Similarly, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was suspended in EMEM medium containing 10%(v/v) fetal bovine serum (manufactured by WAKO) at 250000 cells/mL, andthis suspension (10 mL) was plated on EZ SPHERE (manufactured by ASAHIGLASS CO., LTD.) and cultured for 7 days in a CO₂ incubator (5% CO₂).The suspension (2.5 mL) of the sphere (diameter 100-200 μm) of each cellline obtained here was centrifuged (200G, 5 min) to allow for spheresedimentation, and the supernatant was removed. Successively, theabove-mentioned medium (10 mL) was added to the spheres (about 800spheres) to suspend them and the suspension was transferred to a flatbottom tube (manufactured by BM Equipment Co., Ltd.). Similarly, using amedium composition obtained by adding 0.015% (w/v) deacylated gellan gum(KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) to theabove-mentioned medium, a sphere suspension was produced and transferredto a flat bottom tube (manufactured by BM Equipment Co., Ltd.). Themedium composition added with 0.015% (w/v) deacylated gellan gum wasprepared by first suspending deacylated gellan gum (KELCOGEL CG-LA,manufactured by SANSHO Co., Ltd.) in ultrapure water (Milli-Q water) to0.3% (w/v), dissolving same by stirring with heating at 90° C.,sterilizing this aqueous solution at 121° C. for 20 min in an autoclave,and adding the solution at 1/20 dilution to DMEM medium containing 10%(v/v) fetal bovine serum.

After static culture of the above-mentioned sphere suspension in a CO₂incubator (5% CO₂) at 37° C. for 3 days, a two-fold volume of the mediumwas added. The mixture was centrifuged (200G, 5 min) to allow for spheresedimentation, and is the supernatant was removed. At this point, a partof the sphere was taken, and the shape thereof was observed with anoptical microscope (manufactured by OLMPUS, CK30-F100). Successively,the recovered sphere was washed once with PBS (10 mL), 1 mL oftrypsin-EDTA (ethylenediaminetetraacetic acid) solution (manufactured byWAKO) was added, and the mixture was incubated at 37° C. for 5 min. Theabove-mentioned medium (9 mL) was added, and the cells were collected bycentrifugation (200G, 5 min). To a part of the obtained cell suspension(2 mL) was added the same amount of a Trypan Blue staining solution(manufactured by Invitrogen Corporation), and the numbers of the viablecells and dead cells were measured by a hemocytometer (manufactured byERMA INC.).

As a result, it was confirmed that, using the medium composition of thepresent invention, the spheres of HepG2 cells and HeLa cells could becultivated in a suspended state, and the cells efficiently proliferatein the medium composition. Furthermore, the medium composition of thepresent invention was confirmed to show a small rate of the dead cellsas compared to the existing media when the cells were proliferated, andhave a superior cell proliferation promoting effect. The sphere culturedin an existing medium sedimented on the bottom of the culture container.Furthermore, the shape of the cultured sphere was observed by an opticalmicroscope. As a result, the medium composition of the present inventiondid not show association of the spheres, whereas association of thespheres was observed in the existing media.

The relative number of the HepG2 cells and HeLa cells is shown in Table5, wherein the number of the cells cultured in a medium free ofdeacylated gellan gum is 1. In addition, the relative rate of the deadcells is shown in Table 6, wherein the rate of the dead cells culturedin a medium free of deacylated gellan gum (dead cell number/viable cellnumber) is 1. The is suspended state of the spheres of HepG2 cells andHeLa cells cultured in the medium composition of the present inventionis shown in FIG. 1 and FIG. 2, respectively. Furthermore, the shape ofthe sphere of the cultured HeLa cells is shown in FIG. 3.

TABLE 5 HepG2 HeLa deacylated gellan gum cells cells absent relativecell 1.0 1.0 number present relative cell 1.7 1.5 number

TABLE 6 HepG2 HeLa deacylated gellan gum cells cells absent relative 1.01.0 mortality rate present relative 0.5 0.5 mortality rate

Experimental Example 3: Cell Proliferation Test of Human PluripotentStem Cells in Adhesion Culture

Human pluripotent stem cells (hPSCs) are generally proliferated andmaintained on a feeder or a culture dish coated with Matrigel under flatplane culture conditions permitting adhesion. To evaluate toxicity ofdeacylated gellan gum to hPSCs, deacylated gellan gum was added at aconcentration of 0.000% to 0.020% (w/v) to mTeSR medium (manufactured bySTEM CELL Technologies) under flat plane culture conditions usingMatrigel (manufactured by Becton, Dickinson and Company), and theinfluence on the proliferation of hPSCs was examined. In this case,Kyoto University 253G1 strain was cultured as human iPS cells and KyotoUniversity KhES-1 strain was cultured as human ES cell line. The mediumcomposition added with the above-mentioned concentration of deacylatedgellan gum was prepared by first suspending deacylated gellan gum(KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) in ultrapure water(Milli-Q water) to 0.3% (w/v), dissolving same by stirring with heatingat 90° C., sterilizing the aqueous solution at 121° C. for 20 min in anautoclave, and adding the solution to mTeSR medium at a givenconcentration. As a result, a cell number of the same level as that ofgeneral mTeSR media could be obtained for both human iPS cells and humanES cells by using a medium added with deacylated gellan gum, andtoxicity by deacylated gellan gum was not found. The results are shownin FIG. 4. The cell number after culture as shown in FIG. 4 is arelative value of the cell number, which was obtained by plating hPSCsin Matrigel-coated culture dish and culturing the cells in mTeSR mediumcontaining deacylated gellan gum for 5 days, to the cell number in mTeSRmedium free of deacylated gellan gum as 1.

Experimental Example 4: Sedimentation Suppression Test of DeacylatedGellan Gum in Culture of Human Pluripotent Stem Cell Sphere

hPSCs form a sphere on a low adhesive culture dish such as a petriculture dish and the like. For example, the sphere can be formed by anyof the methods described in NATURE BIOTECHNOLOGY, VOL. 28, NO. 4, April2010, 361-366, NATURE PROTOCOLS, VOL. 6, NO. 5, 2011, 689-700, NATUREPROTOCOLS, VOL. 6, NO. 5, 2011, 572-579, Stem Cell Research, 7, 2011,97-111, Stem Cell Rev and Rep, 6, 2010, 248-259. hPSCs (Kyoto University253G1 strain or Kyoto University KhES-1 strain) maintained on feedercells (mouse fetus fibroblast) was recovered, the feeder cells wereremoved by natural is sedimentation, and hPSCs were resuspended in mTeSRmedium added with a Rho kinase inhibitor Y-27632 (10 μM). Successively,hPSCs colony having a given size was inoculated to a petri culture dish(manufactured by BD Falcon), and cultivated in a CO₂ incubator (5% CO₂)at 37° C. to form a sphere. The medium was exchanged with Y-27632-freemTeSR medium on day 1 and day 3 after passage, and the cells werepassaged in Y-27632-containing mTeSR medium every 5 days. Thethus-prepared hPSCs sphere (day 4 of culture) was suspended in a mediumcomposition obtained by adding deacylated gellan gum to mTeSR medium(prepared in the same manner as in Experimental Example 3) to 0.000% to0.020% (w/v), and transferred to a cuvette. The cuvette was leftstanding in a CO₂ incubator (5% CO₂) at 37° C. overnight, and the spheresedimentation suppressive effect of deacylated gellan gum was examined.The results are shown in FIG. 5. As shown in FIG. 5, the spheres couldbe three-dimensionally maintained in a suspended state in the medium inall concentration ranges by the addition of deacylated gellan gum. Onthe other hand, it was found that, in the existing medium free ofdeacylated gellan gum, the spheres sedimented on the bottom surface ofthe culture container and could not be kept in a suspended state. Inaddition, the effects of deacylated gellan gum were common in the humaniPS cells and human ES cells. The above results show that deacylatedgellan gum can maintain the hPSCs spheres in a suspended state.

Experimental Example 5: Cell Proliferation Test in Culture of HumanPluripotent Stem Cell Sphere

Whether hPSCs can be cultured in a tube in a three-dimensionallysuspended state was examined. hPSCs spheres (600 to 800/3 mL) preparedand passaged in the same manner as in Experimental Example 4 were platedon mTeSR medium containing deacylated gellan gum at 0.000%, 0.015% or0.020% (w/v) in 5 mL polystyrene tubes (manufactured by BD Falcon) suchthat each is tube has the same sphere number, and cultured in a CO₂incubator (5% CO₂) at 37° C. for 5 days. The medium was exchanged on day1 and day 3 after passage by adding 3-fold volume of DMEM/F-12 medium(manufactured by Sigma Ltd.) to the culture medium, sedimenting thespheres by centrifugation (100G, 3 min), and adding a new medium to thespheres. On day 5, an equal amount of DMEM/F-12 medium (manufactured bySigma Ltd.) was added, all spheres were recovered by centrifugation(100G, 3 min) and dissociated into single cells with trypsin-EDTAsolution (manufactured by Invitrogen), and the cell number was measuredby NucleoCounter (manufactured by chemometec). As a result, in a mediumfree of deacylated gellan gum, the spheres sedimented on the bottom ofthe tube to form a large cell aggregate, and did not show proliferation.However, in a medium containing deacylated gellan gum at 0.015% or0.020% (w/v), the size of the sphere grew in a three-dimensionallysuspended state, and cell proliferation was found as evidenced by anabout 10-fold cell number obtained on day 5 relative to the plated cellnumber as 1. The results are shown in FIG. 6. FIG. 6 relatively showsthe cell number on day 5 to the plated cell number as 1. With human EScells, 3,000,000 cells could be actually obtained per 3 mL on day 5 ofculture in the polystyrene tube (corresponding to about 1,000,000,000cells in 1000 mL of medium).

Experimental Example 6: Undifferentiation Maintenance Confirmation Testin Culture of Human Pluripotent Stem Cell Sphere

hPSCs sphere cells subjected to suspension static culture in mTeSRmedium containing deacylated gellan gum at 0.015% or 0.020% (w/v), themaintenance of the undifferentiation property thereof was examined byflow cytometry analysis. In a polystyrene tube in a sphere state, humanES cells (KhES-1) were passaged 3 times, human iPS cells (253G1) werepassaged 4 times. The cells were recovered, stained with SSEA4 antibody(#MAB4304, is manufactured by Millipore) and TRA-1-60 (#MAB4360,manufactured by Millipore) antibody, which are surface markers showingundifferentiation property of hPSCs, and the positive rate of cellstaining with the antibody was evaluated using FACSCantoII (manufacturedby Becton, Dickinson and Company). The results are shown in FIG. 7. Asshown in FIG. 7, in both A: human iPS cells (253G1) and B: human EScells (KhES-1), not less than 90% of the cells subjected to suspensionstatic culture in an addition medium containing deacylated gellan gumexpressed pluripotent stem cell marker, like the cells maintained onMatrigel. As a negative control, staining only with a secondary antibodywas performed. From the above, it was clarified that both in human iPScells and human ES cells, the hPSCs spheres subjected to suspensionstatic culture in an addition medium containing deacylated gellan gummaintain the undifferentiation property.

Experimental Example 7: Property Analysis of Sphere Cultured HumanPluripotent Stem Cells—1

Using mTeSR medium (manufactured by STEM Cell Technologies) containing0.020% (w/v) of deacylated gellan gum (KELCOGEL CG-LA, manufactured bySANSHO Co., Ltd.) prepared by a method similar to Experimental Example3, spheres of human iPS cells (253G1) or human ES cells (KhES-1) werepassage cultured 9 times in total by a method similar to ExperimentalExample 4, the spheres on day 1 of passage of each cell after culturewere plated on mouse fetus fibroblasts. The next day, they were treatedwith 300 μg/mL of thymidine (manufactured by Sigma Aldrich) overnight.Successively, they were treated with 100 ng/mL of colcemid (manufacturedby Nacalai Tesque), dissociated is into single cells with trypsin-EDTAsolution, and subjected to a hypotonic treatment with 0.075 M KCl.Thereafter, the cells were fixed with Carnoy's fixative (methanol:aceticacid=3:1).

The karyotype of the fixed cells was analyzed by Q-banding method(experiments committed to Chromosome Science Labo. Ltd.). As a result,it was clarified that both human iPS cells and human ES cells subjectedto suspension static culture in the medium composition of the presentinvention retained a normal karyotype. The results are shown in FIG. 8.

Experimental Example 8: Property Analysis of Sphere Cultured HumanPluripotent Stem Cells—2

Using mTeSR medium (manufactured by STEM Cell Technologies) containing0.020% (w/v) of deacylated gellan gum (KELCOGEL CG-LA, manufactured bySANSHO Co., Ltd.) prepared by a method similar to Experimental Example3, spheres of human iPS cells (253G1) were passage cultured 21-22 timesin total, every 5 days, by a method similar to Experimental Example 4,and the spheres after culture were fixed with 4% (w/v) para-formaldehyde(manufactured by Nacalai Tesque). They were immersed in PBS containing20% sucrose (w/v), and embedded in an embedding agent for freezing(O.C.T compound, manufactured by Japanese cherry Finetek Japan Co.,Ltd.). 12 μm-Thick sections were prepared in a cryostat (manufactured byThermo Scientific), and stained with antibodies of NANOG (#4903,manufactured by Cell Signaling) and OCT3/4 (#sc-5279, manufactured bySanta Cruz) and SSEA4 (#MAB4304, manufactured by Millipore), showingundifferentiation of hPSCs. As a result, it was clarified that the cellssubjected to suspension static culture in a medium compositioncontaining deacylated gellan gum expressed an undifferentiation markerof pluripotent stem cells. As mentioned above, it was clarified thathuman iPS cell spheres subjected to suspension static culture for notless than 100 days in a medium composition containing deacylated gellangum maintained is undifferentiation property. The results are shown inFIG. 9.

Experimental Example 9: Cell Proliferation Test by Culturing Cell LineAttached onto Microcarrier

Microcarrier Cytodex (registered trade mark) 1 (manufactured by GEHealthcare Life Sciences) was suspended in PBS at 0.02 g/mL, and thesuspension was stood overnight. The supernatant was discarded, and themicrocarrier was washed twice with fresh PBS. Thereafter, it wassuspended again in PBS at 0.02 g/mL, and sterilized at 121° C. for 20min in an autoclave. Successively, this microcarrier was washed twicewith 70% ethanol and three times with PBS, and suspended in DMEM mediumcontaining 10% (v/v) fetal bovine serum (manufactured by WAKO) at 0.02g/mL. Using this microcarrier suspension, DMEM medium (containing 10%(v/v) fetal bovine serum, 20 mL) containing 120 mg of Cytodex(registered trade mark) 1 and 4000000 HepG2 cells was prepared, and thecell suspension was cultured in a beaker treated in advance with asilicon coating agent (manufactured by AGC TECHNO GLASS Co., Ltd.), withstirring (100 rpm) with a stirrer at 37° C. for 6 hr. At this point,adhesion of HepG2 cells to the microcarrier was confirmed with amicroscope. Successively, the microcarrier with the cells adheredthereto was washed twice with DMEM medium containing 10% (v/v) fetalbovine serum, and suspended in the same medium (3 mL).

The above-mentioned microcarrier suspension (300 μL) was added to eachof DMEM medium (20 mL) containing 10% (v/v) fetal bovine serum and amedium composition obtained by adding, to this medium, 0.015% (w/v)deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co.,Ltd.), and the mixtures were cultured at 37° C. for 3 days. In the caseof the culture medium free of deacylated gellan gum, the mixtures werecultured while stirring (100 rpm) with a stirrer. After culture, theattachment state of the cells on the microcarrier was confirmed is witha microscope, and the microcarrier was sedimented by centrifugation(200G, 5 min). This microcarrier was washed with PBS (10 mL), 1 mLtrypsin-EDTA (ethylenediaminetetraacetic acid) solution (manufactured byWAKO) was added, and the mixture was incubated at 37° C. for 5 min.Furthermore, DMEM medium (9 mL) containing 10% (v/v) fetal bovine serumwas added, and the microcarrier was removed by Cell Strainer(manufactured by BD Falcon, mesh size 70 μm). The cells were recoveredfrom the obtained filtrate by centrifugation (200G, 5 min). The cellswere suspended in a medium (500 μL), to a part thereof was added thesame amount of Trypan Blue staining solution (manufactured by InvitrogenCorporation), and the number of viable cells was measured by ahemocytometer (manufactured by ERMA INC.). As a result, the culturemedium free of deacylated gellan gum contained 123,000 cells, but theculture medium containing deacylated gellan gum contained 1,320,000cells. As mentioned above, it was confirmed that the medium compositioncontaining the structure of the particular compound of the presentinvention is superior in the cell proliferation promoting effect ascompared to the existing media, even when the cells were cultured usinga microcarrier. The attachment state of HepG2 cells after 3 days ofmicrocarrier culture using the medium composition containing thestructure of the particular compound of the present invention is shownin FIG. 10.

Experimental Example 10: Cell Suspension Test Using Cell Line-DerivedSphere

Xanthan gum (KELTROL CG, manufactured by SANSHO Co., Ltd.) was suspendedin ultrapure water (Milli-Q water) to a concentration of 1% (w/v), anddissolved by stirring with heating at 90° C. Using this aqueoussolution, DMEM/F-12 medium compositions having a final xanthan gumconcentration of 0.1, 0.15 or 0.2% (w/v) were prepared. In addition, anaqueous solution containing 0.2% (w/v) K-carageenan (GENUGEL WR-80-J, ismanufactured by SANSHO Co., Ltd.) and 0.2% (w/v) locust bean gum(GENUGUM RL-200-J, manufactured by SANSHO Co., Ltd.) was prepared byheating at 90° C. Using the aqueous solution, DMEM/F-12 medium(manufactured by Sigma Ltd.) compositions containing 0.03, 0.04 or 0.05%(w/v) K-carageenan and locust bean gum were prepared.

In the same manner as in Experimental Example 2, spheres of HeLa cellswere formed, and several tens of the spheres were added to each medium(1 mL) prepared above, the mixture was stood still at 37° C. for 1 hr,and the suspended state of the sphere cells was visually observed. As aresult, it was confirmed that the spheres of HeLa cells maintained thesuspended state in any of the above-mentioned medium compositions.Furthermore, it was confirmed that addition of an equal amount of themedium to the cell suspension and centrifugation (300 to 400G, 5 min)thereof result in sedimentation and recovery of the spheres of HeLacells. The suspended state of the spheres of HeLa cells cultured in themedium composition of the present invention is each shown in FIG. 11. Inaddition, the viscosity measured in the same manner as in AnalysisExample 1 is shown in Tables 7 and 8.

TABLE 7 xanthan gum HeLa cell concentration viscosity suspension/ %(w/v) state (mPa · s) sedimentation 0.1 liquid 3.69 Suspension 0.15liquid 5.46 Suspension 0.2 liquid 7.26 Suspension

TABLE 8 κ-carageenan, locust bean gum viscosity HeLa cell concentration% (w/v) state (mPa · s) suspension/sedimentation 0.03 liquid 1.34Suspension 0.04 liquid 1.55 Suspension 0.05 liquid 1.95 Suspension

Experimental Example 11: Cell Suspension Test Using Medium CompositionFiltered with Filter

A DMEM/F-12 medium composition containing 0.015% deacylated gellan gum(KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) was prepared in thesame manner as in Experimental Example 2. Successively, this mediumcomposition (1 mL) was is filtered through 70 μm filter and 40 μm filter(manufactured by BD Falcon), 30 μm filter and 20 μm filter (manufacturedby AS ONE Corporation), 10 μm filter (manufactured by Partec), and 5 μmfilter, 1.2 μm filter, 0.45 μm filter and 0.2 μm filter (manufactured bySartorius Stedim Japan). Spheres of HepG2 cells prepared in the samemanner as in Experimental Example 2 were added by about several tensspheres to the above-mentioned filtrates and stood at 37° C. for 1 hr,and the suspended state of the sphere cells was visually observed. As aresult, it was confirmed that the spheres of HepG2 cells are maintainedin a suspended state in the medium composition passed through a filterof not less than 10 μm, but sedimented in the medium composition passedthrough a filter of less than 5 μm. Furthermore, it was confirmed thatcentrifugation at room temperature, 300G, 5 min, or addition of an equalamount of the medium and centrifugation at room temperature, 200G, 5min, of HepG2 cell spheres in a suspended state result in sedimentationand recovery of the spheres.

Experimental Example 12: Sphere Formation Test

In the same manner as in Experimental Example 2, a composition of EMEMmedium (manufactured by WAKO) containing is 0.01% deacylated gellan gum(KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) and 10% (v/v) fetalbovine serum was prepared. Successively, HeLa cells were added to aconcentration of 1000 cells/mL, and dispensed to a 24-well plate(manufactured by Corning Incorporated). This plate wassuspension-cultured by being stood still at 37° C. for 9 days, andformation of sphere was confirmed with a microscope. Furthermore, thesphere cell forms sediment by a centrifugation treatment (300G, 5 min),and washed once with PBS (5 mL). A 100 μL trypsin-EDTA(ethylenediaminetetraacetic acid) solution (manufactured by WAKO) wasadded, and the mixture was incubated at 37° C. for 5 min. Here, to theobtained cell suspension (100 μL) was added EMEM medium (100 μL)containing 10% (v/v) fetal bovine serum, to a subset of the cellsuspension was added Trypan Blue staining solution (manufactured byInvitrogen Corporation) at same amount, and the number of viable cellswas measured by a hemocytometer (manufactured by ERMA INC.). As aresult, it was confirmed that HeLa cell increases to 170000 cells/mL.The sphere of HeLa cell formed in the medium composition of the presentinvention is shown in FIG. 12.

Experimental Example 13: Optical Microscope Observation of Structure

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in pure water to 0.4% (w/v), and dissolved by stirringwith heating at 90° C. DMEM/F-12 medium (manufactured by Aldrich, 95 mL)at a 2-fold concentration was placed in a 300 mL tall beaker, an aqueousdeacylated gellan gum solution (5 mL) was added with stirring with amagnetic stirrer at room temperature, and the mixture was stirred as itwas for 5 min to give a medium composition containing deacylated gellangum at a final concentration of 0.02%. Furthermore, the mediumcomposition was stirred by a homomixer (3000 rpm) for 5 min. Theprepared medium composition was observed with an optical is microscope(KEYENCE Corporation, BIOREVO BZ-9000). The observed structure is shownin FIG. 13.

Experimental Example 14: Preparation by Mixing Heating Powder Medium andDAG

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.,20 mg) and DMEM/F-12 medium (manufactured by Life Technologies, 1.58 g)were placed in a 200 mL Erlenmeyer flask, and pure water (100 mL) waspoured therein. The mixture was sterilized at 121° C. for 20 min in anautoclave to prepare a DMEM/F-12 medium composition with a deacylatedgellan gum concentration of 0.02%. To the prepared medium were addeddextran beads Cytodex 1 (Size 200 μm, manufactured by GE Healthcare LifeSciences), and the dispersion state of the beads was confirmed by visualobservation. For evaluation, a suspended state is ◯, partialsedimentation/dispersed state is Δ, and sedimented state is X. Theresults are shown in Table 9.

TABLE 9 deacylated gellan gum concentration % (w/v) state Cytodex1dispersion 0.05 liquid ○ 0.02 liquid ○ 0.01 liquid ○

Experimental Example 15: Preparation of Medium Composition ContainingPolysaccharides

Xanthan gum (KELTROL CG, manufactured by SANSHO Co., Ltd.) was suspendedin pure water to a concentration of 0.5% (w/v), and dissolved bystirring with heating at 90° C. Similarly, 0.5% (w/v) aqueous solutionsof sodium alginate (Duck alginic acid NSPM, manufactured by FOOD CHEMIFACo., Ltd.), locust bean gum (GENUGUM RL-200-J, manufactured by SANSHOCo., Ltd.), K-carageenan (GENUGEL WR-80-J, manufactured by SANSHO Co.,Ltd.) and diutan gum (KELCO CRETE DG-F, manufactured by SANSHO Co., isLtd.) were prepared.

This aqueous solution and 0.2 or 0.1% (w/v) deacylated gellan gumsolution and DMEM/F-12 medium at a 10-fold concentration were mixed, andthe mixture was heated at 80° C. for min, allowed to cool to roomtemperature, and 7.5% aqueous sodium hydrogen carbonate solution wasadded to prepare DMEM/F-12 medium compositions containing deacylatedgellan gum at a final concentration of 0.01, 0.02% (w/v) and otherpolysaccharide at a final concentration of 0.1, 0.2, 0.3, 0.4% (w/v). Inaddition, a medium containing deacylated gellan gum was prepared asmentioned above, and a powder of methylcellulose (cP400, manufactured byWAKO) was added. The mixture was stirred in an ice bath to dissolvemethylcellulose to prepare DMEM/F-12 medium compositions containingdeacylated gellan gum at a final concentration of 0.01, 0.02% (w/v) andother methylcellulose at a final concentration of 0.1, 0.2, 0.3, 0.4%(w/v).

Polystyrene beads (Size 500-600 μm, manufactured by Polysciences Inc.)were added to the medium prepared above, and the dispersion state of thebeads was confirmed by visual observation. For evaluation, a suspendedstate is ◯, partial sedimentation/dispersed state is Δ, and sedimentedstate is x. The results are shown in Table 10.

TABLE 10 deacylated gellan polysaccharide locust gum concentrationconcentration xanthan alginic bean κ- diutan % (w/v) % (w/v) gum acid Nagum methylcellulose carageenan gum 0.01 0.1 ○ ○ ○ x ○ ○ 0.2 ○ ○ ○ Δ/xsolidified not measured 0.3 ○ ○ ○ Δ/x solidified not measured 0.4 ○ ○ ○Δ/x solidified not measured 0.02 0.1 ○ ○ ○ ○/x ○ ○ 0.2 ○ ○ ○ ○solidified not measured 0.3 ○ ○ ○ ○ solidified not measured 0.4 ○ ○ ○ ○solidified not measured

Experimental Example 16: Viscosity Measurement of Medium CompositionContaining Polysaccharides

By a method similar to that for the polysaccharide mixture ofExperimental Example 15, DMEM/F-12 media containing deacylated gellangum at a final concentration of 0.005, 0.01% (w/v) and otherpolysaccharide were prepared. The final concentration of polysaccharidewas set to 0.1% (w/v) for xanthan gum, sodium alginate, locust bean gum,0.2% (w/v) for methylcellulose, and 0.05% (w/v) for K-carageenan anddiutan gum. The state of each medium composition and the viscositymeasured by a method similar to that in Analysis Example 1 are shown inTables 11-16.

TABLE 11 xanthan gum deacylated gellan concentration gum concentrationviscosity % (w/v) % (w/v) state (mPa · s) 0.1 0.005 liquid 4.36 0.10.010 liquid 4.59

TABLE 12 sodium alginate deacylated gellan concentration gumconcentration viscosity % (w/v) % (w/v) state (mPa · s) 0.1 0.005 liquid1.53 0.1 0.010 liquid 1.75

TABLE 13 locust bean gum deacylated gellan concentration gumconcentration viscosity % (w/v) % (w/v) state (mPa · s) 0.1 0.005 liquid1.92 0.1 0.010 liquid 2.36

TABLE 14 methylcellulose deacylated gellan concentration gumconcentration viscosity % (w/v) % (w/v) state (mPa · s) 0.2 0.005 liquid3.36 0.2 0.010 liquid 3.81

TABLE 15 κ-carageenan deacylated gellan concentration gum concentrationviscosity % (w/v) % (w/v) state (mPa · s) 0.05 0.005 liquid 1.04 0.050.010 liquid 1.28

TABLE 16 diutan gum deacylated gellan concentration gum concentrationviscosity % (w/v) % (w/v) state (mPa · s) 0.1 0.005 liquid 2.76 0.10.010 liquid 3.04

Experimental Example 17: Preparation of Medium Composition with ChangedDivalent Metal Ion Concentration

Using DMEM/F-12 (D9785, manufactured by Aldrich) free of calciumchloride, magnesium sulfate and magnesium chloride and in the samemanner as in the method of Experimental Example 14, DMEM/F-12 mediumcomposition containing 0.02% (w/v) deacylated gellan gum was prepared.DMEM/F-12 medium compositions added with calcium chloride or magnesiumsulfate, and magnesium chloride such that the final concentration wasset to the defined amount of DMEM/F-12 medium were prepared. In view ofthe defined composition of DMEM/F-12 medium, each final concentrationwas set to 0.116 g/L for calcium chloride, 0.049 g/L for magnesiumsulfate, and 0.061 g/L for magnesium chloride.

To the prepared medium composition were added dextran beads Cytodex 1(manufactured by GE Healthcare Life Sciences), and the dispersion stateof the beads was confirmed 2 days later by visual observation. Forevaluation, a suspended state is ◯, partial sedimentation/dispersedstate is Δ, and sedimented state is x. The results are shown in Table17.

TABLE 17 magnesium deacylated gellan sulfate gum concentration calciummagnesium Cytodex1 % (w/v) chloride chloride dispersion 0.02 + + ○0.02 + − ○ 0.02 − + Δ 0.02 − − x

Experimental Example 18: Preparation of Medium Composition Later Addedwith Divalent Metal Ion

A salt solution was prepared by dissolving 0.1% (w/v) deacylated gellangum solution, a 5-fold concentration of DMEM/F-12 medium (not containingcalcium chloride, magnesium sulfate and magnesium chloride, D9785,manufactured by Aldrich), calcium chloride (1167 mg), magnesium sulfate(489 mg) and magnesium chloride (287 mg) in pure water (300 mL). Anaqueous deacylated gellan gum solution and pure water were placed in a200 mL tall beaker, and the solution was stirred at 200 rpm using ananchor type stirring blade. Solution A, which is a mixture of the mediumsolution and water, was added, and the mixture was directly stirred for10 min. Then, the salt is solution was added, and 7.5% aqueous sodiumhydrogen carbonate solution (1.6 mL) was further added to prepareDMEM/F-12 medium compositions containing deacylated gellan gum at afinal concentration of 0.02%. The mixed amount of each solution is shownin the Table. After 4 hr from the preparation, 6 medium compositionswere subjected to a dispersion evaluation of polystyrene beads andCytodexl. The results are shown in Tables 18, 19.

TABLE 18 salt solution calcium 0.1% (w/v) chloride deacylated solution Amagnesium gellan gum 5-fold chloride aqueous pure concentration puremagnesium solution water DMEM/F-12 water sulfate 1 20 mL 10 mL 20 mL 50mL none 2 20 mL 10 mL 20 mL 47 mL 3 mL 3 20 mL 10 mL 20 mL 40 mL 3mL/water 7 mL 4 20 mL 30 mL 20 mL 30 mL none 5 20 mL 30 mL 20 mL 27 mL 3mL 6 20 mL 30 mL 20 mL 20 mL 3 mL/water 7 mL

TABLE 19 polystyrene deacylated gellan gum salt bead Cytodex1concentration % (w/v) solution dispersion dispersion 1 0.02 − x x 20.02 + ○ ○ 3 0.02 + ○ ○ 4 0.02 − x x 5 0.02 + ○ ○ 6 0.02 + ○ ○

Experimental Example 19: Preparation of Various Medium Compositions

A 0.1% (w/v) deacylated gellan gum solution and a medium solution havinga high concentration were prepared. As a medium solution having a highconcentration, MEM having a 10-fold concentration (M0268, manufacturedby Aldrich), RPMI-1640 having a 10-fold concentration (R6504,manufactured by Aldrich) and DMEM having a 5-fold concentration(high-pressure sterilization corresponding medium, manufactured byNissui) were prepared. A 0.1% (w/v) deacylated gellan gum solution, eachhigh concentration medium, and pure water for adjusting concentrationwere mixed, and the mixture was heated at 80° C. for 30 min. The mixturewas allowed to cool to room temperature, and 7.5% aqueous sodiumhydrogen carbonate solution was added to prepare medium compositionscontaining deacylated gellan gum at a final concentration of 0.01, 0.02,0.03% (w/v).

The prepared 9 medium compositions were evaluated for the suspension anddispersion state of polystyrene beads and dextran is beads Cytodexl,wherein a suspended state is ◯, partial sedimentation/dispersed state isΔ, and sedimented state is x. The results are shown in Tables 20, 21.

TABLE 20 MEM medium deacylated gellan gum polystyrene Cytodex1concentration % (w/v) state bead dispersion dispersion 0.01 liquid Δ Δ0.02 liquid ○ ○ 0.03 liquid ○ ○

TABLE 21 DMEM medium deacylated gellan gum polystyrene Cytodex1concentration % (w/v) state bead dispersion dispersion 0.01 liquid Δ Δ0.02 liquid ○ ○ 0.03 liquid ○ ○

Experimental Example 20: Particle Size Distribution Measurement ofMedium Composition Containing Deacylated Gellan Gum

According to Analysis Example 1, DMEM/F-12 medium composition containing0.038% (w/v) deacylated gellan gum was prepared. The medium was preparedby stirring at 3000 rpm and 6000 rpm for 1 min by a homomixer. Theparticle size distribution of the medium composition was measured byBeckman Instruments Coulter, Inc. Multisizer 4 (precise particle sizedistribution measuring apparatus by Coulter principle) and the mediansize (d50) of the volume standard particle size is distribution wasdetermined. The results are shown in Table 22.

TABLE 22 homomixer rotation number in medium preparation d50 (μm) 3000rpm 1.709 6000 rpm 1.499

Experimental Example 21: Phosphorylation of Deacylated Gellan Gum

Deacylgellan gum (1 g) and pure water (40 mL) were measured in a 100 mLglass test tube, and the mixture was heated at 100° C. for 30 min toprepare a suspension. To this suspension was added aqueous phosphoricacid solution (85%, 1 g), and the mixture was heated under reflux for 5hr. Thereafter, it was allowed to cool to room temperature whilestirring for 12 hr, and the obtained white suspension was poured into99% ethanol (500 mL). The resulting floc white solid was collected byfiltration and dried to give a pale-brown solid (0.4 g) as aphosphorylated substance of deacylgellan gum. Introduction of aphosphate group was confirmed by Fourier-transform infrared isspectroscopic analysis (manufactured by SHIMADZU CORPORATION,IR-Prestage 21) (1700 cm-1; P—OH, 1296 cm-1, 1265 cm-1; P═O). Thepale-brown solid was decomposed by a micro wave heating digestionapparatus (ETHOS TC, manufactured by Milestone General), and the contentof the phosphorus atom was measured by an inductively coupled plasmaemission spectroscopic analyzer (ICP-OES) (SPS 5520, manufactured by SIINanoTechnology). The result was 3.5 wt % (n=2).

Experimental Example 22: Preparation of Medium Composition ContainingPhosphorylated Deacylated Gellan Gum

An optional amount of phosphorylated deacylated gellan gum (30 mg) andDMEM/F-12 medium (manufactured by Life Technologies, 1.56 g) were placedin a 200 mL Erlenmeyer flask, and pure water (100 mL) was pouredtherein. The mixture was sterilized at 121° C. for 20 min in anautoclave to prepare a DMEM/F-12 medium composition having a deacylatedgellan gum concentration of 0.03%. To the prepared medium were addeddextran beads Cytodex 1 (manufactured by GE Healthcare Life Sciences),and the dispersion state of the beads was confirmed by visualobservation. A dispersed state of the beads was found at aphosphorylated deacylated gellan gum concentration of 0.03% (w/v).

Experimental Example 23: Preparation of Medium Composition ContainingDeacylated Gellan Gum

An aqueous deacylated gellan gum solution and a medium solution weremixed at the rates shown in the following Table to prepare a DMEM/F-12medium composition having a deacylated gellan gum concentration of0.02%, and the dispersion state of polystyrene beads (Size 500-600 μm,manufactured by Polysciences Inc.) was evaluated. The results are shownin Tables 23 and 24. By standing for 1 day or longer, the styrene beadswere dispersed under all conditions.

TABLE 23 deacylated gellan DMEM/F12 powder gum/pure water medium/purewater standing time 20 mg/10 mL 1.56 g/90 mL 5 min 20 mg/20 mL 1.56 g/80mL 5 min 20 mg/30 mL 1.56 g/70 mL 5 min 20 mg/40 mL 1.56 g/60 mL 6 h 20mg/50 mL 1.56 g/50 mL 6 h 20 mg/60 mL 1.56 g/40 mL 6 h 20 mg/70 mL 1.56g/30 mL 6 h 20 mg/80 mL 1.56 g/20 mL 1 day 20 mg/90 mL 1.56 g/10 mL 1day “DMEM/F12 powder medium/pure water” was added to “deacylated gellangum/pure water”

TABLE 24 deacylated gellan DMEM/F12 powder gum/pure water medium/purewater standing time 20 mg/10 mL 1.56 g/90 mL 5 min 20 mg/20 mL 1.56 g/80mL 5 min 20 mg/30 mL 1.56 g/70 mL 1 h 20 mg/40 mL 1.56 g/60 mL 6 h 20mg/50 mL 1.56 g/50 mL 6 h 20 mg/60 mL 1.56 g/40 mL 6 h 20 mg/70 mL 1.56g/30 mL 1 day 20 mg/80 mL 1.56 g/20 mL 1 day 20 mg/90 mL 1.56 g/10 mL 1day “Deacylated gellan gum/pure water” was added to “DMEM/F12 powdermedium/pure water”

Experimental Example 24: Preparation of Medium Composition Using Filter

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to a finalconcentration of 0.02 or 0.04% (w/v), and dissolved by heating at 90° C.for 30 min or at 121° C. for 20 min. Furthermore, this aqueous solution(100 mL) was filtered with a polyethersulfone membrane filter having apore size of 0.22 μm (manufactured by Corning Incorporated).Successively, this filtrate was mixed with a 2- to 4-fold concentrationof DMEM/F-12 medium (manufactured by Sigma Aldrich), and the mixture wasshaken by a mild mixer (SI-24, manufactured by TAITEC Co., Ltd.) for 1hr to prepare medium compositions containing deacylated gellan gum at afinal concentration of 0.01 or 0.015% (w/v) (e.g., 25 mL each of 0.02%(w/v) aqueous deacylated gellan gum solution and DMEM/F-12 medium havinga 2-fold concentration were mixed to prepare 0.01% (w/v) deacylatedgellan gum medium composition (50 mL)). By a method similar to that inExperimental Example 2, spheres of HepG2 cells were formed, and severaltens of the spheres were added to the medium (1 mL) prepared above,stood at 37° C., of the suspended state of the sphere cells was visuallyobserved after 1 hr and one night. As a result, it was confirmed thatthe spheres of HepG2 cells were maintained in a suspended state in allof the above-mentioned medium composition. Furthermore, two-fold volumeof the medium was added, and the cell suspension was centrifuged (500G,5 min). It was confirmed that the spheres of HepG2 cells sedimented, andthe cells can be recovered in all medium compositions. The dispersedstate of the sphere after one night was confirmed by visual observationand evaluated, wherein a suspended and dispersed state is ◯, partialsedimentation/dispersed state is Δ, and sedimented state is x. Theevaluation results are shown in Table 25.

TABLE 25 aqueous deacylated gellan gum suspending deacylated gellantemperature (° C.) concentration (%) effect of gum solution during ofmedium HepG2 concentration (%) dissolution composition cells 0.02 900.010 ○ 0.015 ○ 120 0.010 ○ 0.015 ○ 0.04 90 0.010 ○ 0.015 ○ 120 0.010 ○0.015 ○

Experimental Example 25: Cell Proliferation Test by Culturing CellLine-Derived Sphere

Human embryonic kidney cell line HEK293 (manufactured by DS PHARMABIOMEDICAL CO., LTD.) was suspended in EMEM medium containing 10% (v/v)fetal bovine serum (manufactured by WAKO) at 250000 cells/mL, and thissuspension (10 mL) was plated on EZ SPHERE (manufactured by ASAHI GLASSCO., LTD.) and cultured for 2 days in a CO₂ incubator (5% CO₂). Asuspension (10 mL) of the spheres (diameter 100-200 μm) of HEK293 cellsobtained here was centrifuged (200G, 5 min) to allow for spheresedimentation, the supernatant was removed and the sphere was suspendedin 1 mL. Successively, the medium (10 mL) was added to the spheresuspension (200 μL, cell number about 200000) to suspend them and thesuspension was transferred to a flat bottom tube (manufactured by BMEquipment Co., Ltd.). Similarly, using a medium composition obtained byadding 0.015% (w/v) deacylated gellan gum (KELCOGEL CG-LA, manufacturedby SANSHO Co., Ltd.) to the above-mentioned medium, a sphere suspensionwas produced and is transferred to a flat bottom tube (manufactured byBM Equipment Co., Ltd.). The medium composition added with 0.015% (w/v)deacylated gellan gum was prepared by first suspending deacylated gellangum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) in ultrapurewater (Milli-Q water) to 0.3% (w/v), dissolving same by stirring withheating at 90° C., sterilizing this aqueous solution at 121° C. for 20min in an autoclave, and adding the solution at 1/20 dilution to EMEMmedium containing 10% (v/v) fetal bovine serum.

After static culture of the above-mentioned sphere suspension in a CO₂incubator (5% CO₂) at 37° C. for 5 days, a two-fold volume of the mediumwas added. The mixture was centrifuged (500G, 5 min) to allow for spheresedimentation, and the supernatant was removed. Successively, therecovered sphere was washed once with PBS (10 mL), 1 mL of trypsin-EDTA(ethylenediaminetetraacetic acid) solution (manufactured by WAKO) wasadded, and the mixture was incubated at 37° C. for 5 min. Theabove-mentioned medium (9 mL) was added, and the cells were collected bycentrifugation (200G, 5 min). To a part of the obtained cell suspension(2 mL) was added the same amount of a Trypan Blue staining solution(manufactured by Invitrogen Corporation), and the numbers of the viablecells and dead cells were measured by a hemocytometer (manufactured byERMA INC.). As a control, a medium composition free of deacylated gellangum was produced and a similar experiment was performed.

As a result, it was confirmed that, using the medium composition of thepresent invention, the spheres of HEK293 cells can be cultivated in asuspended state, and the cells efficiently proliferate in the mediumcomposition. Furthermore, the medium composition of the presentinvention was confirmed to show a small rate of the dead cells ascompared to a medium composition free of deacylated gellan gum when thecells were is proliferated, and have a superior cell proliferationpromoting effect. The sphere cultured in an existing medium sedimentedon the bottom of the culture container.

The relative number of the HEK293 cells is shown in Table 26, whereinthe number of the cells cultured in a medium free of deacylated gellangum is 1. In addition, the relative rate of the dead cells is shown inTable 27, wherein the rate of the dead cells cultured in a medium freeof deacylated gellan gum (dead cell number/viable cell number) is 1.

TABLE 26 deacylated gellan gum HEK293 cells absent relative cell 1.0number present relative cell 1.6 number

TABLE 27 deacylated gellan gum HEK293 cells absent relative dead 1.0cell rate present relative dead 0.3 cell rate

Experimental Example 26: Cell Proliferation Test by Culturing InsectCell

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to Sf-900 (registered trade mark)III SFM medium (manufactured by Gibco). Successively, is Spodopterafrugiperda derived Sf9 cells (manufactured by Gibco) were inoculated tothe above-mentioned medium composition added with deacylated gellan gumat 100000 cells/mL, and dispensed to the wells of a 24-well flat bottommicroplate (manufactured by Corning Incorporated) at 1 mL/well. The cellsuspensions were cultured by being stood still in an incubator at 25° C.for 5 days. Thereafter, a part of the culture medium was recovered, thesame amount of Trypan Blue staining solution (manufactured by InvitrogenCorporation) was added, and the number of viable cells was measured by ahemocytometer (manufactured by ERMA INC.). As a control, a mediumcomposition free of deacylated gellan gum was produced and subjected toa similar experiment.

As a result, it was confirmed that, using the medium composition of thepresent invention, Sf9 cell can be uniformly cultivated in a suspendedstate, and proliferates in the medium composition. Furthermore, it wasconfirmed that the medium composition of the present invention issuperior in the effect of promoting cell proliferation when the cells isproliferated, as compared to a medium composition free of deacylatedgellan gum. The cell number of Sf9 cells after suspension static culturefor 5 days is shown in Table 28.

TABLE 28 deacylated gellan gum Sf9 cell number (×10000) absent 33.5present 47.4

Experimental Example 27: Cell Proliferation Test by Culturing CD34Positive Cells

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v), 20 ng/mL thrombopoietin(manufactured by WAKO) and 100 ng/mL stem cell factor (SCF, manufacturedby WAKO) to StemSpan SFEM medium (manufactured by StemCellTechnologies). Successively, human cord blood-derived CD34 positivecells (manufactured by Lonza) were inoculated to the above-mentionedmedium composition added with deacylated gellan gum to 10000 cells/mL,and dispensed to the wells of a 24-well flat bottom microplate(manufactured by Corning Incorporated) at 1 mL/well. The cellsuspensions were subjected to static culture at 37° C. for 7 days in aCO₂ incubator (5% CO₂). Thereafter, a part of the culture medium wasrecovered, the same amount of Trypan Blue staining solution(manufactured by Invitrogen Corporation) was added, and the number ofviable cells was measured by a hemocytometer (manufactured by ERMAINC.). A 3-fold volume of the medium was added to the culture medium andthe mixture was centrifuged (500G, 5 min) to allow for sedimentation ofall cells. As a control, a medium composition free of deacylated gellangum was produced and subjected to a similar experiment.

As a result, it was confirmed that, using the medium composition of thepresent invention, CD34 positive cells can be is uniformly cultivated ina suspended state, and proliferates in the medium composition.Furthermore, the medium composition of the present invention wasconfirmed to show a cell proliferation promoting effect of the levelequal to or more than that of the existing media without deacylatedgellan gum. In addition, it was confirmed that centrifugation results insedimentation of the cells and the cells can be recovered. The relativenumber of the cells proliferated from the CD34 positive cells aftersuspension static culture for 7 days, when the number of the cellscultured in a medium free of deacylated gellan gum is 1, is shown inTable 29.

TABLE 29 deacylated gellan gum relative cell number absent 1.0 present1.2

Experimental Example 28: Sphere Formation Test

In the same manner as in Experimental Example 2, a composition of DMEMmedium (manufactured by WAKO) containing 0.015% deacylated gellan gum(KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) and 10% (v/v) fetalbovine serum was prepared. Successively, HepG2 cells were added to acell concentration of 15000 cells/mL, and dispensed by 1 mL to a 24-wellplate (manufactured by Corning Incorporated). This plate wassuspension-cultured by being stood still at 37° C. for 7 days, andformation of sphere was confirmed with a microscope.

Furthermore, the sphere cell forms sediment by a centrifugationtreatment (400G, 5 min), and washed once with PBS (5 mL). A 100 μLtrypsin-EDTA (ethylenediaminetetraacetic acid) solution is (manufacturedby WAKO) was added, and the mixture was incubated at 37° C. for 5 min.Here, to the obtained cell suspension (100 μL) was added DMEM medium(100 μL) containing 10% (v/v) fetal bovine serum, to a subset of thecell suspension was added Trypan Blue staining solution (manufactured byInvitrogen Corporation) at same amount, and the number of viable cellswas measured by a hemocytometer (manufactured by ERMA INC.). As aresult, it was confirmed that HepG2 cells formed a sphere in the mediumcomposition of the present invention and increased to 80800 cells/mL.The sphere of HepG2 cells formed in the medium composition of thepresent invention is shown in FIG. 14.

Experimental Example 29: Cell Suspension Test Using Cell Line-DerivedSphere

Diutan gum (KELKO-CRETE DG, manufactured by SANSHO Co., Ltd.) wassuspended in ultrapure water (Milli-Q water) to a concentration of 0.3%(w/v), and dissolved by stirring with heating at 90° C. Using thisaqueous solution, DMEM/F-12 medium compositions having a final diutangum concentration of 0.1% (w/v) were prepared. In addition, an aqueoussolution containing 0.5% (w/v) native-type gellan gum (KELCO gel HT,manufactured by San-Ei Gen F.F.I., Inc.) was prepared by heating at 90°C. Using the aqueous solution, DMEM/F-12 medium (manufactured by SigmaLtd.) compositions containing 0.05 or 0.1% (w/v) native-type gellan gumwas prepared.

In the same manner as in Experimental Example 2, spheres of HeLa cellswere produced, and several tens of spheres were added to each medium (1mL) prepared above, the mixture was stood still at 37° C. for 1 hr, andthe suspended state of the sphere cells was visually observed. As aresult, it was confirmed that the spheres of HeLa cells maintained thesuspended state in any of the above-mentioned medium compositions.Furthermore, it was confirmed that centrifugation is (200G, 5 min) ofthe cell suspension containing 0.1% (w/v) diutan gum result insedimentation and recovery of the spheres of HeLa cells.

Experimental Example 30: Cell Suspension Test Using Magnetic BeadsHaving Cell Adhesion Ability—1

A suspension of GEM (registered trade mark, Global EukaryoticMicrocarrier, manufactured by GL Sciences Inc.) coated with laminin orfibronectin was dispensed by 500 μL to a 1.5 mL volume micro test tube(manufactured by Eppendorf), GEM was accumulated from theabove-mentioned GEM suspension by using a magnet stand (TA4899N12,manufactured by TAMAGAWA SEIKI CO., LTD.) and the solvent was removed.Furthermore, GEM was washed twice with DMEM medium (manufactured byWAKO, 500 μL) containing 10% (v/v) fetal bovine serum, and suspended inthe same medium (500 μL). This suspension was dispensed to a Sumiloncell tight plate 24F (manufactured by SUMITOMO BAKELITE), which is acell low adhesion plate, at 50 μL per 1 well. Successively, HepG2 cellsprepared separately were added at 250000 cells/mL, and the final volumewas adjusted with the same medium to 500 μL/well. This cell suspensionwas manually stirred, and the plate was stood overnight in a CO₂incubator (5% CO₂). After confirmation of cell adhesion on GEM with amicroscope, the cell suspension was transferred to a 1.5 mL micro testtube (manufactured by Eppendorf), cell-attached GEM was accumulated theabove-mentioned magnet stand and the supernatant was removed.

By a method similar to that in Experimental Example 2, a DMEM medium(manufactured by WAKO) composition containing 0.015% of deacylatedgellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) and 10%(v/v) fetal bovine serum was prepared. This medium composition or theabove medium free of deacylated gellan gum was each added by 1 mL to theHepG2 cell-attached GEM (laminin or fibronectin-coated) prepared above,suspended, and is transferred to Sumilon cell tight plate 24F.Successively, this plate was stood for 6 days in a CO₂ incubator (5%CO₂), and the cell culture medium was transferred to a 1.5 mL micro testtube (manufactured by Eppendorf), the cell-attached GEM was accumulatedwhile gently pipetting on the above-mentioned magnet stand, and thesupernatant was removed. GEM was washed once with PBS (1 mL), 200 μL oftrypsin-EDTA (ethylenediaminetetraacetic acid) solution (manufactured byWAKO) was added, and the mixture was incubated at 37° C. for 10 min. To200 μL of the cell suspension obtained here was added 800 μL of DMEMmedium containing 10% (v/v) fetal bovine serum, the same amount ofTrypan Blue staining solution (manufactured by Invitrogen Corporation)was added to a part of the cell suspension, and the number of viablecells was measured by a hemocytometer (manufactured by ERMA INC.).

As a result, it was confirmed that, using the medium composition of thepresent invention, GEM adhered with HepG2 cells can be cultivated in asuspended state, and efficiently proliferates in the medium composition.Furthermore, it was confirmed that the medium composition of the presentinvention shows a cell proliferation promoting effect superior to thatof the existing media free of deacylated gellan gum. In addition, it wasconfirmed that, using magnetic force, HepG2 cell-attached GEM can becollected from the medium composition of the present invention, andfurther, HepG2 cells can be recovered from this GEM.

The cell number of HepG2 cells when cultured for 6 days on GEM in adeacylated gellan gum-containing or -free medium is shown in Table 30.In addition, the suspended state of HepG2 cell-attached laminin-coatedGEM when cultured in the medium composition of the present invention isshown in FIG. 14.

TABLE 30 HepG2 cell number (×10000/mL) deacylated laminin coatedfibronectin gellan gum GEM coated GEM absent 50.0 54.7 present 112.394.0

Experimental Example 31: Cell Suspension Test Using Magnetic BeadsHaving Cell Adhesion Ability—2

In the same manner as in Experimental Example 30, fibronectin-coated GEM(registered trade mark, Global Eukaryotic Microcarrier, manufactured byGL Sciences Inc.) was suspended in MF-Medium (registered trade mark)mesenchymal stem cell proliferation medium (manufactured by TOYOBO CO.,LTD.). This suspension was dispensed to a Sumilon cell tight plate 24F(manufactured by SUMITOMO BAKELITE), which is a cell low adhesion plate,at 50 μL per 1 well. Successively, separately prepared human bonemarrow-derived mesenchymal stem cell (manufactured by Cell Applications)was added at 250000 cells/mL and, in the same manner as in ExperimentalExample 30, this plate was stood overnight in a CO₂ incubator (5% CO₂)to prepare GEM adhered with mesenchymal stem cells.

By a method similar to that in Experimental Example 2, an MF-Medium(registered trade mark) mesenchymal stem cell proliferation medium(manufactured by TOYOBO CO., LTD.) composition containing 0.015% ofdeacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was prepared. This medium composition or the above medium free ofdeacylated gellan gum was each added by 1 mL to the mesenchymal stemcell-attached GEM (fibronectin-coated) prepared above, suspended, andtransferred to Sumilon cell tight plate 24F. Successively, this platewas stood for 4 days in a CO₂ incubator (5% CO₂), and the cell culturemedium was transferred to a 1.5 mL micro test tube is (manufactured byEppendorf), the cell-attached GEM was accumulated while gently pipettingon the above-mentioned magnet stand, and the supernatant was removed.GEM was washed once with PBS (1 mL), 200 μL of trypsin-EDTA(ethylenediaminetetraacetic acid) solution (manufactured by WAKO) wasadded, and the mixture was incubated at 37° C. for 10 min. To 200 μL ofthe cell suspension obtained here was added 800 μL of DMEM mediumcontaining 10% (v/v) fetal bovine serum, the same amount of Trypan Bluestaining solution (manufactured by Invitrogen Corporation) was added toa part of the cell suspension, and the number of viable cells wasmeasured by a hemocytometer (manufactured by ERMA INC.).

As a result, it was confirmed that, using the medium composition of thepresent invention, GEM adhered with mesenchymal stem cells can becultivated in a suspended state, and efficiently proliferates in themedium composition. Furthermore, it was confirmed that the mediumcomposition of the present invention shows a cell proliferationpromoting effect superior to that of the existing media withoutdeacylated gellan gum. In addition, it was confirmed that, usingmagnetic force, mesenchymal stem cell-attached GEM can be collected fromthe medium composition of the present invention, and further themesenchymal stem cells can be recovered from this GEM.

The cell number of mesenchymal stem cells when cultured for 4 days onGEM in a deacylated gellan gum-containing or -free medium is shown inTable 31.

TABLE 31 deacylated gellan mesenchymal stem cell gum number (×10000/mL)absent 11.3 present 20.9

Experimental Example 32: Cell Suspension Test Using Alginic Acid Bead

The following test was performed according to the method is of analginic acid three-dimensional culture kit manufactured by PG Research.Separately prepared HepG2 cells were added to a sodium alginate solution(manufactured by PG research, 2.5 mL) at 400000 cells/mL, and humanrecombinant laminin 511 (manufactured by Veritas Ltd.) was further addedat 5 μg/mL to prepare a cell suspension. The cell suspension wasrecovered with a 5 mL syringe (manufactured by TERUMO CORPORATION)having a gavage needle, and a 22G injection needle (manufactured byTERUMO CORPORATION) was set to this syringe. Successively, the cellsuspension was added by 10 drops to each well of a 24 well flat bottommicroplate (manufactured by PG research) added with 2 mL each of anaqueous calcium chloride solution (PG research manufactured by). Themixture was stood for 10 min at room temperature, formation of alginicacid bead was confirmed, the calcium chloride solution was removed, PBS(2 mL) was added, and the mixture was stood at room temperature for 15min.

Furthermore, PBS was removed, DMEM medium (manufactured by WAKO, 2 mL)containing 10% (v/v) fetal bovine serum was added and the mixture wasstood at room temperature for 15 min. The medium was removed, DMEMmedium (manufactured by WAKO) composition containing 0.03% deacylatedgellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) and 10%(v/v) fetal bovine serum, which was prepared by a method similar to thatin Experimental Example 2, or the above medium free of deacylated gellangum was added by 1 mL to each well, and the mixture was subjected tostatic culture for 8 days in a CO₂ incubator (5% CO₂). The medium wasexchanged on day 4 of culture.

The cultured alginic acid beads were transferred to a 1.5 is mL microtest tube (manufactured by Eppendorf) using a 1 mL tip, a sodium citratesolution (1 mL, manufactured by PG research) was added to each tube, andthe mixture was stirred at room temperature for 15 min to dissolve thealginic acid beads. Successively, cells were sedimented bycentrifugation at 300G for 3 min and the supernatant was removed. To thecells was added 200 μL of trypsin-EDTA (ethylenediaminetetraacetic acid)solution (manufactured by WAKO), and the mixture was incubated at 37° C.for 5 min. To the obtained cell suspension (200 μL) was added 800 μL ofDMEM medium containing 10% (v/v) fetal bovine serum, and to a part ofthe cell suspension was added the same amount of Trypan Blue stainingsolution (manufactured by Invitrogen Corporation), and the number of theviable cells was measured by a hemocytometer (manufactured by ERMAINC.).

As a result, it was confirmed that, using the medium composition of thepresent invention, alginic acid bead-embedded HepG2 cells can becultivated in a suspended state, and efficiently proliferates in themedium composition. Furthermore, it was confirmed that the mediumcomposition of the present invention shows a cell proliferationpromoting effect superior to that of the existing media withoutdeacylated gellan gum.

The cell number of HepG2 cells when cultured in alginic acid beads in adeacylated gellan gum-containing or -free medium for 8 days is shown inTable 32. In addition, the suspended state when the HepG2 cell-embeddedalginic acid beads were cultured in the medium composition of thepresent invention is shown in FIG. 16.

TABLE 32 deacylated gellan gum HepG2 cell number (×10000/mL) absent 34.9present 51.8

Experimental Example 33: Cell Suspension Test Using Collagen Gel Capsule

A: tissue culture collagen Cell matrix (registered trade mark) Type I-A(cell matrix, manufactured by Nitta Gelatin Inc.), B: 10-foldconcentration of DMEM/F-12 medium (manufactured by Aldrich), C:reconstitution buffer (obtained by adding sodium hydrogen carbonate (2.2g), HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)) (4.77 g)to 0.05N sodium hydroxide solution (100 mL) and subjecting the mixtureto filtration sterilization) were mixed at A:B:C=8:1:1 while cooling inice. Furthermore, human recombinant laminin 511 (manufactured by VeritasLtd.) was added at 5 μg/mL to prepare a collagen mixed solution (500μL). To the mixed solution was added separately-prepared HepG2 cells at200000 cell/mL, and the total amount was recovered using a 1.5 mLsyringe (manufactured by TERUMO CORPORATION) with a 25G injection needle(manufactured by TERUMO CORPORATION). Successively, the cell suspensionwas added dropwise by one drop to a flat bottom tube (manufactured by BMEquipment Co., Ltd.) containing DMEM medium (manufactured by WAKO) (10mL) containing 10% (v/v) fetal bovine serum and incubated in advance at37° C. using the above-mentioned syringe. The mixture was incubated in awater bath at 37° C. for 10 min and formation of an indeterminatecollagen gel capsule with a diameter of about 2 mm was confirmed,deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was added at a final concentration of 0.04% by a method similar to thatin Experimental Example 2, and the above-mentioned capsule was suspendedby gently stirring. Successively, the tube was subjected to staticculture in a CO₂ incubator (5% CO₂) for 5 days.

PBS (25 mL) was added to a culture medium containing a collagen gelcapsule, and the collagen gel capsule was sedimented by centrifugationat 400G for 5 min and the is supernatant was removed. Again, PBS (25 mL)was added, the mixture was centrifuged, and the supernatant was removedto make the amount of the rest 5 mL. To this solution was added 1% (W/V)collagenase L (manufactured by Nitta Gelatin Inc., 20 μL), and themixture was shaken at 37° C. for 2 hr. After confirming dissolution ofthe collagen gel, PBS (10 mL) was added, and the cells were sedimentedby centrifugation at 400G for 5 min and the supernatant was removed. Tothe cells was added 1 mL of trypsin-EDTA (ethylenediaminetetraaceticacid) solution (manufactured by WAKO), and the mixture was incubated at37° C. for 5 min. To the obtained cell suspension was added 4 mM of DMEMmedium containing 10% (v/v) fetal bovine serum, and the cells weresedimented by centrifugation at 400G for 5 min and the supernatant wasremoved. The obtained cells were suspended in 2 mL of the same mediumabove, and to a part thereof was added the same amount of Trypan Bluestaining solution (manufactured by Invitrogen Corporation), and thenumber of the viable cells was measured by a hemocytometer (manufacturedby ERMA INC.).

As a result, it was confirmed that, using the medium composition of thepresent invention, collagen gel capsule embedded with HepG2 cells can becultivated in a suspended state, and the cells efficiently proliferatein the medium composition. Furthermore, the medium composition of thepresent invention was confirmed to show a cell proliferation promotingeffect superior to that of the existing media without deacylated gellangum.

The cell number of HepG2 cells when cultured in collagen gel capsule ina deacylated gellan gum-containing or -free medium for 5 days is shownin Table 33. In addition, the suspended state when the HepG2cell-embedded collagen gel capsule was cultured in the mediumcomposition of the present invention is shown in FIG. 17.

TABLE 33 deacylated gellan gum HepG2 cell number (×10000/mL) absent 62.4 present 106.0

Experimental Example 34: Sphere Recovery Test Using Filter

A DMEM medium (manufactured by WAKO) composition containing 0.015%deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)and 10% (v/v) fetal bovine serum was prepared by a method similar tothat in Experimental Example 2. In addition, as a control, the samemedium free of deacylated gellan gum was prepared. HepG2 cell sphereswere formed by a method similar to that in Experimental Example 2, andadded to the medium (1 mL) prepared above by 86000 cells, the mixturewas stood at 37° C. for 1 hr, and the sphere cell suspension wasvisually observed. Furthermore, the cell suspension was added onto CellStrainers (manufactured by Becton, Dickinson and Company) having a meshsize of 40 μm to trap the spheres on the filter. Successively, PBS (10mL) was flowed from the backside of the filter to recover the spheres ina 15 mL tube, the spheres were sedimented by centrifugation at 300G for5 min. The supernatant was removed, 500 μL of trypsin-EDTA(ethylenediaminetetraacetic acid) solution (manufactured by WAKO) wasadded to the spheres, and the mixture was incubated at 37° C. for 5 min.To the obtained cell suspension was added a DMEM medium (1 mL)containing 10% (v/v) fetal bovine serum, to a part thereof was added thesame amount of Trypan Blue staining solution (manufactured by InvitrogenCorporation), and the number of viable cells was measured by ahemocytometer (manufactured by ERMA INC.). As a result, the sphere ofHepG2 cells was confirmed to maintain a suspended state in theabove-mentioned medium composition. Furthermore, it was confirmed thatthe cells of HepG2 cell sphere can be recovered at a recovery rateequivalent to that of a medium free of deacylated gellan gum by a filtertreatment of a sphere suspension containing 0.015% deacylated gellangum. The relative number recovered from the medium containing deacylatedgellan gum is shown in Table 34, wherein the number of the HepG2 cellsrecovered with a filter and using a medium free of deacylated gellan gumis 1.

TABLE 34 deacylated gellan gum relative HepG2 cell number absent 1.0present 1.1

Experimental Example 35: Cell Suspension Test of Sphere UsingCombination Agent of Various Polysaccharides

A DMEM/F-12 medium composition containing a combination of xanthan gum(KELTROL CG, manufactured by SANSHO Co., Ltd.), sodium alginate (Duckalginic acid NSPM, manufactured by FOOD CHEMIFA Co., Ltd.), locust beangum (GENUGUM RL-200-J, manufactured by SANSHO Co., Ltd.),methylcellulose (cP400, manufactured by WAKO), K-carageenan (GENUGELWR-80-J, manufactured by SANSHO Co., Ltd.), pectin (GENU pectinLM-102AS, manufactured by SANSHO Co., Ltd.) or diutan gum (KELCO CRETEDG-F, manufactured by SANSHO Co., Ltd.), and deacylated gellan gum(KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) was prepared by amethod similar to that in Experimental Example 15. In the same manner asin Experimental Example 2, spheres of HepG2 cells were produced, andseveral tens of spheres were added to each medium (1 mL) prepared above,the mixture was stood still at is 37° C. for 1 hr or one night, and thesuspended state of the sphere cells was visually observed. As a result,it was confirmed that the spheres of HepG2 cells maintained thesuspended state in any of the above-mentioned medium compositions.Furthermore, it was confirmed in all medium compositions that additionof a 2-fold amount of the medium and centrifugation (500G, 5 min) of thecell suspension result in sedimentation and recovery of the spheres ofHepG2 cells. The dispersion state of the sphere after one night wasconfirmed by visual observation, wherein a suspended and dispersed stateis ◯, partial sedimentation/dispersed state is Δ, and sedimented stateis x. The evaluation results are shown in Table 35 and Table 36. In theTable, —shows not performed.

TABLE 35 deacylated saccharides gellan gum addition diutan concentration(%) concentration (%) methylcellulose gum 0.005 0.05 — Δ 0.2  Δ —

TABLE 36 deacylated saccharides gellan gum addition locust concentrationconcentration xanthan sodium bean κ- diutan (%) (%) gum alginate gummethylcellulose carageenan pectin gum 0.01 0.05 — — — — ○ — ○ 0.1 ○ ○ ○— — Δ — 0.2 — — — ○ — — —

Comparison of Dispersibility of Beads and Cells—1

The dispersion state of dextran bead Cytodex (registered trade mark) 1(manufactured by GE Healthcare Life Sciences) and HeLa cell sphere wascompared between deacylgellan gum containing medium prepared above(Comparative Example) and a methylcellulose-containing medium. Theresults are shown in Table. Since the dispersion states of Cytodexl andHeLa cell sphere correlate well, Cytodexl can be used as a cell spheremodel.

TABLE 37 Cytodex1 HeLa cell deacylgellan gum suspension/ suspension/concentration % (w/v) sedimentation sedimentation 0.01suspension/partial suspension sedimentation 0.02 suspension suspension0.03 suspension suspension 0.05 suspension suspension

TABLE 38 Cytodex1 HeLa cell Methylcellulose suspension/ suspension/ %(w/v) sedimentation sedimentation 0.1 sedimentation sedimentation 0.3sedimentation sedimentation 0.6 sedimentation sedimentation 1.0sedimentation sedimentation

Comparison of Dispersibility of Beads and Cells—2

The dispersion state of polystyrene bead (Size 500-600 μm, manufacturedby Polysciences Inc.) and HepG2 cell sphere was compared between thepolysaccharide prepared in Experimental Example 15 and deacylgellangum-containing medium. A suspended and dispersed state is ◯, partialsedimentation/dispersed state is Δ, and sedimented state is x in theevaluation. The results are shown in Table. Since the dispersion statesof polystyrene bead and HepG2 cell sphere correlate well, polystyrenebead can be used as a cell sphere model.

TABLE 39 alginic locust bean xanthan gum acid Na gum diutan gumpolysaccharide PS HepG2 PS HepG2 PS HepG2 PS HepG2 concentration beadmass bead mass bead mass bead mass deacylated 0.05% ○ ○ gellan gum 0.1%○ ○ ○ ○ ○ ○ ○ concentration 0.01% (w/v) 0.2% ○ ○ ○

Experimental Example 36: Floating Culture Test of Rice-Derived PlantCallus

Fifty seeds of a fully ripe seed of rice Nipponbare selected with a saltsolution (purchased from Koto agricultural cooperatives) weretransferred to a 50 mL polystyrene tube (manufactured by BD Falcon),washed with sterilized water (50 mL), and stirred in 70% ethanol water(30 mL) for 1 min. Ethanol water was removed, Kitchen Haiter(manufactured by Kao Corporation, 30 mL) was added, and the mixture wasstirred for 1 is hr. Kitchen Haiter was removed, and washed 4 times withsterilized water (50 mL). The sterilized seeds were cultured onMurashige Skoog basal medium (M9274, manufactured by Sigma Aldrich)containing 2 μg/mL 2,4-dichlorophenoxyacetic acid (manufactured by SigmaAldrich) and agar at 1.5 mL/well (24 well flat bottom microplate(manufactured by Corning Incorporated)). They were cultured under theconditions of 30° C., 16 hr dark place/8 hr dark place for 3 weeks, andcream-colored calluses (1-2 mm) grown on the seed blastocyst wereharvested.

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.03% (w/v) to Murashige Skoog basal medium(M9274, manufactured by Sigma Aldrich) containing 2 μg/mL2,4-dichlorophenoxyacetic acid (manufactured by Sigma Aldrich). 15calluses prepared above were added to this medium composition in a 10mL/flat bottom tube (manufactured by BM Equipment Co., Ltd.), andcultured with shaking at 25° C. for 7 days. As a result, it wasconfirmed that, using the medium composition of the present invention,rice-derived callus could be cultivated in a suspended state, and thecalluses were maintained in the medium composition. The suspended stateis shown in FIG. 18 when the rice-derived callus was cultured in themedium composition of the present invention.

Experimental Example 37: Cell Proliferation Test by Dispersing HeLaCells

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at is 90° C. This aqueous solutionwas sterilized at 121° C. for 20 min in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.015% (w/v) or 0.030% (w/v) to DMEMmedium containing 10% (v/v) fetal bovine serum (manufactured by WAKO).Successively, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 50000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) to 200μL/well. As a negative control, HeLa cells were suspended in theabove-mentioned medium free of deacylated gellan gum and the suspensionwas dispensed. Successively, this plate was cultured by being stoodstill in a CO₂ incubator (37° C., 5% CO₂) for 8 days. After culturingfor 3 and 8 days, to the culture medium was added a WST-8 solution(manufactured by DOJINDO Laboratories, 20 μL), and the mixture wasincubated at 37° C. for 100 min. The absorbance at 450 nm was measuredby an absorbance spectrometer (manufactured by Molecular Devices,SPECTRA MAX 190), and the number of viable cells was measured bysubtracting the absorbance of the medium alone. The culture mediumcontaining the cells after 8 days of culture was stirred with a pipetteand the obtained stirred solution (20 μL) was mixed with Trypan Bluestain 0.4% (manufactured by Invitrogen, 20 μL) and the cell density wasmeasured under a microscope.

As a result, it was confirmed that, using the medium composition of thepresent invention, HeLa cells can be cultivated in a uniformly dispersedstate without forming a cell aggregate having an excessive size, andefficiently proliferates in the medium composition. The results ofmicroscopic observation of an aggregate of HeLa cells after culture for8 is days are shown in FIG. 19. In addition, the absorbance at 450 nm(corresponding to the number of HeLa cells) after static culture for 3,8 days is shown in Table 40. The cell density of HeLa cells afterculturing for 8 days is shown in Table 41.

TABLE 40 culture day number 3 8 cell negative control 0.119 0.191 numberdeacylgellan gum 0.015% 0.426 0.329 deacylgellan gum 0.030% 0.547 0.423

TABLE 41 experiment group cell density (10⁴ cells/mL) negative control3.7 deacylgellan gum 0.015% 8.9 deacylgellan gum 0.030% 11.2

Experimental Example 38: Cell Proliferation Test by Dispersing A549 Celland HCT116 Cell

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to DMEM medium containing 10% (v/v)fetal bovine serum (manufactured by WAKO) or McCoy's 5a medium(manufactured by DS PHARMA BIOMEDICAL CO., LTD.). Successively, humanlung cancer cell line A549 (manufactured by DS PHARMA is BIOMEDICAL CO.,LTD.) or human colorectal cancer cell line HCT116 (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 50000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 200μL/well. As a negative control, A549 cells and HCT116 cells weresuspended in the above-mentioned medium free of deacylated gellan gumand the suspension was dispensed. Successively, this plate was culturedby being stood still in a CO₂ incubator (37° C., 5% CO₂) for 7 days.After culturing for 3, 5 and 7 days, to the culture medium was added aWST-8 solution (manufactured by DOJINDO Laboratories, 20 μL), and themixture was incubated at 37° C. for 100 min. The absorbance at 450 nmwas measured by an absorbance spectrometer (manufactured by MolecularDevices, SPECTRA MAX 190), and the number of viable cells was measuredby subtracting the absorbance of the medium alone.

As a result, it was confirmed that, using the medium composition of thepresent invention, A549 cells and HCT116 cells can be cultivated in auniformly dispersed state without forming a cell aggregate having anexcessive size, and efficiently proliferate in the medium composition.The results of microscopic observation of an aggregate of A549 cells andHCT116 cells after culture for 5 days are shown in FIG. 20. In addition,after static culture for 3, 5, 7 days, the absorbance at 450 nm(corresponding to the number of A549 cells) is shown in Table 42 and theabsorbance at 450 nm (corresponding to the number of HCT116 cells) isshown in Table 43.

TABLE 42 culture day number 3 5 7 cell negative control 0.152 0.1390.213 number deacylgellan gum 0.435 1.406 2.041

TABLE 43 culture day number 3 5 7 cell negative control 0.177 0.1140.115 number deacylgellan gum 1.444 1.959 2.191

Experimental Example 39: Cell Proliferation Test Using Low AdhesionSurface Plate with U Bottom

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to DMEM medium containing 10% (v/v)fetal bovine serum (manufactured by WAKO). Successively, human cervicalcancer cell line HeLa (manufactured by DS PHARMA BIOMEDICAL CO., LTD.)was inoculated to the above-mentioned medium composition added withdeacylated gellan gum at 50000 cells/mL, and dispensed to the wells of a96-well U bottom low adhesion surface microplate (manufactured bySUMITOMO BAKELITE, #MS-9096U) at 200 μL/well. As a negative control,HeLa cells were suspended in the above-mentioned medium free ofdeacylated gellan gum and the suspension was dispensed. Successively,this plate was cultured by being stood still in a CO₂ incubator (37° C.,5% CO₂) for 7 days. To the culture medium after culturing for 2, 5 and 7days was added a TWT-8 solution (manufactured by DOJINDO Laboratories,20 μL), and the mixture was incubated at 37° C. for 100 min. Theabsorbance at 450 nm was measured by an absorbance is spectrometer(manufactured by Molecular Devices, SPECTRA MAX 190), and the number ofviable cells was measured by subtracting the absorbance of the mediumalone.

As a result, efficient proliferation also in other low adhesion plate byusing the medium composition of the present invention was confirmed. Theabsorbance at 450 nm (corresponding to the number of HeLa cells) afterstatic culture for 2, 5, 7 days is shown in Table 44.

TABLE 44 culture day number 2 5 7 cell negative control 0.042 0.0480.019 number deacylgellan gum 0.357 0.488 0.451

Experimental Example 40: Cell Proliferation Test by Using Low AdhesionSurface Plate Manufactured by Other Company

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at finalconcentrations of 0.005% and 0.030% (w/v) to DMEM medium containing 10%(v/v) fetal bovine serum (manufactured by WAKO). Successively, humancervical cancer cell line HeLa (manufactured by DS PHARMA BIOMEDICALCO., LTD.) was inoculated to the above-mentioned medium compositionadded with deacylated gellan gum at 50000 cells/mL, and dispensed to thewells of a 96-well flat bottom low adhesion surface microplate(manufactured by IWAKI, #Ez-BindShut) at 200 μL/well. As a negativecontrol, HeLa cells is were suspended in the above-mentioned medium freeof deacylated gellan gum and the suspension was dispensed. Successively,this plate was cultured by being stood still in a CO₂ incubator (37° C.,5% CO₂) for 7 days. To the culture medium after culturing for 3 days wasadded a WST-8 solution (manufactured by DOJINDO Laboratories, 20 μL),and the mixture was incubated at 37° C. for 100 min. The absorbance at450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190), and the number of viable cells wasmeasured by subtracting the absorbance of the medium alone.

As a result, efficient proliferation also in other low adhesion plate byusing the medium composition of the present invention was confirmed. Theabsorbance at 450 nm (corresponding to the number of HeLa cells) afterstatic culture for 3 days is shown in Table 45.

TABLE 45 culture day number 3 cell negative control 0.064 numberdeacylgellan gum 0.005% 0.140 deacylgellan gum 0.030% 0.257

Experimental Example 41: Cell Proliferation Comparison Test with HappyCell ASM Medium

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to DMEM medium containing 10% (v/v)is fetal bovine serum (manufactured by WAKO). Happy Cell ASM medium(manufactured by biocroi) was adjusted with DMEM medium (manufactured byWAKO) in advance to a given concentration (mixed at 1:1). Successively,human cervical cancer cell line HeLa (manufactured by DS PHARMABIOMEDICAL CO., LTD.) or human lung cancer cell line A549 (manufacturedby DS PHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum or Happy Cell ASMmedium composition at 50000 cells/mL, and dispensed to the wells of a96-well flat bottom ultra low adhesion surface microplate (manufacturedby Corning Incorporated, #3474) at 200 μL/well. As a negative control,HeLa cells and A549 cells were suspended in the above-mentioned mediumfree of deacylated gellan gum and the suspension was dispensed.Successively, the plate was cultured by being stood still in a CO₂incubator (37° C., 5% CO₂) for 5 days. To the culture medium afterculturing for 3 and 5 days was added a WST-8 solution (manufactured byDOJINDO Laboratories, 20 μL), and the mixture was incubated at 37° C.for 100 min. The absorbance at 450 nm was measured by an absorbancespectrometer (manufactured by Molecular Devices, SPECTRA MAX 190), andthe number of viable cells was measured by subtracting the absorbance ofthe medium alone.

As a result, it was confirmed that, using the medium composition of thepresent invention, the cell efficiently proliferated in the mediumcomposition as compared to Happy Cell ASM. The absorbance at 450 nm(corresponding to the number of HeLa cells) after static culture for 3,5 days is shown in Table 46 and the absorbance at 450 nm (correspondingto the number of A549 cells) is shown in Table 47.

TABLE 46 culture day number 3 5 cell negative control 0.111 0.091 numberdeacylgellan gum 0.288 0.325 Happy Cell ASM 0.074 0.063

TABLE 47 culture day number 3 5 cell negative control 0.244 0.262 numberdeacylgellan gum 0.696 2.177 Happy Cell ASM 0.286 0.546

Experimental Example 42: Cell Proliferation Test Using OtherPolysaccharides

Diutan gum (KELCO CRETE DG-F, manufactured by SANSHO Co., Ltd.) wassuspended in ultrapure water (Milli-Q water) to 1.5% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding diutan gum at finalconcentrations of 0.2% and 0.3% (w/v) to DMEM medium (manufactured byNISSUI PHARMACEUTICAL CO., LTD.) containing 10% (v/v) fetal bovineserum. Successively, human lung cancer cell line A549 (manufactured byDS PHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with diutan gum at 50000 cells/mL, anddispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 200μL/well. As a negative control, A549 cells were suspended in theabove-mentioned medium free of diutan gum and the suspension wasdispensed.

Successively, this plate was cultured by being stood still in a CO₂incubator (37° C., 5% CO₂) for 3 days. To the culture medium afterculturing for 3 days was added a WST-8 solution (manufactured by DOJINDOLaboratories, 20 μL), and the mixture was incubated at 37° C. for 100min. The absorbance at 450 nm was measured by an absorbance spectrometer(manufactured by Molecular Devices, SPECTRA MAX 190), and the number ofviable cells was measured by subtracting the absorbance of the mediumalone.

As a result, efficient proliferation in the medium composition of thepresent invention containing other polysaccharides was confirmed. Theabsorbance at 450 nm (corresponding to the number of A549 cells) afterstatic culture for 3 days is shown in Table 48.

TABLE 48 culture day number 3 cell negative control 0.696 number diutangum 0.1% 1.781 diutan gum 0.030% 2.367

Experimental Example 43: Cell Proliferation Test Using VariousAnticancer Drugs

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.030% (w/v) and various anticancer drugs at isfinal concentrations of 0.001, 0.01, 0.1, 1 μM to DMEM medium containing10% (v/v) fetal bovine serum (manufactured by WAKO). The anticancer drugused was Adriamycin (manufactured by WAKO), Paclitaxel (manufactured byWAKO) or Mitomycin C (manufactured by WAKO). Successively, humancervical cancer cell line HeLa (manufactured by DS PHARMA BIOMEDICALCO., LTD.) was inoculated to the above-mentioned medium compositionadded with deacylated gellan gum at 50000 cells/mL, and dispensed to thewells of a 96-well flat bottom ultra low adhesion surface microplate(manufactured by Corning Incorporated, #3474) at 200 μL/well.

As without addition, HeLa cells were suspended in the above-mentionedmedium containing only deacylated gellan gum at a final concentration of0.030% (w/v) and the suspension was dispensed. Successively, this platewas cultured by being stood still in a CO₂ incubator (37° C., 5% CO₂)for 7 days. After culturing for 3, 5, 7 days, to the culture medium wasadded a WST-8 solution (manufactured by DOJINDO Laboratories, 20 μL),and the mixture was incubated at 37° C. for 100 min. The absorbance at450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190), and the number of viable cells wasmeasured by subtracting the absorbance of the medium alone. The culturemedium containing the cells after 5 days of culture was stirred with apipette and the obtained stirred solution (20 μL) was mixed with TrypanBlue stain 0.4% (manufactured by Invitrogen, 20 μL) and the cell densitywas measured under a microscope.

As a result, it was confirmed that anticancer drugs can be efficientlyevaluated by the cell proliferation test method using the mediumcomposition of the present invention. In addition, the absorbance at 450nm (corresponding to the number of HeLa cells) after static culture for3, 5, 7 days is shown in Table 49. The cell density of HeLa cells 5 dayslater is shown is in Table 50.

TABLE 49 culture day number 3 5 7 cell without addition 0.200 0.2540.242 number Adriamycin 0.237 0.246 0.184 0.001 μM Adriamycin 0.2300.098 0.068 0.01 μM Adriamycin 0.037 0.005 <0 0.1 μM Adriamycin <0 <0 <01 μM Paclitaxel 0.276 0.223 0.222 0.001 μM Paclitaxel 0.019 <0 <0 0.01μM Paclitaxel <0 <0 <0 0.1 μM Paclitaxel <0 <0 <0 1 μM Mitomycin C 0.0890.016 <0 0.01 μM Mitomycin C 0.032 <0 <0 0.1 μM Mitomycin C <0 <0 <0 1μM

TABLE 50 experiment group cell density (10⁴ cells/mL) without addition4.8 Adriamycin 0.001 μM 5.1 Adriamycin 0.01 μM 2.6 Adriamycin 0.1 μM 1.7Adriamycin 1 μM 0.6 Paclitaxel 0.001 μM 5.3 Paclitaxel 0.01 μM 1.6Paclitaxel 0.1 μM 0.9 Paclitaxel 1 μM 0.2 Mitomycin C 0.01 μM 1.0Mitomycin C 0.1 μM 0.4 Mitomycin C 1 μM 0.1

Experimental Example 44: Maintenance and Function Test of Human PrimaryHepatocytes

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at is 90° C. This aqueous solutionwas sterilized at 121° C. for 20 min in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.015% or 0.030% (w/v) to HBM medium(manufactured by Lonza Japan) added with additives (HCM single Quots(registered trade mark), BSA-Fatty acid free, EGF, Ascorbic acid,Transferrin, Insulin, GA-1000, Hydrocortisone 21 hemisuccinate; LonzaJapan). Successively, the frozen human primary hepatocytes (manufacturedby Xenotech) were inoculated to the above-mentioned medium compositionadded with deacylated gellan gum at 250000 cells/mL, and dispensed tothe wells of a 96-well U bottom ultra low adhesion surface microplate(manufactured by SUMITOMO BAKELITE, PrimeSurface, MS-9096U) at 200μL/well. As a negative control, human primary hepatocytes were suspendedin the above-mentioned medium free of deacylated gellan gum and thesuspension was dispensed. Successively, this plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂) for 3 days.

1. Measurement of Number of Viable Cells

To the culture medium after culturing for 4 hr, 8 hr, 1 day was added aTWT-8 solution (manufactured by DOJINDO Laboratories, 20 μL), and themixture was incubated at 37° C. for 100 min. The absorbance at 450 nmwas measured by an absorbance spectrometer (manufactured by MolecularDevices, SPECTRA MAX 190) to measure the number of viable cells.

2. Analysis of Secretion Amount of Albumin

After culturing for 3 days, the culture medium containing hepatocyteswas recovered, and the culture supernatant was recovered bycentrifugation (400 g, 3 min). The concentration of human albumin in themedium was measured using an Albumin ELISA Quantitation kit(manufactured by Bethyl Laboratories).

3. mRNA Expression Analysis by Real-Time PCR Method

The culture medium containing hepatocytes after culturing for 8 hr wasrecovered, and the cells were recovered by centrifugation (400 g, 3min). The total RNA was extracted from the cells using RNeasy Mini kit(manufactured by QIAGEN). Using the total RNA and PrimeScript(registered trade mark) RT Master Mix (manufactured by Takara Bio Inc.),a reverse transcription reaction was performed using GeneAmp PCR System9700 (manufactured by Applied Biosystems) to synthesize cDNA. As eachcDNA sample used for PCR reaction was obtained by dispensing anddiluting 1/10 with sterilized water. In addition, as a sample to be usedfor calibration curve, cDNA dispensed and mixed was used, and set withinthe quantification range of 1/3 to 1/243 dilution at 3-fold commonratio. The PCR reaction was performed using each cDNA sample,calibration sample, Premix Ex Taq (registered trade mark) (manufacturedby Takara Bio Inc.) and various Taqman probes (manufactured by AppliedBiosystems), and 7500 Real-time PCR System (manufactured by AppliedBiosystems). The specificity was calculated using mRNA of GAPDH as anendogenous control, expression of each mRNA was corrected is with thevalue of GAPDH (Glyceraldehyde 3-phosphate dehydrogenase), and thenegative control as 100%.

Each probe (manufactured by Applied Biosystems) used is shown below.

GAPDH: HS99999905

Albumin: HS99999922

Cyp3A4: HS00604506

Cyp2C9: HS02383631

PXR (Pregnane X receptor): HS01114267

ApoA1 (Apolipoprotein A1): HS00163641

As a result, the medium composition of the present invention wasconfirmed to have an effect of maintaining human primary hepatocytes ina dispersed state and suppressing a decrease in the viable cell numberby protection. Also, it was confirmed that the medium composition showsa higher albumin producing ability and a higher mRNA group expressingability relating to the pharmacokinetics than the negative control. Theabsorbance at 450 nm (corresponding to the number of human 35 primaryhepatocytes) after static culture for 4 hr, 8 hr, 1 day is shown inTable 51. The albumin value of the culture supernatant after staticculture for 3 days is shown in Table 52. In addition, each mRNAexpression value based on the negative control after static culture for8 hr as 100% is shown in Table 53. The cell state when human primaryhepatocytes were cultured for 4 hr is shown in FIG. 21.

TABLE 51 culture day number 4 hr 8 hr 1 day cell negative control 0.7630.470 0.267 number deacylgellan gum 1.223 0.779 0.376 0.015%deacylgellan gum 0.918 0.739 0.352 0.030%

TABLE 52 experiment group Albumin (ng/mL) negative control 452deacylgellan gum 0.015% 614 deacylgellan gum 0.030% 685

TABLE 53 deacylgellan deacylgellan negative gum gum control 0.015%0.030% Albumin 100 124 135 Cyp3A4 100 101 113 Cyp2C9 100 106 125 PXR 100117 202 ApoA1 100 95 153

Experimental Example 45: Maintenance and Function Test of CynomolgusMonkey Primary Hepatocytes

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal is concentration of 0.015% or 0.030% (w/v) to HBM medium(manufactured by Lonza Japan) added with additives (HCM single Quots(registered trade mark), BSA-Fatty acid free, EGF, Ascorbic acid,Transferrin, Insulin, GA-1000, Hydrocortisone 21 hemisuccinate; LonzaJapan). Successively, the frozen Cynomolgus monkey primary hepatocytes(manufactured by Ina Research) were inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 250000 cells/mL,and dispensed to the wells of a 96-well U bottom ultra low adhesionsurface microplate (manufactured by SUMITOMO BAKELITE, PrimeSurface,MS-9096U) at 200 μL/well. As a negative control, Cynomolgus monkeyprimary hepatocytes were suspended in the above-mentioned medium free ofdeacylated gellan gum and the suspension was dispensed. Successively,this plate was cultured by being stood still in a CO₂ incubator (37° C.,5% CO₂) for 3 days.

1. Measurement of Number of Viable Cells

To culture media after culturing for 4 hr, 8 hr, 1 day and 3 days wasadded a TWT-8 solution (manufactured by DOJINDO Laboratories, 20 μL),and the mixtures were incubated at 37° C. for 100 min. The absorbance at450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190) to measure the number of viablecells.

2. Analysis of Secretion Amount of Albumin

After culturing for 3 days, the culture medium containing hepatocyteswas recovered, and the culture supernatant was recovered bycentrifugation (400 g, 3 min). The concentration of human albumin in themedium was measured using an Albumin ELISA Quantitation kit(manufactured by Bethyl Laboratories).

3. Expression Analysis of mRNA by Real-Time PCR

The culture media containing hepatocytes after culturing is for 1, 2, 3days were recovered, and the cells were recovered by centrifugation (400g, 3 min). Total RNA was extracted from the cells using RNeasy Mini kit(manufactured by QIAGEN). Using the total RNA and PrimeScript(registered trade mark) RT Master Mix (manufactured by Takara Bio Inc.),a reverse transcription reaction was performed using GeneAmp PCR System9700 (manufactured by Applied Biosystems) to synthesize cDNA. As eachcDNA sample used for PCR reaction was obtained by dispensing anddiluting 1/10 with sterilized water. In addition, as a sample to be usedfor calibration curve, cDNA dispensed and 25 mixed was used, and setwithin the quantification range of 1/3 to 1/243 dilution at 3-foldcommon ratio. The PCR reaction was performed using each cDNA sample,calibration sample, Premix Ex Taq (registered trade mark) (manufacturedby Takara Bio Inc.) and various Taqman probes (manufactured by AppliedBiosystems), and 7500 Real-time PCR System (manufactured by AppliedBiosystems). The specificity was calculated using mRNA of GAPDH as anendogenous control, expression of each mRNA was amended with the valueof GAPDH.

Each probe (manufactured by Applied Biosystems) used is shown below.

GAPDH: Rh02621745

Albumin: Rh02789672

ApoA1 (Apolipoprotein A1): Rh02794272

As a result, the medium composition of the present invention wasconfirmed to provide a suppressive effect on a decrease in the viablecell number by protecting Cynomolgus monkey primary hepatocytes. Also,it was confirmed that the hepatocytes cultured in the medium compositionshows a higher albumin producing ability and a higher mRNA groupexpressing ability of Albumin and ApoA1 than the negative control. Theabsorbance at 450 nm (corresponding to the number of Cynomolgus ismonkey primary hepatocytes) after static culture for 4 hr, 8 hr, 1 day,3 days is shown in Table 54. The albumin value of the culturesupernatant after static culture for 3 days is shown in Table 55. Inaddition, the mRNA expression value of Albumin after static culture for2, 3 days based on the negative control as 100% is shown in Table 56,and the mRNA expression value of ApoA1 is shown in Table 57. The cellstate when Cynomolgus monkey primary hepatocytes were cultured for 4 hris shown in FIG. 22.

TABLE 54 culture day number 4 hr 8 hr 1 day 3 day cell negative control0.442 0.328 0.267 0.240 number deacylgellan gum 0.708 0.563 0.360 0.2660.015% deacylgellan gum 0.662 0.542 0.381 0.251 0.030%

TABLE 55 experiment group Albumin (ng/mL) negative control 420 deacylgellan gum 0.015% 485 deacyl gellan gum 0.030% 499

TABLE 56 negative deacylgellan gum deacylgellan gum Albumin control0.015% 0.030% day 2 100 124 111 day 3 100 132 153

TABLE 57 negative deacylgellan deacylgellan gum ApoA1 control gum 0.015%0.030% day 2 100 139 221 day 3 100 118 105

Experimental Example 46: Maintenance and Function Test of Hepatocytes inCollagen-Coated Microplate

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% or 0.030% (w/v) to HBM medium(manufactured by Lonza Japan) added with additives (HCM single Quots(registered trade mark), BSA-Fatty acid free, EGF, Ascorbic acid,Transferrin, Insulin, GA-1000, Hydrocortisone 21 hemisuccinate; LonzaJapan). Successively, the frozen Cynomolgus monkey primary hepatocytes(manufactured by Ina Research) were inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 100000 cells/mL,and dispensed to the wells of a 96-well collagen coated microplate(manufactured by IWAKI, 4860-010) at 200 μL/well. As a negative control,Cynomolgus monkey primary hepatocytes were suspended in theabove-mentioned medium free of deacylated is gellan gum and thesuspension was dispensed. Successively, this plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂) for 3 days.

1. Measurement of Number of Viable Cells

To the culture medium after culturing for 1 day was added a WST-8solution (manufactured by DOJINDO Laboratories, 20 μL), and the mixturewas incubated at 37° C. for 100 min. The absorbance at 450 nm wasmeasured by an absorbance spectrometer (manufactured by MolecularDevices, SPECTRA MAX 190) to measure the number of viable cells.

2. Analysis of Amount of Albumin to be Secreted

After culturing for 3 days, the culture medium containing hepatocyteswas recovered, and a culture supernatant was recovered by centrifugation(400 g, 3 min). The concentration of human albumin in the medium wasmeasured using an Albumin ELISA Quantitation kit (manufactured by BethylLaboratories).

As a result, it was confirmed that, using the medium composition of thepresent invention, protection of the primary hepatocytes in the mediumcomposition suppresses a decrease in the viable cell number even when acollagen-coated plate is used. Also, it was confirmed that the mediumcomposition shows higher albumin production ability than the negativecontrol. The absorbance at 450 nm (corresponding to the number ofCynomolgus monkey primary hepatocytes) after static culture for 1 day isshown in Table 58. In addition, the albumin value of the culturesupernatant after static culture for 3 days is shown in Table 59.

TABLE 58 culture day number 1 day cell negative control 0.038 numberdeacylgellan gum 0.067 0.015% deacylgellan gum 0.087 0.030%

TABLE 59 experiment group Albumin (ng/mL) negative control 97deacylgellan gum 0.015% 161 deacylgellan gum 0.030% 157

Experimental Example 47: Comparison Test with Happy Cell ASM Medium

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by mixing HBM medium (manufactured byLonza Japan) added with additives (HCM single Quots (registered trademark), BSA-Fatty acid free, EGF, Ascorbic acid, Transferrin, Insulin,GA-1000, Hydrocortisone 21 hemisuccinate; Lonza Japan) to DMEM medium(manufactured by WAKO) at 1:1 and adding deacylated gellan gum at afinal concentration of 0.015% (w/v). The Happy Cell ASM medium(manufactured by biocroi) was prepared with DMEM medium in advance to agiven concentration (mixed at 1:1). Successively, the frozen humanprimary hepatocytes (manufactured by Xenotech) were inoculated to theabove-mentioned medium composition added with deacylated gellan gum orHappy Cell ASM is medium composition at 250000 cells/mL, and dispensedto the wells of a 96-well U bottom ultra low adhesion surface microplate(manufactured by SUMITOMO BAKELITE) at 200 μL/well. As a negativecontrol, human primary hepatocytes were suspended in the above-mentionedmedium free of deacylated gellan gum and the suspension was dispensed.Successively, this plate was cultured by being stood still in a CO₂incubator (37° C., 5% CO₂) for 6 days.

1. Measurement of Number of Viable Cells

To the culture media after culturing for 2 hr, 4 hr, 8 hr, 1 day, 4 daysand 6 days was added a WST-8 solution (manufactured by DOJINDOLaboratories, 20 μL), and the mixtures were incubated at 37° C. for 100min. The absorbance at 450 nm was measured by an absorbance spectrometer(manufactured by Molecular Devices, SPECTRA MAX 190) to measure thenumber of viable cells.

As a result, it was confirmed that the medium composition of the presentinvention is superior in the effect of suppressing a decrease in theviable cell number by protection of the primary hepatocytes, as comparedto Happy Cell ASM. The absorbance at 450 nm (corresponding to the numberof human primary hepatocytes) after static culture for 2 hr, 4 hr, 8 hr,1 day, 4 days, 6 days is shown in Table 60.

TABLE 60 culture day number 2 hr 4 hr 1 day 4 days 6 days cell negative1.162 0.544 0.396 0.336 0.241 number control deacylgellan 2.057 1.0600.478 0.390 0.314 gum 0.015% Happy Cell 1.184 0.564 0.368 0.229 0.223ASM

Experimental Example 48: Toxicity Test of Compound to Hepatocytes

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. On the other hand,HepG2 cells was mixed with DMEM medium (manufactured by WAKO) at 100000cells/mL, and the cell suspension was dispensed to the wells of a96-well flat bottom ultra low adhesion surface microplate (manufacturedby Corning Incorporated, #3474) at 100 μL/well. To the above-mentionedaqueous deacylated gellan gum solution was added Troglitazone(manufactured by WAKO, #71750) at each concentration, and this solution(10 μL) was added to the above-mentioned cell suspension (100 μL). Bythe above-mentioned treatments, a cell suspension having a DMSOconcentration of 0.18% (v/v), a Troglitazone concentration of 20.0,40.0, 60.0, 100 (μmol/L), and a deacylated gellan gum concentration of0.015% (w/v) was prepared. Successively, this plate was cultured bybeing stood still in a CO₂ incubator (37° C., 5% CO₂) for 1 day.

1. Measurement of Number of Viable Cells

The culture medium (50 μL) after culturing for 1 day was dispensed to a96-well titer plate (manufactured by Corning Incorporated), to thisculture medium was added a Cell Titer-Glo (registered trade mark)reagent (manufactured by Promega, 50 μL), and the mixture was incubatedat room temperature for 10 min. The luminescence intensity was measuredby a multiplate reader is (manufactured by Molecular Devices,FlexStation3) to measure the number of viable cells.

2. Lactic Acid Dehydrogenase (LDH) Activity Measurement

To the culture medium (100 μL) after culturing for 1 day was added DMEMmedium (manufactured by WAKO, 100 μL), and the plate was centrifuged by440G for 15 min. The supernatant (100 μL) was dispensed to a 96-welltiter plate (manufactured by Corning Incorporated), a reaction mixture(100 μL) in a cytotoxicity detection kit (manufactured by Roche AppliedScience) was added, and the mixture was stood under shading at roomtemperature for 30 min. Successively, according to the protocol of theabove-mentioned kit, the absorbance at 490 nm (reference; 600 nm) wasmeasured by an absorbance spectrometer (manufactured by MolecularDevices, SPECTRA MAX 190), whereby the rate of the disordered cell, thatis, cell disorder rate (%), was measured.

As a result, it was confirmed that, using the medium composition of thepresent invention, Troglitazone has cytotoxicity of hepatocytes. Therelative cell number and cell disorder rate (%) are shown in Table 61when no addition condition after culturing for 1 day is 1.

TABLE 61 culture day number Troglitazone (μM) negative 0 20 40 60 100control relative cell 1.00 0.68 0.50 0.48 0.39 number cell disorder 02.68 14.7 22.5 60.7 rate (%)

Experimental Example 49: Cell Proliferation Test Using A549 Cell by ATPQuantification Method

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at is 90° C. This aqueous solutionwas sterilized at 121° C. for 20 min in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.005% (w/v), 0.015% (w/v) or 0.030%(w/v) to DMEM medium containing 10% (v/v) fetal bovine serum(manufactured by WAKO). Successively, human lung cancer cell line A549(manufactured by DS PHARMA BIOMEDICAL CO., LTD.) was inoculated to theabove-mentioned medium composition added with deacylated gellan gum at100000 cells/mL, and dispensed to the wells of a 96-well flat bottomultra low adhesion surface microplate (manufactured by CorningIncorporated, #3474) at 100 μL/well. As a negative control, A549 cellswere suspended in the above-mentioned medium free of deacylated gellangum and the suspension was dispensed. Successively, this plate wascultured by being stood still in a CO₂ incubator (37° C., 5% CO₂) for 5days. To the culture medium after culturing for 1, 3 and 5 days wasadded a ATP reagent (100 μL) (CellTiter-Glo (registered trade mark)Luminescent Cell Viability Assay, manufactured by Promega) to give asuspension, which was stood for about 10 min at room temperature, andthe luminescence intensity (RLU value) was measured by FlexStation3(manufactured by Molecular Devices), and the number of viable cells wasmeasured by subtracting the luminescence value of the medium alone. ForWST-8 measurement, a WST-8 solution (manufactured by DOJINDOLaboratories, 10 μL) was added to the cells after culturing for 3 days,and the is mixture was incubated at 37° C. for 100 min. The absorbanceat 450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190), and the number of viable cells wasmeasured by subtracting the absorbance of the medium alone.

As a result, it was also confirmed by the ATP measurement method thatA549 cell efficiently proliferates when the medium composition of thepresent invention is used. The RLU value (ATP measurement, luminescenceintensity) after static culture for 1, 3 and 5 days is shown in Table62. The absorbance at 450 nm (WST-8) and RLU value (ATP measurement,luminescence intensity) after culturing for 3 days is shown in Table 63.

TABLE 62 culture day number 1 3 5 cell negative control 7931 11183 16169number deacylgellan gum 7931 17623 29535 0.005% deacylgellan gum 856721021 39506 0.015% deacylgellan gum 7688 20492 39020 0.030%

TABLE 63 experiment group WST-8 ATP negative control 0.617 11183deacylgellan gum 0.906 17623 0.005% deacylgellan gum 1.149 21021 0.015%deacylgellan gum 1.239 20492 0.030%

Experimental Example 50: Comparison with Single Layer Culture Method inCell Proliferation Test Using Anticancer Drug

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at is 90° C. This aqueous solutionwas sterilized at 121° C. for 20 min in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.015% (w/v) to DMEM medium containing10% (v/v) fetal bovine serum (manufactured by WAKO), and a mediumcomposition free of deacylated gellan gum was prepared.

Successively, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single layer culture method, human cervical cancer cellline HeLa was inoculated to the above-mentioned medium composition freeof deacylated gellan gum at 37000 cells/mL, and dispensed to the wellsof a 96-well flat bottom microplate (manufactured by CorningIncorporated, #3585) at 135 μL/well. Each plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂). On culture day 1,medium compositions containing a 10-fold concentration of variousanticancer drugs to make the final concentration 0.001 to 1 μM, and afinal concentration 0.015% (w/v) of deacylated gellan gum (deacylatedgellan gum addition group), and a medium composition containing a10-fold concentration of various anticancer drugs alone (single layerculture group) were each added by 15 μL, and the cells were issuccessively cultured for 3 days. The anticancer drug used wasAdriamycin (manufactured by WAKO), Paclitaxel (manufactured by WAKO) orMitomycin C (manufactured by WAKO). To the culture medium on day 4 wasadded an ATP reagent (150 μL) (CellTiter-Glo (registered trade mark)Luminescent Cell Viability Assay, manufactured by Promega) to give asuspension, which was stood for about 10 min at room temperature, andthe luminescence intensity (RLU value) was measured by FlexStation3(manufactured by Molecular Devices), and the number of viable cells wasmeasured by subtracting the luminescence value of the medium alone. ForWST-8 measurement, a WST-8 solution (manufactured by DOJINDOLaboratories, 15 μL) was added, the mixture was incubated at 37° C. for100 min, the absorbance at 450 nm was measured by an absorbancespectrometer (manufactured by Molecular Devices, SPECTRA MAX 190), andthe number of viable cells was measured by subtracting the absorbance ofthe medium alone.

As a result, it was found that the cell proliferation test method usingthe medium composition of the present invention strongly showed theefficacy of Mitomycin C as compared to the single layer culture method.The % Control value of the RLU value (ATP measurement, luminescenceintensity) on day 4 of the static culture is shown in Table 64. The %Control value of the absorbance at 450 nm (WST-8 measurement) on day 4of the static culture is shown in Table 65.

TABLE 64 single layer deacylated gellan culture conditions culture groupgum addition group % DMSO 100 100 Control Adriamycin 97 96 0.001 μMAdriamycin 97 81 0.01 μM Adriamycin 65 41 0.1 μM Adriamycin 5 15 1 μMPaclitaxel 95 107 0.001 μM Paclitaxel 36 34 0.003 μM Paclitaxel 10 180.01 μM Paclitaxel 4 17 0.03 μM Mitomycin C 99 83 0.005 μM Mitomycin C89 48 0.05 μM Mitomycin C 86 29 0.5 μM

TABLE 65 single layer deacylated gellan culture conditions culture groupgum addition group % DMSO 100 100 Control Adriamycin 109 105 0.001 μMAdriamycin 107 86 0.01 μM Adriamycin 74 36 0.1 μM Adriamycin 6 4 1 μMPaclitaxel 99 125 0.001 μM Paclitaxel 32 33 0.003 μM Paclitaxel 10 50.01 μM Paclitaxel 5 3 0.03 μM Mitomycin C 101 94 0.005 μM Mitomycin C83 37 0.05 μM Mitomycin C 71 12 0.5 μM

Experimental Example 51: Comparison with Single Layer Culture Method inCell Proliferation Test Using Agent for Inducing Apoptosis

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal is concentration of 0.015% (w/v) to DMEM medium containing 10%(v/v) fetal bovine serum (manufactured by WAKO), and a mediumcomposition free of deacylated gellan gum was prepared.

Successively, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single layer culture method, human cervical cancer cellline HeLa was inoculated to the above-mentioned medium composition freeof deacylated gellan gum at 37000 cells/mL, and dispensed to the wellsof a 96-well flat bottom microplate (manufactured by CorningIncorporated, #3585) at 135 μL/well. Each plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂). On culture day 1,medium compositions containing a 10-fold concentration of various agentsfor inducing apoptosis to make the final concentration 0.2 to 10 μM, anda final concentration 0.015% (w/v) of deacylated gellan gum (deacylatedgellan gum addition group), and a medium composition containing a10-fold concentration of various agents for inducing apoptosis (singlelayer culture group) alone were each added by 15 μL, and the cells weresuccessively cultured for 3 days. The agent for inducing apoptosis usedwas Apoptosis Inducer set (manufactured by Merck Millipore, APT800:Actinomycin D, Camptothecin, Cycloheximide, Dexamethasone, Etoposide).To the culture medium on day 4 was added an ATP reagent (150 μL)(CellTiter-Glo (registered trade mark) Luminescent Cell Viability Assay,manufactured by Promega) to give a suspension, which was stood for about10 min at room temperature, and the luminescence intensity (RLU value)was measured by FlexStation3 (manufactured by Molecular Devices), andthe number of viable cells was measured by subtracting the luminescencevalue of the medium alone. For WST-8 measurement, a WST-8 solution(manufactured by is DOJINDO Laboratories, 15 μL) was added, the mixturewas incubated at 37° C. for 100 min, the absorbance at 450 nm wasmeasured by an absorbance spectrometer (manufactured by MolecularDevices, SPECTRA MAX 190), and the number of viable cells was measuredby subtracting the absorbance of the medium alone.

As a result, it was found that the cell proliferation test method usingthe medium composition of the present invention strongly showed theefficacy of Camptothecin and Etoposide as compared to the single layerculture method. The % Control value of the RLU value (ATP measurement,luminescence intensity) on day 4 of the static culture is shown in Table66. The % Control value of the absorbance at 450 nm (WST-8 measurement)on day 4 of the static culture is shown in Table 67.

TABLE 66 single layer deacylated gellan culture conditions culture groupgum addition group % DMSO 100 100 Control Adriamycin 3 5 1 μMActinomycin D 2 4 1 μM Actinomycin D 2 6 10 μM Camptothecin 63 27 0.2 μMCamptothecin 44 11 2 μM Cycloheximide 29 9 10 μM Cycloheximide 9 4 100μM Dexamethasone 117 232 1 μM Dexamethasone 116 241 10 μM Etoposide 6435 1 μM Etoposide 65 24 10 μM

TABLE 67 single layer deacylated gellan culture conditions culture groupgum addition group % DMSO 100 100 Control Adriamycin 3 3 1 μMActinomycin D 2 3 1 μM Actinomycin D 4 12 10 μM Camptothecin 68 24 0.2μM Camptothecin 28 7 2 μM Cycloheximide 21 4 10 μM Cycloheximide 7 1 100μM Dexamethasone 89 184 1 μM Dexamethasone 92 173 10 μM Etoposide 68 391 μM Etoposide 63 23 10 μM

Experimental Example 52: Comparison with Single Layer Culture Method inHeLa Cell Proliferation Test Using Trametinib and MK-2206

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal is concentration of 0.015% (w/v) to DMEM medium containing 10%(v/v) fetal bovine serum (manufactured by WAKO), and a mediumcomposition free of deacylated gellan gum was prepared.

Successively, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single layer culture method, human cervical cancer cellline HeLa was inoculated to the above-mentioned medium composition freeof deacylated gellan gum at 7400 cells/mL, and dispensed to the wells ofa 96-well flat bottom microplate (manufactured by Corning Incorporated,#3585) at 135 μL/well. Each plate was cultured by being stood still in aCO₂ incubator (37° C., 5% CO₂). On culture day 1, medium compositionscontaining a 10-fold concentration of various anticancer drugs to makethe final concentration 0.001 to 30 μM, and a final concentration 0.015%(w/v) of deacylated gellan gum (deacylated gellan gum addition group),and medium compositions containing only a 10-fold concentration ofvarious anticancer drugs (single layer culture group) were each added by15 μL, and the cells were successively cultured for 5 days. Theanticancer drugs used were Trametinib (manufactured by Santa Cruz, MEKinhibitor) and MK-2206 (manufactured by Santa Cruz, Akt inhibitor). Tothe culture medium on day 6 was added an ATP reagent (150 μL)(CellTiter-Glo (registered trade mark) Luminescent Cell Viability Assay,manufactured by Promega) to give a suspension, which was stood for about10 min at room temperature, and the luminescence intensity (RLU value)was measured by FlexStation3 (manufactured by Molecular Devices), andthe number of viable cells was measured by subtracting the luminescencevalue of the medium alone.

As a result, it was found that the cell proliferation test method usingthe medium composition of the present invention strongly showed theefficacy of MK-2206 and Trametinib as compared to the single layerculture method. The % Control value of the RLU value (ATP measurement,luminescence intensity) on day 4 of the static culture is shown in Table68.

TABLE 68 single layer deacylated gellan culture conditions culture groupgum addition group % DMSO 100 100 Control Paclitaxel 89 104 0.001 μMPaclitaxel 15 46 0.003 μM Paclitaxel 2 5 0.01 μM Trametinib 102 73 0.001μM Trametinib 93 12 0.01 μM Trametinib 20 1 0.1 μM Trametinib 3 1 1 μMMK-2206 93 57 0.03 μM MK-2206 84 21 0.3 μM MK-2206 69 21 3 μM MK-2206 00 30 μM

Experimental Example 53: Comparison with Single Layer Culture Method inA549 Cell Proliferation Test Using Trametinib and MK-2206

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min is in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.015% (w/v) to DMEM medium containing10% (v/v) fetal bovine serum (manufactured by WAKO), and a mediumcomposition free of deacylated gellan gum was prepared.

Successively, human lung cancer cell line A549 (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 14800 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single is layer culture method, human lung cancer cellline A549 was inoculated to the above-mentioned medium composition freeof deacylated gellan gum at 14800 cells/mL, and dispensed to the wellsof a 96-well flat bottom microplate (manufactured by CorningIncorporated, #3585) at 135 μL/well. Each plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂). On culture day 1,medium compositions containing a 10-fold concentration of variousanticancer drugs to make the final concentration 0.001 to 30 μM, and afinal concentration 0.015% (w/v) of deacylated gellan gum (deacylatedgellan gum addition group), and medium compositions containing only a10-fold concentration of various anticancer drugs (single layer culturegroup) were each added by 15 μL, and the cells were successivelycultured for 5 days. The anticancer drugs used were Trametinib(manufactured by Santa Cruz, MEK inhibitor) and MK-2206 (manufactured bySanta Cruz, Akt inhibitor). To the culture medium on day 6 was added anATP reagent (150 μL) (CellTiter-Glo (registered trade mark) LuminescentCell Viability Assay, manufactured by Promega) to give a suspension,which was stood for about 10 min at room temperature, and theluminescence intensity (RLU value) was measured by FlexStation3(manufactured by Molecular Devices), and the number of viable cells wasmeasured by subtracting the luminescence value of the medium alone.

As a result, it was found that the cell proliferation test method usingthe medium composition of the present invention strongly showed theefficacy of MK-2206 as compared to the single layer culture method. The% Control value of the RLU value (ATP measurement, luminescenceintensity) on day 4 of the static culture is shown in Table 69.

TABLE 69 single layer deacylated gellan culture conditions culture groupgum addition group % DMSO 100 100 Control Paclitaxel 81 93 0.001 μMPaclitaxel 31 52 0.003 μM Paclitaxel 16 32 0.01 μM Trametinib 71 720.001 μM Trametinib 37 35 0.01 μM Trametinib 5 2 0.1 μM Trametinib 1 0 1μM MK-2206 93 84 0.03 μM MK-2206 79 45 0.3 μM MK-2206 53 21 3 μM MK-22060 0 30 μM

Experimental Example 54: Comparison with Single Layer Culture Method inProliferation Action of HeLa Cell Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal is concentration of 0.015% (w/v) to DMEM medium containing 10%(v/v) fetal bovine serum (manufactured by WAKO), and a mediumcomposition free of deacylated gellan gum was prepared.

Successively, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single layer culture method, human cervical cancer cellline HeLa was inoculated to the above-mentioned medium composition freeof deacylated gellan gum at 37000 cells/mL, and dispensed to the wellsof a 96-well flat bottom microplate (manufactured by CorningIncorporated, #3585) at 135 μL/well. Each plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂). On culture day 1, amedium composition containing a 10-fold concentration of human HB-EGF(heparin binding EGF-like growth factor, manufactured by PEPROTECH) tomake the final concentration of 10, 30 and 100 ng/ml, and a finalconcentration 0.015% (w/v) of deacylated gellan gum (deacylated gellangum addition group), and a medium composition containing only a 10-foldconcentration of human HB-EGF (single layer culture group) were eachadded by 15 μL, and the cells were successively cultured for 7 days. Tothe culture medium on days 6 and 8 was added an ATP reagent (150 μL)(CellTiter-Glo (registered trade mark) Luminescent Cell Viability Assay,manufactured by Promega) to give a suspension, which was stood for about10 min at room temperature, and the luminescence intensity (RLU value)was measured by FlexStation3 (manufactured by Molecular Devices), andthe number of viable cells was measured by subtracting the luminescencevalue of the medium alone.

As a result, it was found that the HeLa cell proliferation test methodusing the medium composition of the present is invention strongly showedthe cell proliferation promoting effect of human HB-EGF as compared tothe single layer culture method. The % Control value of the RLU value(ATP measurement, luminescence intensity) on day 6 of the static cultureis shown in Table 70. The % Control value of the RLU value (ATPmeasurement, luminescence intensity) on day 8 of the static culture isshown in Table 71.

TABLE 70 culture conditions single layer deacylated gellan day 6 culturegroup gum addition group % negative control 100 100 Control human HB-EGF102 109 10 ng/ml human HB-EGF 99 109 30 ng/ml human HB-EGF 105 133 100ng/ml

TABLE 71 culture conditions single layer deacylated gellan day 8 culturegroup gum addition group % negative control 100 100 Control human HB-EGF100 107 10 ng/ml human HB-EGF 99 115 30 ng/ml human HB-EGF 88 161 100ng/ml

Experimental Example 55: Comparison with Single Layer Culture Method inProliferation Action of A549 Cells Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min is in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.015% (w/v) to DMEM medium containing10% (v/v) fetal bovine serum (manufactured by WAKO), and a mediumcomposition free of deacylated gellan gum was prepared.

Successively, human lung cancer cell line A549 (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum to 14800 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single layer culture method, human lung cancer cell lineA549 was inoculated to the above-mentioned medium composition free ofdeacylated gellan gum at 14800 cells/mL, and dispensed to the wells of a96-well flat bottom microplate (manufactured by Corning Incorporated,#3585) at 135 μL/well. Each plate was cultured by being stood still in aCO₂ incubator (37° C., 5% CO₂). On culture day 1, a medium compositioncontaining a 10-fold concentration of human HB-EGF (manufactured byPEPROTECH) to make the final concentration from 10, 30 and 100 ng/ml,and a final concentration 0.015% (w/v) of deacylated gellan gum(deacylated gellan gum addition group), and a medium compositioncontaining only a 10-fold concentration of human HB-EGF (single is layerculture group) were each added by 15 μL, and the cells were successivelycultured for 7 days. To the culture medium on days 6 and 8 was added anATP reagent (150 μL) (CellTiter-Glo (registered trade mark) LuminescentCell Viability Assay, manufactured by Promega) to give a suspension,which was stood for about 10 min at room temperature, and theluminescence intensity (RLU value) was measured by FlexStation3(manufactured by Molecular Devices), and the number of viable cells wasmeasured by subtracting the luminescence value of the medium alone.

As a result, it was found that the A549 cell proliferation test methodusing the medium composition of the present invention strongly showedthe cell proliferation promoting effect of human HB-EGF as compared tothe single layer culture method. The % Control value of the RLU value(ATP measurement, luminescence intensity) on day 6 of the static cultureis shown in Table 72. The % Control value of the RLU value (ATPmeasurement, luminescence intensity) on day 8 of the static culture isshown in Table 73.

TABLE 72 culture conditions single layer deacylated gellan day 6 culturegroup gum addition group % negative control 100 100 Control human HB-EGF92 99 10 ng/ml human HB-EGF 95 115 30 ng/ml human HB-EGF 96 140 100ng/ml

TABLE 73 culture conditions single layer deacylated gellan day 8 culturegroup gum addition group % negative 100 100 Control control human HB-EGF97 103  10 ng/ml human HB-EGF 99 108  30 ng/ml human HB-EGF 100 128 100ng/ml

Experimental Example 56: Comparison with Single Layer Culture Method inProliferation Action of A431 Cells Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to EMEM medium (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) containing 10% (v/v) fetal bovine serum,and a medium composition free of deacylated gellan gum was prepared.Successively, human squamous carcinoma cell line A431 (manufactured byDS PHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface is microplate (manufactured by Corning Incorporated, #3474) at135 μL/well. In the single layer culture method, human squamous cellcarcinoma cell line A431 was inoculated to the above-mentioned mediumcomposition free of deacylated gellan gum at 37000 cells/mL, anddispensed to the wells of a 96-well flat bottom microplate (manufacturedby Corning Incorporated, #3585) at 135 μL/well. Each plate was culturedby being stood still in a CO₂ incubator (37° C., 5% CO₂). On culture day1, a medium composition containing a 10-fold concentration of humanHB-EGF (manufactured by PEPROTECH) to make the final concentration from10, 30 and 100 ng/ml, and a final concentration 0.015% (w/v) ofdeacylated gellan gum (deacylated gellan gum addition group), and amedium composition containing only a 10-fold concentration of humanHB-EGF (single layer culture group) were each added by 15 μL, and thecells were successively cultured for 7 days. To the culture medium ondays 6 and 8 was added an ATP reagent (150 μL) (CellTiter-Glo(registered trade mark) Luminescent Cell Viability Assay, manufacturedby Promega) to give a suspension, which was stood for about 10 min atroom temperature, and the luminescence intensity (RLU value) wasmeasured by FlexStation3 (manufactured by Molecular Devices), and thenumber of viable cells was measured by subtracting the luminescencevalue of the medium alone.

As a result, it was found that the A431 cell proliferation test methodusing the medium composition of the present invention strongly showedthe cell proliferation promoting effect of human HB-EGF as compared tothe single layer culture method. The % Control value of the RLU value(ATP measurement, luminescence intensity) on day 6 of the static cultureis shown in Table 74. The % Control value of the RLU value (ATPmeasurement, luminescence intensity) on day 8 of the static culture isshown in Table 75.

TABLE 74 culture conditions single layer deacylated gellan day 6 culturegroup gum addition group % negative 100 100 Control control human HB-EGF96 241  10 ng/ml human HB-EGF 95 557  30 ng/ml human HB-EGF 83 1018 100ng/ml

TABLE 75 culture conditions single layer deacylated gellan day 8 culturegroup gum addition group % negative 100 100 Control control human HB-EGF105 370  10 ng/ml human HB-EGF 100 772  30 ng/ml human HB-EGF 89 1886100 ng/ml

Experimental Example 57: Comparison with Single Layer Culture Method inProliferation Action of SKOV3 Cells Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min is in an autoclave. Using thissolution, a medium composition was prepared by adding deacylated gellangum at a final concentration of 0.015% (w/v) to McCoy's 5a medium(manufactured by DS PHARMA BIOMEDICAL CO., LTD.) containing 15% (v/v)fetal bovine serum, and a medium composition free of deacylated gellangum was prepared. Successively, human ovarian cancer cell line SKOV3(manufactured by DS PHARMA BIOMEDICAL CO., LTD.) was inoculated to theabove-mentioned medium composition added with deacylated gellan gum at37000 cells/mL, and dispensed to the wells of a 96-well flat bottomultra low adhesion surface microplate (manufactured by CorningIncorporated, #3474) at 135 μL/well. In the single layer culture method,human ovarian cancer cell line SKOV3 was inoculated to theabove-mentioned medium composition free of deacylated gellan gum at37000 cells/mL, and dispensed to the wells of a 96-well flat bottommicroplate (manufactured by Corning Incorporated, #3585) at 135 μL/well.Each plate was cultured by being stood still in a CO₂ incubator (37° C.,5% CO₂). On culture day 1, a medium composition containing a 10-foldconcentration of human HB-EGF (manufactured by PEPROTECH) to make thefinal concentration from 10, 30 and 100 ng/ml, and a final concentration0.015% (w/v) of deacylated gellan gum (deacylated gellan gum additiongroup), and a medium composition containing only a 10-fold concentrationof human HB-EGF (single layer culture group) were each added by 15 μL,and the cells were successively cultured for 8 days. To the culturemedium on days 6 and 9 was added an ATP reagent (150 μL) (CellTiter-Glo(registered trade mark) Luminescent Cell Viability Assay, manufacturedby Promega) to give a suspension, which was stood for about 10 min atroom temperature, and the luminescence intensity (RLU value) wasmeasured by FlexStation3 (manufactured by Molecular Devices), and thenumber of viable cells was measured by subtracting the luminescencevalue of the medium alone.

As a result, it was found that the SKOV3 cell proliferation test methodusing the medium composition of the present invention strongly showedthe cell proliferation promoting effect of human HB-EGF as compared tothe single layer culture method. The % Control value of the RLU value(ATP measurement, luminescence intensity) on day 6 of the static cultureis shown in Table 76. The % Control value of the RLU value (ATPmeasurement, luminescence intensity) on day 9 of the static culture isshown in Table 77.

TABLE 76 culture conditions single layer deacylated gellan day 6 culturegroup gum addition group % negative 100 100 Control control human HB-EGF103 138  10 ng/ml human HB-EGF 103 191  30 ng/ml human HB-EGF 121 282100 ng/ml

TABLE 77 culture conditions single layer deacylated gellan day 9 culturegroup gum addition group % negative 100 100 Control control human HB-EGF100 136  10 ng/ml human HB-EGF 101 176  30 ng/ml human HB-EGF 108 343100 ng/ml

Experimental Example 58: Comparison with Single Layer Culture Method inVEGF mRNA Expression in HeLa Cells Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to DMEM medium containing 10% (v/v)fetal bovine serum (manufactured by WAKO), and a medium composition freeof deacylated gellan gum was prepared.

Successively, human cervical cancer cell line HeLa (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. In the single layer culture method, human cervical cancer cellline HeLa was inoculated to the above-mentioned medium composition freeof deacylated gellan gum at 37000 cells/mL, and dispensed to the wellsof a 96-well flat bottom microplate (manufactured by CorningIncorporated, #3585) at 135 μL/well. Each plate was cultured by beingstood still in a CO₂ incubator (37° C., 5% CO₂). On culture day 1, amedium composition containing a 10-fold concentration of human HB-EGF(manufactured by PEPROTECH) to make the final concentration from 10, 30and 100 ng/ml, and a final concentration 0.015% (w/v) of deacylatedgellan gum (deacylated gellan gum addition group), and a mediumcomposition containing only a 10-fold concentration of human HB-EGF(single layer culture group) were each added by 15 μL, and the cellswere successively cultured for 6 days. The culture medium containingcancer cells on day 7 was recovered, and the cells were recovered bycentrifugation (400 g, 3 min). Total RNA was extracted from the cells byusing RNeasy Mini kit (manufactured by QIAGEN). Using total RNA andPrimeScript (registered trade mark) RT Master Mix (manufactured byTakara Bio Inc.), a reverse transcription reaction was performed usingGeneAmp PCR System 9700 (manufactured by Applied Biosystems), and cDNAwas synthesized. Each cDNA sample used in PCR reaction was dispensed anddiluted with sterilization water to 1/10. In addition, the sample usedfor the calibration curve was cDNA dispensed and mixed, and adjustedwithin the quantification range of 1/3 to 1/243 dilution at a 3-foldcommon ratio. The PCR reaction was performed using each cDNA sample, acalibration sample, Premix Ex Taq (registered trade mark) (manufacturedby Takara Bio Inc.) and various Taqman probes (manufactured by AppliedBiosystems), and 7500 Real-time PCR System (manufactured by AppliedBiosystems). Specificity was calculated using mRNA of GAPDH(Glyceraldehyde 3-phosphate dehydrogenase) as an endogenous control,amending the expression of VEGF (Vascular endothelial growth factor)mRNA with the value of GAPDH, and using a negative control as 100%. Eachprobe (manufactured by Applied Biosystems) used is shown below.

GAPDH: HS99999905

VEGF: HS00173626

As a result, it was found that the HeLa cells cultured using the mediumcomposition of the present invention strongly showed mRNA expressionpromoting effect of VEGF by human HB-EGF as compared to the single layerculture method. In addition, the VEGF mRNA expression value when thenegative control on day 7 of the static culture is 100% is shown inTable 78.

TABLE 78 culture conditions single layer deacylated gellan day 7 culturegroup gum addition group % negative 100 100 Control control human HB-EGF82 121  10 ng/ml human HB-EGF 88 148  30 ng/ml human HB-EGF 89 195 100ng/ml

Experimental Example 59: Effect of Gefinitib on Cell Proliferation ofA549 Cell Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to DMEM medium containing 10% (v/v)fetal bovine serum (manufactured by WAKO), and a medium composition freeof deacylated gellan gum was prepared.

Successively, human lung cancer cell line A549 (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 14800 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. Each plate was cultured by being stood still in a CO₂ incubator(37° C., 5% CO₂). On culture day 1, to make the final concentration 0.1to 30 μm for each anticancer drug and the final concentration 0 ng/ml or100 ng/ml for human HB-EGF, a medium composition containing a 10-foldconcentration of each anticancer drug, human HB-EGF (manufactured byPEPROTECH) and a final concentration 0.015% (w/v) of deacylated gellangum (deacylated gellan gum addition group) was each added by 15 μL, andthe cells were successively cultured for 5 days. The anticancer drugused was Gefitinib (manufactured by Santa Cruz, EGF receptor inhibitor).To the culture medium on day 6 was added an ATP reagent (150 μL)(CellTiter-Glo (registered trade mark) Luminescent Cell Viability Assay,manufactured by Promega) to give a suspension, which was stood for about10 min at room temperature, and the luminescence intensity (RLU value)was measured by FlexStation3 (manufactured by Molecular Devices), andthe number of viable cells was measured by subtracting the luminescencevalue of the medium alone.

As a result, according to the A549 cell proliferation test method usingthe medium composition of the present invention and human HB-EGF, theculture conditions added with HB-EGF showed a stronger suppressiveeffect of Gefitinib. The % Control value of the RLU value (ATPmeasurement, luminescence intensity) on day 6 of the static culture isshown in Table 79.

TABLE 79 culture conditions HB-EGF HB-EGF day 6 no addition 100 ng/ml %DMSO 100 100 Control Gefitinib 89 91 0.1 μM Gefitinib 84 74 0.3 μMGefitinib 77 59   1 μM Gefitinib 69 53   3 μM

Experimental Example 60: Effect of Gefinitib, Elrotinib on GrowthProliferated Action of A431 Cells Stimulated with Human HB-EGF

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.015% (w/v) to EMEM medium (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) containing 10% (v/v) fetal bovine serum,and a medium composition free of deacylated gellan gum was prepared.Successively, human squamous carcinoma cell line A431 (manufactured byDS PHARMA BIOMEDICAL CO., LTD.) was inoculated to the above-mentionedmedium composition added with deacylated gellan gum at 37000 cells/mL,and dispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 135μL/well. Each plate was cultured by being stood still in a CO₂ incubator(37° C., 5% CO₂). On culture day 1, to make the final concentration 0.1to 30 μm for each anticancer drug and the final concentration of 0 ng/mlor 100 ng/ml for human HB-EGF, a medium composition containing a 10-foldconcentration of each anticancer drug, human HB-EGF (manufactured byPEPROTECH) and a final concentration 0.015% (w/v) of deacylated gellangum (deacylated gellan gum addition group) was each added by 15 μL, andthe cells were successively cultured for 7 days. The anticancer drugsused were Gefitinib (manufactured by Santa Cruz, EGF receptor inhibitor)and Elrotinib (manufactured by Santa Cruz, EGF receptor inhibitor). Tothe culture medium on days 4, 6 and 8 was added an ATP reagent (150 μL)(CellTiter-Glo (registered trade mark) Luminescent Cell Viability Assay,manufactured by Promega) to give a suspension, which was stood for about10 min at room temperature, and the luminescence intensity (RLU value)was measured by FlexStation3 (manufactured by Molecular Devices), andthe number of viable cells was measured by subtracting the luminescencevalue of the medium alone.

As a result, by the culture method combining the medium composition ofthe present invention and human HB-EGF, A431 cell proliferation underlow adhesion culture conditions was observed. Furthermore, by the A431cell proliferation test method combining the medium composition of thepresent invention and human HB-EGF, suppressive effects of Gefitinib andElrotinib on an HB-EGF-induced cell proliferation could be evaluated.For the human HB-EGF growth promoting action, the RLU value (ATPmeasurement, luminescence intensity) on day 4, day 6, day 8 of thestatic culture is shown in Table 80. Furthermore, for an action of eachanticancer drug on a human HB-EGF proliferation promoting action, the %Control value of the RLU value (ATP measurement, luminescence intensity)on day 4, day 8 is shown in Table 81.

TABLE 80 HB-EGF HB-EGF culture conditions no addition 100 ng/ml cell day4 2532 15303 number day 6 1332 23273 day 8 613 38854

TABLE 81 culture conditions day 4 day 8 % DMSO 100 100 Control Gefitinib83 68 0.1 μM Gefitinib 82 45 0.3 μM Gefitinib 10 2   1 μM Gefitinib 3 0  3 μM Elrotinib 88 56 0.1 μM Elrotinib 89 27 0.3 μM Elrotinib 21 4   1μM Elrotinib 4 0   3 μM

Experimental Example 61: Cell Proliferation Test by Dispersing MCF-7Cells

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.005% (w/v) or 0.015% (w/v) to EMEM medium(manufactured by DS PHARMA BIOMEDICAL CO., LTD.) containing 10% (v/v)fetal bovine serum. Successively, human breast cancer cell line MCF-7(manufactured by DS PHARMA BIOMEDICAL CO., LTD.) was inoculated to theabove-mentioned medium composition added with deacylated gellan gum at50000 cells/mL, and dispensed to the wells of a 96-well flat bottomultra low adhesion surface microplate (manufactured by CorningIncorporated, #3474) at 100 μL/well. As a negative control, MCF-7 cellswere suspended in the above-mentioned medium free of deacylated gellangum and the suspension was dispensed. Successively, this plate wascultured by being stood still in a CO₂ incubator (37° C., 5% CO₂) for 5days. To the culture medium after culturing for 2 and 5 days was addedan ATP reagent (100 μL) (CellTiter-Glo (registered trade mark)Luminescent Cell Viability Assay, manufactured by Promega) to give asuspension, which was stood for about 10 min at room temperature, andthe luminescence intensity (RLU value) was measured by FlexStation3(manufactured by Molecular Devices), and the number of viable cells wasmeasured by subtracting the luminescence value of the medium alone. ForWST-8 measurement, a WST-8 solution (manufactured by DOJINDOLaboratories, 10 μL) was added to the cells after culturing for 2 and 5days, the mixture was incubated at 37° C. for 100 min, the absorbance at450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190), and the number of viable cells wasmeasured by subtracting the absorbance of the medium alone.

As a result, it was confirmed that, using the medium composition of thepresent invention, MCF-7 cells efficiently proliferates according to theATP measurement method and WST-8 measurement method. The RLU value (ATPmeasurement, luminescence intensity) after static culture for 2, 5 daysis shown in Table 82. The absorbance at 450 nm (WST-8) after staticculture for 2, 5 days is shown in Table 83. The results of microscopicobservation of an aggregate of MCF-7 cells after culture for 5 days areshown in FIG. 23.

TABLE 82 culture day number 2 5 cell negative control 5765 9556 numberdeacylgellan gum 6242 15103 0.005% deacylgellan gum 6024 18314 0.015%

TABLE 83 culture day number 2 5 cell negative control 0.070 0.095 numberdeacylgellan gum 0.075 0.117 0.005% deacylgellan gum 0.065 0.173 0.015%

Experimental Example 62: Cell Proliferation Test when A375 Cell andMNNG/HOS Cells were Dispersed

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.005% (w/v) or 0.015% (w/v) to DMEM mediumcontaining 10% (v/v) fetal bovine serum (manufactured by WAKO) or EMEMmedium (manufactured by DS PHARMA BIOMEDICAL CO., LTD.). Successively,each human melanoma cell line A375 (manufactured by ATCC) and humanosteosarcoma cancer cell line MNNG/HOS (manufactured by ATCC) wasinoculated to the above-mentioned medium composition added withdeacylated gellan gum at 50000 cells/mL, and dispensed to the wells of a96-well flat bottom ultra low adhesion surface microplate (manufacturedby Corning Incorporated, #3474) at 100 μL/well. As a negative control,A375 cells and MNNG/HOS cells were suspended in the above-mentionedmedium free of deacylated gellan gum and the suspension was dispensed.Successively, this plate was cultured by being stood still in a CO₂incubator (37° C., 5% CO₂) for 4 days. To the culture medium afterculturing for 4 days was added an ATP reagent (100 μL) (CellTiter-Glo(registered trade mark) Luminescent Cell Viability Assay, manufacturedby Promega) to give a suspension, which was stood for about 10 min atroom temperature, and the luminescence intensity (RLU value) wasmeasured by FlexStation3 (manufactured by Molecular Devices), and thenumber of viable cells was measured by subtracting the luminescencevalue of the medium alone. After culturing for 4 days, to the culturemedium was added a WST-8 solution (manufactured by DOJINDO Laboratories,10 μL), the mixture was incubated at 37° C. for 100 min, the absorbanceat 450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190), and the number of viable cells wasmeasured by subtracting the absorbance of the medium alone.

As a result, it was confirmed that, using the medium composition of thepresent invention, A375 cells and MNNG/HOS cells can be cultivated in auniformly dispersed state without forming a cell aggregate having anexcessive size, and efficiently proliferates in the medium composition.The results of microscopic observation of aggregates of A375 cells andMNNG/HOS cells after culture for 4 days are shown in FIG. 24. Inaddition, in A375 cells, the absorbance at 450 nm (WST-8) and RLU value(ATP measurement, luminescence intensity) after static culture for 4days are shown in Table 84. In MNNG/HOS cells, the absorbance at 450 nm(WST-8) and RLU value (ATP measurement, luminescence intensity) afterstatic culture for 4 days are shown in Table 85.

TABLE 84 experiment group WST-8 ATP negative control 0.738 55193deacylgellan gum 2.088 98739 0.005% deacylgellan gum 3.336 115365 0.015%

TABLE 85 experiment group WST-8 ATP negative control 0.294 41529deacylgellan gum 0.005% 0.843 66913 deacylgellan gum 2.197 102199 0.015%

Experimental Example 63: Cell Proliferation Test by Dispersing MIAPaCa-2Cells

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.)was suspended in ultrapure water (Milli-Q water) to 0.3% (w/v), anddissolved by stirring with heating at 90° C. This aqueous solution wassterilized at 121° C. for 20 min in an autoclave. Using this solution, amedium composition was prepared by adding deacylated gellan gum at afinal concentration of 0.005% (w/v) or 0.015% (w/v) to DMEM mediumcontaining 10% (v/v) fetal bovine serum (manufactured by WAKO).Successively, human pancreatic carcinoma cell line MIAPaCa-2(manufactured by ATCC) was inoculated to the above-mentioned mediumcomposition added with deacylated gellan gum at 50000 cells/mL, anddispensed to the wells of a 96-well flat bottom ultra low adhesionsurface microplate (manufactured by Corning Incorporated, #3474) at 100μL/well. As a negative control, MIAPaCa-2 cells were suspended in theabove-mentioned medium free of deacylated gellan gum and the suspensionwas dispensed. Successively, this plate was cultured by being stoodstill in a CO₂ incubator (37° C., 5% CO₂) for 6 days. To the culturemedium after culturing for 6 days was added an ATP reagent (100 μL)(CellTiter-Glo (registered trade mark) Luminescent Cell Viability Assay,manufactured by Promega) to give a suspension, which was stood for about10 min at room temperature, and the luminescence intensity (RLU value)was measured by FlexStation3 (manufactured by Molecular Devices), andthe number of viable cells was measured by subtracting the luminescencevalue of the medium alone. After culturing for 6 days, to the culturemedium was added a WST-8 solution (manufactured by DOJINDO Laboratories,10 μL), the mixture was incubated at 37° C. for 100 min, the absorbanceat 450 nm was measured by an absorbance spectrometer (manufactured byMolecular Devices, SPECTRA MAX 190), and the number of viable cells wasmeasured by subtracting the absorbance of the medium alone.

As a result, it was confirmed that, using the medium composition of thepresent invention, MIAPaCa-2 cells can be cultivated in a uniformlydispersed state without forming a cell aggregate having an excessivesize, and efficiently proliferates in the medium composition. Theresults of microscopic observation of aggregate of MIAPaCa-2 cells afterculture for 6 days are shown in FIG. 25. In addition, the absorbance at450 nm (WST-8) and RLU value (ATP measurement, luminescence intensity)of MIAPaCa-2 cells after static culture for 4 days are shown in Table86.

TABLE 86 experiment group WST-8 ATP negative control 2.030 52674deacylgellan gum 0.005% 3.102 86650 deacylgellan gum 0.015% 3.621 85412

Experimental Example 64: Concentration and Dilution of Deacylated GellanGum-Containing Medium

DMEM medium (manufactured by WAKO) containing 0.015% (w/v) deacylatedgellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.) preparedin the same manner as in Experimental Example 2 was dispensed in a 15 mLcentrifugation tube (manufactured by VIOLAMO) by 10 mL, and thedeacylated gellan gum was sedimented by centrifugation (700G, 5 min) inswing rotor LC-200 (manufactured by TOMY SEIKO Co., Ltd.). Thesupernatant (8 mL) was removed by an aspirator, whereby the mediumcontaining deacylated gellan gum was concentrated. Furthermore, DMEMmedium (manufactured by WAKO) free of deacylated gellan gum was added tothis concentrated medium, and mixed by pipetting to give a medium havingan optional concentration rate.

On the other hand, human liver cancer cell HepG2 (manufactured by DSPHARMA BIOMEDICAL CO., LTD.) was suspended in DMEM medium containing 10%(v/v) fetal bovine serum (manufactured by WAKO) at 500000 cells/mL, thissuspension (10 mL) was inoculated to EZ SPHERE (manufactured by ASAHIGLASS CO., LTD.), and the cells were cultured in a 37° C., CO₂ incubator(5% CO₂) for 7 days. Here, a suspension (10 mL) of the obtained sphere(diameter 100-200 μm) was centrifuged (200G, 5 min) to allow forsedimentation, and the supernatant was removed to prepare a spheresuspension (1.0 mL). To the medium prepared to the above-mentionedoptional concentration was added this sphere suspension by 100 μL, thespheres were dispersed by pipetting and incubated at 37° C., and thedispersed state of the spheres was visually observed 1 hr later. Theresults are shown in Table 87.

As shown in Table 87, deacylated gellan gum can be concentrated anddiluted to an optional concentration, after preparing as a mediumcomposition. The medium composition concentrated and diluted in thismanner was confirmed to have a suspending effect of the spheres.

TABLE 87 concentration 0.33 0.66 1.00 1.67 2.50 5.00 rate (fold) ofdeacylated gellan gum state (sedimented sedi- sus- sus- sus- sus- sus-or suspended) mented pended pended pended pended pended of sphere

Experimental Example 65: Production of Deacylgellan Gum-ContainingDMEM/Ham's F12 Medium

Deacylated gellan gum (KELCOGEL CG-LA, manufactured by SANSHO Co., Ltd.,120 mg) was suspended in pure water (72 mL), and dissolved by stirringwith heating at 90° C. Thereto was added pure water to prepare a 0.017%(w/v) solution (720 mL) of deacylgellan gum, and the solution wassterilized using a sterilization filter (pore size 0.22 μm). On theother hand, pure water corresponding to 1/10 of the amount recommendedfor preparation of a medium was added to a medium containing a mixedpowder medium of equal amounts of DMEM/Ham's F12 (Life TechnologiesCorporation), and sodium hydrogen carbonate to prepare a 80 mL aqueoussolution at a 10-fold concentration, and the solution was sterilizedusing a sterilization filter (pore size 0.22 μm). This was mixed withstirring at 25° C. under sterilization conditions to prepare the objectmedium (800 mL) having a deacylgellan gum concentration of 0.015% (w/v).

INDUSTRIAL APPLICABILITY

The medium composition of the present invention shows a superior effectof suspending cells and/or tissues, and is extremely useful forlarge-scale cultivation of cells and/or tissues derived from animals andplants while maintaining the function thereof. In addition, the cellsand/or tissues cultured by the method of the present invention areextremely useful for efficacy and toxicity evaluation of chemicalsubstances, pharmaceutical products and the like, large-scale productionof useful substances such as enzymes, cell growth factors, antibodiesand the like, and in the field of regenerative medicine forsupplementing organ, tissue and cell that were lost by disease anddeficiency, and the like.

The invention claimed is:
 1. A method of producing a sphere, comprisingcultivating an adherent cell in a suspended state in a liquid mediumcomposition comprising deacylated gellan gum or a salt thereof.